

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
27 February 2003 (27.02.2003)

PCT

(10) International Publication Number  
**WO 03/016351 A2**

(51) International Patent Classification<sup>7</sup>: **C07K 16/00**

(21) International Application Number: **PCT/DK02/00541**

(22) International Filing Date: 19 August 2002 (19.08.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
PA 2001 01228 17 August 2001 (17.08.2001) DK  
PA 2002 00667 2 May 2002 (02.05.2002) DK

(71) Applicant (for all designated States except US): **ENKAM PHARMACEUTICALS A/S** [DK/DK]; Høstvej 7, DK-2920 Charlottenlund (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KISELYOV, Vladislav, V.** [UA/DK]; Visbygade 6, st.th., DK-2100 Copenhagen Ø (DK). **SKLADCHIKOVA, Galina** [RU/DK]; Callisensvej 20, 4.th., DK-2900 Hellerup (DK). **BEREZIN, Vladimir** [UA/DK]; Nørrebrogade 223, 1.th., DK-2200 Copenhagen N (DK). **BOCK, Elisabeth** [DK/DK]; Tonyvej 20, DK-2920 Charlottenlund (DK).

(74) Agent: **HØIBERG A/S**; Store Kongensgade 59 A, DK-1264 Copenhagen K (DK).

(81) Designated States (national): AE, AG, AL, AM, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,

LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— of inventorship (Rule 4.17(iv)) for US only

**Published:**

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOUNDS CAPABLE OF AFFECTING DIFFERENTIATION, PROLIFERATION, REGENERATION, PLASTICITY AND SURVIVAL OF CELLS

(57) Abstract: The present invention relates to a compound comprising the third Immunoglobulin (Ig3) module, and/or the fourth Immunoglobulin (Ig4) module, and/or the fifth Immunoglobulin (Ig5) module, and/or the first Fibronectin III (Fn3, 1) module, and/or the second Fibronectin III (Fn3, 2) module of neural cell adhesion molecule (NCAM), or a fragment, or a variant thereof, capable of interacting with a Fibroblast Growth Factor (FGF) receptor and/or Adenosine-Tri-Phosphate (ATP) and/or L1, and thereby the compounds are capable of inducing differentiation, modulating proliferation, stimulate regeneration, neuronal plasticity and/or survival of cells. Further, the present invention relates to a pharmaceutical composition comprising said compound, a process of producing a pharmaceutical composition and the use of said compound.

**Compounds capable of affecting differentiation, proliferation, regeneration, plasticity  
and survival of cells**

5 The present invention relates to a compound comprising the third Immunoglobulin (Ig3) module, and/or the fourth Immunoglobulin (Ig4) module, and/or the fifth Immunoglobulin (Ig5) module, and/or the first Fibronectin III (Fn3,1) module, and/or the second Fibronectin III (Fn3,2) module of neural cell adhesion molecule (NCAM), or a fragment, or a variant thereof, capable of interacting with an Fibroblast Growth Factor (FGF) receptor and/or Adenosine-Tri-  
10 Phosphate (ATP) and/or L1, and thereby the compounds are capable of inducing differentiation, modulating proliferation, stimulate regeneration, neuronal plasticity and/or survival of cells. Further, the present invention relates to a pharmaceutical composition comprising said compound, a process of producing a pharmaceutical composition and the use of said compound.

15 **Background of the invention**

Cell adhesion molecules (CAMs) constitute a group of proteins mediating adhesion between cells. A major group of CAMs belongs to the immunoglobulin (Ig) superfamily characterised by the presence of immunoglobulin domains. The neural cell adhesion molecule (NCAM) is  
20 such a cell adhesion molecule of the Ig superfamily that is particularly abundant in the nervous system. NCAM is expressed on the external membrane of nerve cells. When an NCAM molecule on one cell binds to another NCAM molecule on another cell (homophilic binding), the binding between the two cells is strengthened. NCAM not only binds to NCAM but also to other proteins and/or glycoconjugates found on nerve cells or in the extracellular matrix (het-  
25 erophilic binding). NCAM also binds ATP. NCAM interactions influence migration of cells, extension of neurites, fasciculation of neurites, cell proliferation, cell survival, and formation of synapses.

NCAM is encoded by a single gene, containing at least 25 exons. Due to alternative splicing  
30 of precursor mRNA, a variety of mature mRNA species and thereby protein isoforms of NCAM can be produced. Three major NCAM isoforms are generated by alternative splicing of exons 15 and 18 determining the mode of attachment of NCAM to the plasma membrane and the size of the intracellular NCAM domains, respectively. In the nervous system a glyco-  
35 sylphosphatidyl inositol (GPI) anchored 120 kDa isoform is expressed on the surface of glial cells, a transmembrane 140 kDa isoform is expressed on both neurons and glial cells, whereas a transmembrane 180 kDa isoform is found predominantly on the surface of neurons. The extracellular part of NCAM comprises five Ig-like homology modules (Ig1, Ig2, Ig3, Ig4 and Ig5) and two fibronectin type III modules (F3,1 and F3,2) (Berezin et al., 2000).

**CONFIRMATION COPY**

Heterophilic ligands of NCAM comprise a variety of heparan sulfate proteoglycans (e.g. agrin) and chondroitin sulfate proteoglycans (e.g. neurocan). NCAM Ig1 and Ig2 are probably the structural determinants of the interaction of NCAM with heparan sulfate proteoglycans since these two modules have been shown to bind heparin (Kiselyov et al. 1997). Reports on whether the core protein or the carbohydrate moieties are responsible for the binding of proteoglycans to NCAM are contradictory, and the contribution of this interaction to NCAM-mediated cellular functions is currently not understood (Retzler et al. 1996). The neural cell adhesion molecule L1 and the fibroblast growth factor (FGF) receptor are other heterophilic ligands of NCAM. The interaction between NCAM and L1 has been shown to be mediated by N-linked oligo-mannosidic glycans carried by L1 and a lectin-like binding site localised in the fourth Ig module of NCAM. Through this binding NCAM has been suggested to participate in a so-called assisted L1-L1 homophilic interaction (Horstkorte et al., 1993) presenting an interesting example of co-operation between two neural CAMs.

Three different models of homophilic binding have been suggested: 1) a binding between the third Ig-like modules (Rao *et al.*, 1992) of two opposing molecules; 2) involvement of all five Ig-like modules in an antiparallel interaction (Ranheim *et al.*, 1996); and 3) a reciprocal binding of the first and second Ig-like modules (Kiselyov *et al.*, 1997). The latter model has recently been confirmed by nuclear magnetic resonance (NMR) analysis (Jensen *et al.*, 1999) and X-ray crystallography (Kasper *et al.*, 2000).

NCAM plays a crucial role during the development of the nervous system and of organs, such as kidney, bowel, heart, gonads, pancreas, and muscles. In the mature nervous system NCAM is important for the plasticity of neuronal connections associated with regeneration, learning and memory. In the peripheral nervous system NCAM is involved in the initiation of outgrowth of nerve fibres and formation of nerve-muscle connections in regeneration after damage including lesions.

In signal transduction NCAM transduces extracellular signals leading to tyrosine phosphorylation, such as for example of the FGF-receptor, and an increase in intracellular calcium concentration.

Doherty and Walsh (1999) describe that NCAM, N-cadherin and L1 stimulate axonal growth by activating the fibroblast growth factor receptor (FGFR) in neurons.

NCAM binding compounds capable of stimulating differentiation and/or neurite outgrowth from cells presenting NCAM are disclosed in WO 00/18801, in which the compounds are used in the treatment for regeneration of NCAM presenting cells.

The identification of one such compound, C3, is described by Rønn et al. (1999). C3 stimulates outgrowth by activating a signalling pathway identical to that activated by homophilic NCAM binding, but it does not bind directly to FGF receptors.

- 5 Various factors may cause neuronal cell death. Preventing neuronal cell death in individuals being exposed to risk factors causing cell death may be called maintaining/stimulating or promoting survival of the cells, or it may be called neuroprotection.

- 10 When neuronal cells are damaged, e.g. by reduced oxygen supply, the processes of cell death start and lead to cellular dysfunction, "collapse" of the intercellular communication between cells (network), retraction of cell processes and eventually cell death. Preventing neuronal cell death, i.e. stimulating/promoting survival means that the cells are protected from initiation of the processes of cell death.

- 15 Survival of nerve cells has been discussed in some references, for example Hulley et al. (1998) disclose that the L1 neural cell adhesion molecule is capable of stimulating survival and differentiation in fetal mid-brain dopaminergic neurons cultured in the presence of the toxin MPP+.

- 20 US 6,037,320 describes the identification of a neurotrophic factor, NT-4 and in US 5,767,240 an activity-dependent neurotrophic factor capable of increasing the survival of spinal cord neuronal cells, cerebral cortical cells and hippocampal neurons is revealed.

- 25 Further, US 5,567,682 concerns a method of treating the symptoms of Alzheimer's disease by intranasal administration of short chain peptides. The peptides promote neuronal survival by reducing or halting progressive neuronal degeneration.

- 30 NCAM has recently been demonstrated to have an ecto-adenosine triphosphatase (ATPase) activity (Dzhandzhugazyan and Bock, 1993 and 1997). The role of this activity in ATP is one of the most abundant neurotransmitters in the nervous system In a recent study it has been demonstrated that ATP modulates NCAM induced neurite outgrowth, indicating that ATP may be a regulator of the putative NCAM-FGF-receptor signalling pathway (Skladchikova et al., 1999).

- 35 However, the inventors of the present invention have surprisingly found that a compound comprising the third Immunoglobulin (Ig3) module, and/or the fourth Immunoglobulin (Ig4) module, and/or the fifth Immunoglobulin (Ig5) module, and/or the first Fibronectin III (Fn3,1) module, and/or the second Fibronectin III (Fn3,2) module of neural cell adhesion molecule (NCAM), or a fragment, or a variant thereof is capable of inducing differentiation, modulating

proliferation, stimulating regeneration, neuronal plasticity and survival of cells through an interaction with the Fibroblast Growth Factor (FGF) receptor and/or adenosine-tri-phosphate (ATP) and/or L1.

## 5      **Summary of the invention**

The present invention concerns a compound comprising the third Immunoglobulin (Ig3) module, and/or the fourth Immunoglobulin (Ig4) module, and/or the fifth Immunoglobulin (Ig5) module, and/or the first Fibronectin III (Fn3,1) module, and/or the second Fibronectin III (Fn3,2) module of neural cell adhesion molecule (NCAM), or a fragment, or a variant thereof, capable of interacting with Fibroblast Growth Factor (FGF) receptor and/or Adenosine-Tri-Phosphate (ATP) and/or L1. In the present context first Fibronectin III module and second Fibronectin III module are equal to the denomination "F3,1 and F3,2" or "FnIII,1 and FnIII,2" or "Fn3,1 and Fn3,2".

15      In a further aspect the invention concerns a compound comprising the fourth Immunoglobulin (Ig4) module, and/or the fifth Immunoglobulin (Ig5) module, and/or the first Fibronectin III (Fn3,1) module, and/or the second Fibronectin III (Fn3,2) module of neural cell adhesion molecule (NCAM), or a fragment, or a variant, capable of interacting with the FGF receptor and/or adenosine-tri-phosphate (ATP) and/or L1.

20      The compound of the invention is capable of inducing differentiation, modulating proliferation, stimulate regeneration, neuronal plasticity and survival of cells presenting the FGF receptor and/or NCAM ligand presenting cells.

25      Further, the invention describes a pharmaceutical composition comprising at least one compound of the invention, and a process of producing such a pharmaceutical composition. Also, the use of a compound of the invention is within the scope of the invention as well as a method for treating diseases and conditions with the compound.

30

## **Figures**

35      Figure 1. shows the structure of NCAM F3,2 determined by means of  $^1\text{H}$ ,  $^{15}\text{N}$  NMR spectroscopy. Structure of the second F3 module of NCAM, a) Stereo view of an overlay of the backbone atoms of 30 superimposed structures, b) Ribbon representation of the structure. The structure consists of 7 anti-parallel  $\beta$ -strands arranged in a sandwich of two  $\beta$ -sheets, one containing three strands (ABE) and the other four strands (CDFG).

Figure 2. Demonstration of interaction between the second F3 module of NCAM and the

third Ig module of the FGF-receptor or ATP. *a-d*) Changes in the chemical shifts of  $^1\text{H}$  and  $^{15}\text{N}$  atoms of 0.05 mM  $^{15}\text{N}$  labeled sample of the second F3 module of NCAM after addition of 1 mM unlabeled sample of the third Ig module of the FGF-receptor (*a, b*) or 5 mM AMP-PCP (*c, d*). *e*) Mapping of the residues of the second F3 module of NCAM with changes in the chemical shifts (in the presence of the third Ig module of the FGF-receptor) greater than 0.006 ppm for  $^1\text{H}$  or 0.03 ppm for  $^{15}\text{N}$  atoms, onto the structure of the module. The residues with strong changes in the chemical shifts (greater than 0.01 ppm for  $^1\text{H}$  or 0.1 ppm for  $^{15}\text{N}$  atoms) are colored blue (shown by A) and with weak changes – red (shown by B); all other residues are colored yellow (shown by C). *f*) Mapping of the residues of the second F3 module perturbed by AMP-PCP (blue color – shown by C) and the residues of the ATP binding Walker motif A (red color – shown by A) and Lys 85 (green color – shown by B) to the structure of the module; all other residues are colored yellow (shown by D). *g*) A possible arrangement of the complex of the second F3 module of NCAM with ATP.

**Figure 3.** Effect of the second F3 module, its FGF-receptor binding part (the FG loop peptide) on phosphorylation of the FGF-receptor 1. HEK293 cells, transiently transfected with a His-tagged version of the FGF-receptor 1, were stimulated for 20 min with either 5  $\mu\text{g}/\text{ml}$  F3,2 module or 50  $\mu\text{g}/\text{ml}$  FG loop peptide. *a*) The total amount of the FGF-receptor 1 and the amount of the FGF-receptor phosphorylation was estimated by immunoblotting using anti-pentahis (anti-His) and anti-phosphotyrosine (anti-P-tyr) antibodies, respectively. *b*) Quantification of the FGF-receptor phosphorylation by densitometric analysis of the band intensity. Phosphorylation was estimated relative to the control (untreated cells), which has been normalized to 1.0. Error bar represents one standard deviation (SD).  $P < 0.05$  by paired t test comparing treated cells with controls. The t test was performed on array of six independent sets of non-normalized data.

**Figure 4.** Effect of the second F3 module and its FGF-receptor binding part (the FG loop peptide) on neurite outgrowth from hippocampal neurons. *a*) Micrographs of the control (untreated) neurons. *b*) Micrographs of neurons treated with 5  $\mu\text{M}$  second F3 module. *c*) Plot of the neurite length versus the concentration of the second F3 module, the FG-loop peptide and a truncated version of the peptide. *d*) Effect of an anti-FGF-receptor antibody on neurite outgrowth induced by 5  $\mu\text{M}$  second F3 module or 50  $\mu\text{M}$  FG loop peptide.

**Figure 5.** Effect of various modifications of the FG loop peptide and a peptide derived from basic FGF on their peptides potency to stimulate neurite outgrowth from hippocampal neurons. Concentration of the various peptides was 50  $\mu\text{M}$ . *a*) Effect of truncations and substitutions of the various amino acids with Ala in the FG loop peptide or truncated versions of the

peptide. *b)* effect of substitution of the various amino acids with Ala in a peptide derived from basic FGF.

5 Figure 6. Sequential and structural similarity between heptameric peptides derived from the FGF-receptor binding part of NCAM and basic FGF. *a)* Sequential alignment of the heptamers, in which signs “|”, “|”, “:”, and “.” indicate the level of similarity in a decreasing order from strong to low similarity. *b)* Structural alignment of the backbone atoms of the heptamers from NCAM (blue color – shown by A) and basic FGF (red color – shown by B).

10 Figure 7. Effect of ATP (*a*) and AMP-PCP (*b*) on the potency of the second F3 module, the FG loop peptide and a modified version of the peptide to stimulate neurite outgrowth from hippocampal neurons. Neurons were stimulated with either 5  $\mu$ M second F3 module or 50  $\mu$ M peptide in the presence of various concentrations of ATP or AMP-PCP (0, 0.4, 1.0 mM). “cnt” stands for control, “F3” – the second F3 module, “FGL” – the FG loop peptide, and  
15 “YKK” – the FGL peptide in which Tyr 74, Lys 83 and Lys 85 were substituted for Ala.

Figure 8. Cerebellar granule neurons from seven days old rats were grown in the presence of 40 mM potassium. The cells were subsequently transferred to serum-free medium containing only five mM potassium and grown for two days in serum-free medium supplemented  
20 with various concentrations of the FGL-peptide (see figure 8). Subsequently, the number of cells were determined and the amount of cells surviving in the presence of high-concentration of potassium was set at 100 %. As can be seen approx. Only 60 % survived in the presence of brains-derived neurotrophic factor or basic fibroblast growth factor. When FGL was added in a dose-range of 2-250 microgram per ml statistically significant survival  
25 was observed up to 90 % of the positive control at a dose of 250 microgram per ml of the monomeric form of the FGL peptide.

Figure 9a. Peptides derived from the FG-loops of the neural cell adhesion molecules L1 and NCAM (third F3-module of L1 and first F3 module of NCAM) were prepared in different  
30 lengths, see Fig. 9a, and their effect on neurite outgrowth from primary hippocampal neurons were tested adding the various peptides in a concentration of 25 microM. Figure 9b. The NCAM peptides are referred to as FN3,1 and the L1 peptides are referred to as L1. The variants indicated in Fig. 9a are indicated by the number of amino acids in each peptide. As can be seen from the figure, the peptides had a stimulatory effect on neurite outgrowth reaching  
35 statistically significance for the nine amino acid variant of the Fgloop of first fibronectin type III module of NCAM and the nine amino acid variant of the FG-loop of the third fibronectin type III-module of L1.

**Detailed description of the invention**

The compound according to the invention relates to the induction of differentiation, modulation of proliferation, stimulation of regeneration, neuronal plasticity and survival of cells.

5

By the term FGL peptide is meant FG loop peptide of NCAM, which is an FGF receptor binding site of NCAM corresponding to SEQ ID NO: 1.

By the term "modulation" is meant a change, for example either an inhibition or a stimulation.

10

In the present context the term "interacting" refers to the direct or indirect contact between a compound of the invention and the FGF receptor, preferably a direct interaction. The term "direct interaction" means that the compound in question binds directly to the receptor.

15

By the term "cells presenting the FGF receptor" is meant cells expressing the FGF receptor on the external membrane of the cells, these cells are for example neurons, glial cells, all types of muscle cells, neuroendocrine cells, gonadal cells and kidney cells, endothelial cells and fibroblasts.

20

By the term "cells presenting an NCAM ligand" is meant cells expressing a receptor or ligand where to NCAM and/or parts of NCAM may bind (i.e.: so-called counter-receptor). Examples of NCAM ligands are the FGF (fibroblast growth factor) receptor, L1 or glyco-conjugates or glucose-aminoglycans, such as heparin, heparan sulphate proteoglycans, and chondroitin sulphate proteoglycans and ATP.

25

In the present context the wording "stimulate/promote survival" is used synonymously with the wording "preventing cell death" or "neuroprotection". By stimulating/promoting survival it is possible to prevent diseases or prevent further degeneration of the nervous system in individuals suffering from a degenerative disorder.

30

"Survival" refers to the process, wherein a cell has been traumatised and would under normal circumstances, with a high probability die, if not the compound of the invention was used to prevent said cell from degenerating, and thus promoting or stimulating survival of said traumatised cell.

35

"Neuronal plasticity" refers to the capability of remodelling neuronal connections.

Peripheral nerve cells possess to a limited extent a potential to regenerate and re-establish functional connections with their targets after various injuries. However, functional recovery is rarely complete and peripheral nerve cell damage remains a considerable problem. In the



central nervous system, the potential for regeneration is even more limited. Therefore, the identification of substances with the ability to prevent neuronal cell death in the peripheral and the central nervous system is significant and of great commercial value.

5 Accordingly, the present invention relates to the finding that a compound comprising the third Immunoglobulin (Ig3) module, and/or the fourth Immunoglobulin (Ig4) module, and/or the fifth Immunoglobulin (Ig5) module, and/or the first Fibronectin III (F3,1) module, and/or the second Fibronectin III (F3,2) module of neural cell adhesion molecule (NCAM), or a fragment, or  
10 a variant, is capable of interacting with the Fibroblast Growth Factor (FGF) receptor and/or Adenosine-Tri-Phosphate (ATP) and/or L1.

In the present context the NCAM molecule referred to is NCAM having the sequence shown in database SWISSPROT, accession No: P13591

15 In this sequence the position of the domains mentioned herein are as follows:

	Ig3:	203-308
	Ig4:	309-404
	Ig5:	405-500
20	F3,1:	501-601
	F3,2:	602-695

Further the invention concerns the finding that a compound comprising the fourth Immunoglobulin (Ig4) module, and/or the fifth Immunoglobulin (Ig5) module, and/or the first Fibro-  
25 nectin III (Fn3,1) module, and/or the second Fibronectin III (Fn3,2) module of neural cell adhesion molecule (NCAM), or a fragment, or a variant thereof, is capable of interacting with the FGF receptor and/or Adenosine-Tri-Phosphate (ATP) and/or L1, such as a compound comprising the fourth Immunoglobulin (Ig4) module, and/or the first Fibronectin III (Fn3,1) module, and/or the second Fibronectin III (Fn3,2) module of neural cell adhesion molecule  
30 (NCAM), or a fragment, or a variant thereof, is capable of interacting with the FGF receptor and/or Adenosine-Tri-Phosphate (ATP) and/or L1, or such as a compound comprising the fifth Immunoglobulin (Ig5) module, and/or the first Fibronectin III (Fn3,1) module, and/or the second Fibronectin III (Fn3,2) module of neural cell adhesion molecule (NCAM), or a fragment, or a variant thereof, is capable of interacting with the FGF receptor and/or Adenosine-  
35 Tri-Phosphate (ATP) and/or L1, such as a compound comprising the first Fibronectin III (Fn3,1) module, and/or the second Fibronectin III (Fn3,2) module of neural cell adhesion molecule (NCAM), or a fragment, or a variant thereof, is capable of interacting with the FGF receptor and/or Adenosine-Tri-Phosphate (ATP) and/or L1.

In the present context the "fragment thereof" is to be understood as being any part of the NCAM molecule capable of interacting with an FGF-receptor and/or ATP and/or L1 and through said binding modulate proliferation, and/or induce differentiation, and/or stimulate regeneration, neuronal plasticity and/or survival of cells. The "variant thereof" is to be understood as being any peptide sequence capable of interacting with FGF-receptors and/or ATP and/or L1, and via said binding induce differentiation, modulate proliferation, stimulate regeneration, neuronal plasticity and survival of cells. Thus, fragment or variant may be defined as

- i) Fragments/variants comprising an amino acid sequence capable of being recognised by an antibody also capable of recognising the predetermined NCAM amino acid sequence, and/or
- ii) Fragments/variants comprising an amino acid sequence capable of binding to a receptor moiety also capable of binding the predetermined NCAM amino acid sequence, and/or
- iii) Fragments/variants having at least a substantially similar binding affinity to at least one FGF receptor and/or ATP and/or L1 as said predetermined NCAM amino acid sequence.

In the present context the term "functional equivalent" means a variant as defined above.

The binding affinity of the compound according to the invention preferably has a binding affinity (Kd value) to NCAM and/or the NCAM ligand in the range of  $10^{-3}$  to  $10^{-10}$  M, such as preferably in the range of  $10^{-4}$  to  $10^{-8}$  M. According to the present invention the binding affinity is determined by one of the following assays of surface plasmon resonance analysis or nuclear magnetic resonance spectroscopy.

In the present context, a variant of the NCAM domains mentioned above is to be understood as being any compound interacting with any cell presenting a FGF receptor or an NCAM ligand, and/or L1 and through said interaction modulates proliferation, and/or induce differentiation, and/or stimulate regeneration, neuronal plasticity and/or survival of FGF receptor presenting cells, i.e. functional variants. Variants may be peptides, peptide derivatives, antibodies and non-peptide compounds such as small organic compounds, sugars and fats, as well as peptido-mimetics. In a preferred embodiment the variant is a peptide as discussed above.

In one embodiment variants may be understood to exhibit amino acid sequences gradually differing from the preferred predetermined sequence, as the number and scope of insertions, deletions and substitutions including conservative substitutions increase. This difference is measured as a reduction in homology between the predetermined sequence and the variant.

5

The peptides may be modified, for example by substitution of one or more of the amino acid residues. Both L-amino acids and D-amino acids may be used. Other modification may comprise derivatives such as esters, sugars, etc. Examples are methyl and acetyl esters. Polymerisation such as repetitive sequences or attachment to various carriers are well-known in the art, e.g. lysine backbones, such as lysine dendrimers carrying 4 peptides, 8 peptides, 16 peptides, or 32 peptides. Other carriers may be protein moieties, such as bovine serum albumin (BSA), or lipophilic dendrimers, or micelle-like carriers formed by lipophilic derivatives, or starburst (star-like) carbon chain polymer conjugates.

15 Variants of the fragments according to the invention may comprise, within the same variant, or fragments thereof or among different variants, or fragments thereof, at least one substitution, such as a plurality of substitutions introduced independently of one another. Variants of the complex, or fragments thereof may thus comprise conservative substitutions independently of one another, wherein at least one glycine (Gly) of said variant, or fragments thereof is substituted with an amino acid selected from the group of amino acids consisting of Ala, Val, Leu, and Ile, and independently thereof, variants, or fragments thereof, wherein at least one alanine (Ala) of said variants, or fragments thereof is substituted with an amino acid selected from the group of amino acids consisting of Gly, Val, Leu, and Ile, and independently thereof, variants, or fragments thereof, wherein at least one valine (Val) of said variant, 20 or fragments thereof is substituted with an amino acid selected from the group of amino acids consisting of Gly, Ala, Leu, and Ile, and independently thereof, variants, or fragments thereof, wherein at least one leucine (Leu) of said variant, or fragments thereof is substituted with an amino acid selected from the group of amino acids consisting of Gly, Ala, Val, and Ile, and independently thereof, variants, or fragments thereof, wherein at least one isoleucine (Ile) of said variants, or fragments thereof is substituted with an amino acid selected from the group of amino acids consisting of Gly, Ala, Val and Leu, and independently thereof, variants, or fragments thereof wherein at least one aspartic acids (Asp) of said variant, or fragments thereof is substituted with an amino acid selected from the group of amino acids consisting of Glu, Asn, and Gln, and independently thereof, variants, or fragments thereof, wherein at least one asparagine (Asn) of said variants, or fragments thereof is substituted with an amino acid selected from the group of amino acids consisting of Asp, Glu, and Gln, and independently thereof, variants, or fragments thereof, wherein at least one glutamine (Gln) of said variants, or fragments thereof is substituted with an amino acid selected from the group of amino acids consisting of Asp, Glu, and Asn, and wherein at least one phenylalanine 35

(Phe) of said variants, or fragments thereof is substituted with an amino acid selected from the group of amino acids consisting of Tyr, Trp, His, Pro, and preferably selected from the group of amino acids consisting of Tyr and Trp, and independently thereof, variants, or fragments thereof, wherein at least one tyrosine (Tyr) of said variants, or fragments thereof is substituted with an amino acid selected from the group of amino acids consisting of Phe, Trp, His, Pro, preferably an amino acid selected from the group of amino acids consisting of Phe and Trp, and independently thereof, variants, or fragments thereof, wherein at least one arginine (Arg) of said fragment is substituted with an amino acid selected from the group of amino acids consisting of Lys and His, and independently thereof, variants, or fragments thereof, wherein at least one lysine (Lys) of said variants, or fragments thereof is substituted with an amino acid selected from the group of amino acids consisting of Arg and His, and independently thereof, variants, or fragments thereof, and independently thereof, variants, or fragments thereof, and wherein at least one proline (Pro) of said variants, or fragments thereof is substituted with an amino acid selected from the group of amino acids consisting of Phe, Tyr, Trp, and His, and independently thereof, variants, or fragments thereof, wherein at least one cysteine (Cys) of said variants, or fragments thereof is substituted with an amino acid selected from the group of amino acids consisting of Asp, Glu, Lys, Arg, His, Asn, Gln, Ser, Thr, and Tyr.

It is clear from the above outline that the same equivalent or fragment thereof may comprise more than one conservative amino acid substitution from more than one group of conservative amino acids as defined herein above.

Conservative substitutions may be introduced in any position of a preferred predetermined peptide of the invention or fragment thereof. It may however also be desirable to introduce non-conservative substitutions, particularly, but not limited to, a non-conservative substitution in any one or more positions.

A non-conservative substitution leading to the formation of a functionally equivalent fragment of the peptide of the invention would for example differ substantially in polarity, for example a residue with a non-polar side chain (Ala, Leu, Pro, Trp, Val, Ile, Leu, Phe or Met) substituted for a residue with a polar side chain such as Gly, Ser, Thr, Cys, Tyr, Asn, or Gln or a charged amino acid such as Asp, Glu, Arg, or Lys, or substituting a charged or a polar residue for a non-polar one; and/or ii) differ substantially in its effect on peptide backbone orientation such as substitution of or for Pro or Gly by another residue; and/or iii) differ substantially in electric charge, for example substitution of a negatively charged residue such as Glu or Asp for a positively charged residue such as Lys, His or Arg (and vice versa); and/or iv) differ substantially in steric bulk, for example substitution of a bulky residue such as His, Trp, Phe or Tyr for one having a minor side chain, e.g. Ala, Gly or Ser (and vice versa).

5 Substitution of amino acids may in one embodiment be made based upon their hydrophobicity and hydrophilicity values and the relative similarity of the amino acid side-chain substituents, including charge, size, and the like. Exemplary amino acid substitutions which take various of the foregoing characteristics into consideration are well known to those of skill in the art and include: arginine and lysine; glutamate and aspartate; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine.

10 The addition or deletion of an amino acid may be an addition or deletion of from 2 to preferably 10 amino acids, such as from 2 to 8 amino acids, for example from 2 to 6 amino acids, such as from 2 to 4 amino acids. However, additions of more than 10 amino acids, such as additions from 2 to 10 amino acids, are also comprised within the present invention. In the multimeric forms additions/deletions may be made individually in each monomer of the multimer.

15 The invention also concerns non-peptide variants of the compounds disclosed herein. In particular, such variants should be understood to be compounds which bind to or in other ways interact with a Fibroblast Growth Factor (FGF) receptor and/or Adenosine-Tri-Phosphate (ATP) and/or L1 and thereby stimulating FGF receptor signalling and/or modulating proliferation and/or inducing differentiation and/or stimulating regeneration, neuronal plasticity and/or survival of cells presenting an FGF receptor.

20 It will thus be understood that the invention concerns a compound comprising at least one fragment capable of binding at least one receptor, or a variant thereof including any variants and functional equivalents of such at least one fragment.

30 A functional equivalent obtained by substitution may well exhibit some form or degree of native NCAM activity, and yet be less homologous, if residues containing functionally similar amino acid side chains are substituted. Functionally similar in the present respect refers to dominant characteristics of the side chains such as hydrophobic, basic, neutral or acidic, or the presence or absence of steric bulk. Accordingly, in one embodiment of the invention, the degree of identity between i) a given functional equivalent capable of effect and ii) a preferred predetermined fragment, is not a principal measure of the fragment as a variant or functional equivalent of a preferred predetermined peptide fragment according to the present invention.

35

Fragments sharing at least some homology with a preferred predetermined fragment of at least 3 amino acids, more preferably at least 5 amino acids, are to be considered as falling within the scope of the present invention when they are at least about 25 percent homolo-

gous with the preferred predetermined NCAM peptide, or fragment thereof, such as at least about 30 percent homologous, for example at least about 40 percent homologous, such as at least about 50 percent homologous, for example at least about 55 percent homologous, such as at least about 60 percent homologous, for example at least about 65 percent homologous, such as at least about 70 percent homologous, such as at least about 75 percent homologous, for example at least about 80 percent homologous, such as at least about 85 percent homologous.

Sequence identity can be measured using sequence analysis software (for example, the Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Centre, 1710 University Avenue, Madison, WI 53705), with the default parameters as specified therein.

Throughout the description and claims either the three letter code or the one letter code for natural amino acids are used. Where the L or D form has not been specified it is to be understood that the amino acid in question has the natural L form, cf. Pure & Appl. Chem. Vol. (56(5) pp 595-624 (1984) or the D form, so that the peptides formed may be constituted of amino acids of L form, D form, or a sequence of mixed L forms and D forms.

Where nothing is specified it is to be understood that the C-terminal amino acid of a polypeptide of the invention exists as the free carboxylic acid, this may also be specified as "-OH". However, the C-terminal amino acid of a compound of the invention may be the amidated derivative, which is indicated as "-NH<sub>2</sub>". Where nothing else is stated the N-terminal amino acid of a polypeptide comprise a free amino-group, this may also be specified as "H-".

Where nothing else is specified amino acid can be selected from any amino acid, whether naturally occurring or not, such as alfa amino acids, beta amino acids, and/or gamma amino acids. Accordingly, the group comprises but are not limited to: Ala, Val, Leu, Ile, Pro, Phe, Trp, Met, Gly, Ser, Thr, Cys, Tyr, Asn, Gln, Asp, Glu, Lys, Arg, His, Aib, Nal, Sar, Orn, Lysine analogues DAP and DAPA., 4Hyp

In one aspect of the invention the compound comprises the first Fibronectin III (F3,1) module of NCAM, or a fragment, or a variant thereof.

More particularly the invention relates to a compound comprising the first Fibronectin III (F3,1) module of neural cell adhesion molecule (NCAM), or a fragment, or a variant thereof capable of interacting with the FGF receptor.

Thus, in one preferred embodiment of the invention the compound comprises an amino acid sequence of the formula

L1-A-L2-B-L3-C-L4

wherein

one of A, B, C is selected from a basic amino acid,  
one of A, B, C is selected from a hydrophobic amino acid,  
one of A, B, C is glycine, and  
L1, L2, L3, L4 may be selected from a chemical bond or an amino acid sequence having  
n amino acid residues, wherein n is an integer of from 0 to 5.

In yet another embodiment B is glycine, A is a basic amino acid residue, and C is a hydrophobic amino acid residue.

Further, in another embodiment A is lysine (K) or arginine (R), and C is leucine (L) or alanine (A).

In another embodiment the compound of the invention comprises the sequence NGKGL (Asparagine, Glycine, Lysine, Glycine, Leucine), NGKGA, NGRGL and/or NGRGA. The sequence NGRGL is for example found in L1 and the sequence NGKGL is for example found in F3,1 of NCAM.

The invention further discloses that F3,2 is a ligand of the FGF receptor and is capable of interacting with cells presenting the FGF receptor. Thus, in another aspect of the invention the compound comprises a peptide homologous to the FG loop of the second FnIII module of the NCAM molecule, or a fragment, or a variant thereof.

A fragment comprising the FG loop of the F3,2 module of NCAM is particularly preferred. However, the invention is not limited to fragments of the F3,2 module comprising the FG loop. Deletions of such fragments generating functionally equivalent fragments comprising less than the FG loop are also comprised within the present invention. Functionally equivalent peptides and fragments thereof according to the present invention, may comprise less or more amino acid residues than the FG loop of the F3,2 module capable of binding to cells presenting an FGF receptor and/or NCAM ligands.

All functional equivalents of F3,2 peptides are included within the scope of this invention, regardless of the degree of homology that they show to a predetermined sequence of the F3,2 peptide or FG loop. The reason for this is that some parts of the binding regions are most likely readily mutable, or capable of being peptide deleted, without any significant effect on the binding activity of the resulting fragment.

Such a peptide, fragment or variant may be a compound comprising an amino acid sequence of the formula

L1-A-L2-B-L3-C-L4-D-L5

5

wherein

one of A, B, C, D is selected from a basic amino acid residue,

one of A, B, C, D is selected from a hydrophobic amino acid residue,

one of A, B, C, D is selected from an acidic amino acid residue,

10

one of A, B, C, D is glycine, and

L1, L2, L3, L4 and L5 may be selected from a chemical bond or an amino acid sequence having n amino acid residues, wherein n is an integer of from 0 to 5.

In particular a peptide, fragment or variant may be a compound comprising an amino acid sequence of the formula

15

A-B-L3-L4-C-L4 wherein

A is a hydrophobic amino acid residue,

20

B is an acidic amino acid residue,

L3 is one or more hydrophilic amino acid residue(s),

L4 is an amino acid sequence as defined above for L4, and

C is glycine.

In a preferred embodiment the compound comprise an amino acid sequence with the formula

25

AENQ-L4-G,

wherein A, E, N, Q, and G are the one-letter notation for amino acid residues, and L4 may be selected from a chemical bond or an amino acid sequence having n amino acid residues, wherein n is an integer of from 0 to 5.

30

In another embodiment a peptide, fragment or variant according to the invention may comprise a peptide homologous to the FG loop of the Fn3,2 module of the NCAM molecule, or a fragment, or a variant thereof. In one embodiment of the invention the peptide comprises a sequence having the amino acid residue motif A-E-N-Q-X-X-K, wherein X may be any amino acid residue. X may for example be selected individually from Glutamine (Q), Alanine (A), Glycine (G) and/or Asparagine (N).

35



In particular a peptide, fragment or variant may be a compound comprising an amino acid sequence of the formula

5 A-L2-B-L3-L4-C-L4 wherein

A is a hydrophobic amino acid residue,

L2 may be selected from a chemical bond or an amino acid sequence having n amino acid residues, wherein n is an integer of from 0 to 5

10 B is a basic amino acid residue,

L3 is one or more hydrophilic amino acid residue(s),

L4 may be selected from a chemical bond or an amino acid sequence having n amino acid residues, wherein n is an integer of from 0 to 5, and

C is glycine.

15

In a preferred embodiment the compound comprise an amino acid sequence with the formula

AM-B-L3-L4-G,

20

wherein A, M, and G are the one-letter notation for amino acid residues, L3 is one or more hydrophilic amino acid residue(s), and L4 may be selected from a chemical bond or an amino acid sequence having n amino acid residues, wherein n is an integer of from 0 to 5.

25

Examples may be the following sequence: AMKEDGR (SEQ ID NO: 7)

30

In yet another aspect of the invention the compound is capable of binding adenosine-tri-phosphate (ATP). Without being bound by theory it is speculated that release of ATP from the synapse may effect the coupling between NCAM and the FGF-receptor and therefore regulate the axonal growth in the area of a newly formed synaptic contact, i.e. that ATP indirectly effects the plasticity in the area of synaptic contact.

35

In one such embodiment the compound comprises a sequence of the formula

L1-A-L2-B-L3-C-L4-D-L5-E-L6, wherein

at least one of L1, L2, L3, or L4 comprises the amino acid residue Y and one of the other comprises the amino acid residue K, and L5 and/or L6 individually is K, and A, B, C, D, E is

any amino acid, with the proviso, that the distance between Y and K is at least 5 amino acids, such as at least 7 amino acid residues, such as at least 9 amino acid residues, such as at least 11 amino acid residues.

5 It is preferred that the amino acid Y is in closer proximity to the N-terminal than the amino acid K.

In a further embodiment of the invention the compound comprises a sequence of the formula A-Xaa-B-C-C, wherein

10

A is tyrosine (Y),  
B is glycine (G),  
C is lysine (K), and  
Xaa is any amino acid

15

In a preferred embodiment the compound according to the invention comprises at least one peptide comprising the sequence

20 EVYVVAENQQGKSKA (SEQ ID NO 1),  
EVAVVAENQQGASAA (SEQ ID NO 2),  
VAENQQGKS (SEQ ID NO 3),  
AENQQGKS (SEQ ID NO 4),  
AENQQGK (SEQ ID NO 5),  
AENQAGK (SEQ ID NO 6),  
25 AMKEDGR (SEQ ID NO 7),  
ALNGKGLG (SEQ ID NO 8),  
AFNGRGLG (SEQ ID NO 9),  
LNGKGLG (SEQ ID NO 10),  
LNGKGL (SEQ ID NO 11),  
30 ALNGKG (SEQ ID NO 12),  
LNGNALGE (SEQ ID NO 13),  
LNGKALG (SEQ ID NO 14),  
ALNGKAL (SEQ ID NO 15),  
ALNLKGLGD (SEQ ID NO 16),  
35 LNGKELG (SEQ ID NO 17),  
LTGKGLAE (SEQ ID NO 18),  
LKGKGLLE (SEQ ID NO 19),  
LNSKGLVE (SEQ ID NO 20),  
LNGKALVE (SEQ ID NO 21),

5 LAAKGLGE (SEQ ID NO 22),  
LDGKGL (SEQ ID NO 23),  
KGLGE (SEQ ID NO 24),  
DGKSLGE (SEQ ID NO 25),  
NGKGL (SEQ ID NO 26),  
NGRGL (SEQ ID NO 27),  
QAFNGRGLGP (SEQ ID NO 28),  
EVQAFNGRGLGPPAS (SEQ ID NO 29),  
AALNGKGLGE (SEQ ID NO 30),  
10 RLAALNGKGLGEIS (SEQ ID NO 31),  
ALNGKGAP (SEQ ID NO 32),  
VALNGKGAPR (SEQ ID NO 33),  
MYVALNGKGAPRRQ (SEQ ID NO 34),  
LNGRG (SEQ ID NO 35),  
15 LNGKG (SEQ ID NO 36),  
MYVALNGKGAPRRGQ (SEQ ID NO 37),  
MFLALDRRGPRPGG (SEQ ID NO 38),  
MFLALDSQGIPRQGQ (SEQ ID NO 39),  
MFVALNQKGIPVRG (SEQ ID NO 40),  
20 MFVALNQKGIPVKG (SEQ ID NO 41),  
MFVALNQKGLPVKG (SEQ ID NO 42),  
WYVSVNGKGRPRRG (SEQ ID NO 43),  
YYVALNKDGTPREG (SEQ ID NO 44),  
YYVALNKDGSPREG (SEQ ID NO 45),  
25 YFVALNKDGTPRDG (SEQ ID NO 46),  
WYVALNKRKGAKRG (SEQ ID NO 47),  
WYLGLNKEGEIMKG (SEQ ID NO 48),  
WFLGLNKEGQIMKG (SEQ ID NO 49),  
TYIALSKYGRVKRG (SEQ ID NO 50),  
30 WFLGLNKEGQAMKG (SEQ ID NO 51),  
WFLGLNKEGQVMKG (SEQ ID NO 52),  
WYLGLDKEGQVMKG (SEQ ID NO 53),  
WYLGLDKEGRVMKG (SEQ ID NO 54),  
WYVALKRTGQYKLG (SEQ ID NO 55),  
35 WFLGLKKNKSCKRG (SEQ ID NO 56),  
ANRYLAMKEDGRLLAS (SEQ ID NO 57),  
TGQYLAMDTGGLLYGS (SEQ ID NO 58),  
TGQYLAMDTDGGLLYGS (SEQ ID NO 59),  
TGQYLAMDTSGGLLYGS (SEQ ID NO 60),

5 TGQFLAMDTDGLLYGS (SEQ ID NO 61),  
SRFFVAMSSKGKLYGS (SEQ ID NO 62),  
SRFFVAMSSRGKLFV (SEQ ID NO 63),  
SRFFVAMSSRGRLYGS (SEQ ID NO 64),  
SGLFVAMNSKGKLYGS (SEQ ID NO 65),  
SNKFLAMSKKGKLHAS (SEQ ID NO 66),  
SALFVAMNSKGRLYAT (SEQ ID NO 67),  
SALFIAMNSKGRLYTT (SEQ ID NO 68),  
10 SGRYLAMNKRGRLYAS (SEQ ID NO 69),  
SEYYLAMNKEGKLYAK (SEQ ID NO 70),  
SEYYLAMNKQGLYAK (SEQ ID NO 71),  
SEFYLAMNKEGKLYAK (SEQ ID NO 72),  
SGLYLGMNEKGELYGS (SEQ ID NO 73),  
SGLYLGMNDKGELYGS (SEQ ID NO 74),  
15 SGLYLGMNERGELYGS (SEQ ID NO 75),  
SGLYLGMNERGELFGS (SEQ ID NO 76),  
SNYYLAMNKKGKLYGS (SEQ ID NO 77),  
SGFYVAMNRRGRLYGS (SEQ ID NO 78),  
TGLYIAMNGEGYLYPS (SEQ ID NO 79),  
20 ASLYVAMNGEGYLYSS (SEQ ID NO 80),  
TKLYLAMNSEGYLYTS (SEQ ID NO 81),  
TGLYICMNKKGKLIAS (SEQ ID NO 82),  
LGHYMAMNAEGLLYSS (SEQ ID NO 83),  
TEFYLCMNRKGKLVGK (SEQ ID NO 84),  
25 SVRYLCMGADGKMQL (SEQ ID NO 85),  
WVGLKKNKS CKRG (SEQ ID NO 86),  
WYVALKRTGQ YKLG (SEQ ID NO 87),  
WYVSVNGKGR PRRG (SEQ ID NO 88),  
GMFIALSKNG KTKKG (SEQ ID NO 89),  
30 GMFMALSKNG RTKKG (SEQ ID NO 91),  
GMFIALSKNG KAKKG (SEQ ID NO 92),  
WYVALNKRKG AKRG (SEQ ID NO 93),  
TYIALSKYGR VKRG (SEQ ID NO 94),  
MFVALNQKGI PVRG (SEQ ID NO 95),  
35 MFVALNQKGI PVKG (SEQ ID NO 96),  
MFVALNQKGL PVKG (SEQ ID NO 97),  
WYMAFTRKGR PRKG (SEQ ID NO 98),  
YYVALNKDGT PREG (SEQ ID NO 99),  
MYVALNGKGA PRRGQ (SEQ ID NO 100),

WYLGLDKEGQ VMKG (SEQ ID NO 101),  
WYLGLDKEGR VMKG (SEQ ID NO 102),  
WFLGLNKEGQ IMKG (SEQ ID NO 103),  
WYLGLNKEGE IMKG (SEQ ID NO 104),  
5 WFLGLNKEGQ AMKG (SEQ ID NO 105),  
WFLGLNKEGQ VMKG (SEQ ID NO 106),  
YYVALNKDGS PREG (SEQ ID NO 107),  
WFMAFTRQGR PRQ (SEQ ID NO 108),  
WFBVLKKNKS CKRG (SEQ ID NO 109),  
10 WYVGFTKKGR PRKG (SEQ ID NO 110),  
YFVALNKDGT PRDG (SEQ ID NO 111),  
MFLALDRRGG PRPGG (SEQ ID NO 112),  
MFLALDSQGI PRQQG (SEQ ID NO 113),  
TGQYLAMDTE GLLYGS (SEQ ID NO 114),  
15 TGQYLAMDTD GLLYGS (SEQ ID NO 115),  
TGQYLAMDTG GLLYGS (SEQ ID NO 116),  
TGQFLAMDTD GLLYGS (SEQ ID NO 118),  
ANRYLAMKED GRLLAS (SEQ ID NO 119),  
SGRYLAMNKR GRLYAS (SEQ ID NO 120),  
20 SRFFVAMSSK GKLYGS (SEQ ID NO 121),  
SRFFVAMSSR GKLFGV (SEQ ID NO 122),  
SRFFVAMSSR GRLYGS (SEQ ID NO 123),  
SGLFVAMNSK GKLYGS (SEQ ID NO 124),  
SNKFLAMSKK GKLHAS (SEQ ID NO 125),  
25 SALFVAMNSK GRLYAT (SEQ ID NO 126),  
SALFIAMNSK GRLYTT (SEQ ID NO 127),  
SEYYLAMNKE GKLYAK (SEQ ID NO 128),  
SEYYLAMNKQ GLYAK (SEQ ID NO 129),  
SEFYLAMNKE GKLYAK (SEQ ID NO 130),  
30 TGLYICMNKK GKLIAS (SEQ ID NO 131),  
SGLYLGMNEK GELYGS (SEQ ID NO 132),  
SNYYLAMNKK GKLYGS (SEQ ID NO 133),  
LGHYMAMNAE GLLYSS (SEQ ID NO 134),  
ASLYVAMNGE GYLYSS (SEQ ID NO 135),  
35 TKLYLAMNSE GYLYTS (SEQ ID NO 136),  
TGLYIAMNGE GYLYPS (SEQ ID NO 137),  
SVRYLCMSAD GKIYG (SEQ ID NO 138),  
SGLYLGMNER GELYGS (SEQ ID NO 139),  
SGLYLGMNER GELFGS (SEQ ID NO 140),

SEKYICMNRK GKLIG (SEQ ID NO 141),  
TEFYLCMNRK GKLVGK (SEQ ID NO 142),  
SVRYLCMGAD GKMQL (SEQ ID NO 143),  
SGLYLGMNDK GELYGS (SEQ ID NO 144),  
5 TSRFLCQRPD GALYG (SEQ ID NO 145),  
ASRFLCQQPD GALYG (SEQ ID NO 146),  
SGFYVAMNRR GRLYGS (SEQ ID NO 147),  
SRRYLCMDFR GNIFGS (SEQ ID NO 148),  
TRRFLCMDLH GNIFGS (SEQ ID NO 149),  
10 GLKKNNGSC (SEQ ID NO 150),  
ALKRTGQY (SEQ ID NO 151),  
SVNGKGRP (SEQ ID NO 152),  
IALSKNGKT (SEQ ID NO 153),  
MALSKNGRT (SEQ ID NO 154),  
15 IALSKNGKA (SEQ ID NO 155),  
ALNKRGA (SEQ ID NO 156),  
ALSKYGRV (SEQ ID NO 157),  
ALNQKGIP (SEQ ID NO 158),  
ALNQKGLP (SEQ ID NO 159),  
20 AFTRKGRP (SEQ ID NO 160),  
ALNKDGTP (SEQ ID NO 161),  
ALNGKGAPR (SEQ ID NO 162),  
GLDKEGQV (SEQ ID NO 163),  
GLDKEGRV (SEQ ID NO 164),  
25 GLNKEGQI (SEQ ID NO 165),  
GLNKEGEI (SEQ ID NO 166),  
GLNKEGQA (SEQ ID NO 167),  
GLNKEGQV (SEQ ID NO 168),  
ALNKDGSP (SEQ ID NO 169),  
30 AFTRQGR (SEQ ID NO 170),  
GLKKNNGSC (SEQ ID NO 171),  
GFTKKGRP (SEQ ID NO 172),  
ALNKDGTP (SEQ ID NO 173),  
ALDRRGPR (SEQ ID NO 174),  
35 ALDSQGIPR (SEQ ID NO 175),  
AMDTDGL (SEQ ID NO 176),  
AMDTEGL (SEQ ID NO 177),  
AMDTSGL (SEQ ID NO 178),  
AMKEDGR (SEQ ID NO 179),

5 AMNKRGR (SEQ ID NO 180),  
AMSSKGK (SEQ ID NO 181),  
AMSSRGK (SEQ ID NO 182),  
AMNSKGK (SEQ ID NO 183),  
AMSKKGK (SEQ ID NO 184),  
AMNSKGR (SEQ ID NO 185),  
AMNKEGK (SEQ ID NO 186),  
AMNKEGK (SEQ ID NO 187),  
10 AMNKQGL (SEQ ID NO 188),  
CMNKKGK (SEQ ID NO 189),  
GMNEKGE (SEQ ID NO 190),  
AMNKKGK (SEQ ID NO 191),  
AMNAEGL (SEQ ID NO 192),  
AMNGEGY (SEQ ID NO 193),  
15 AMNSEGY (SEQ ID NO 194),  
AMNGEGY (SEQ ID NO 195),  
CMSADGK (SEQ ID NO 196),  
GMNERGE (SEQ ID NO 197),  
CMNKRKGK (SEQ ID NO 198),  
20 CMNRKGK (SEQ ID NO 199),  
CMGADGK (SEQ ID NO 200),  
GMNDKGE (SEQ ID NO 201),  
LCQRPDG (SEQ ID NO 202),  
LCQQPDG (SEQ ID NO 203),  
25 AMNRRGR (SEQ ID NO 204),  
CMDFRGN (SEQ ID NO 205), and/or  
CMDLHGN (SEQ ID NO 206)

30 The sequences listed above may be part of naturally occurring proteins, for example the peptide having the sequence of AMKEDGR (SEQ ID NO 7) is found in the Fibroblast Growth factor 2 (FGF 2).

In one embodiment of the invention the sequences 86-206 are homologue sequences to the FGL peptide (FG loop peptide) in the F3,I and F3,II domains.

35 By the term "homologue" is meant a sequence which is structurally and/or functionally identical with the FGL peptide of the invention. Sequence identity can be measured using sequence analysis software (for example, the Sequence Analysis Software Package of the

Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705), with the default parameters as specified therein.

5 In one embodiment of the invention the compound is capable of interacting with the Fibroblast Growth Factor (FGF) receptor. A variety of FGF receptors exist. It is preferred that the FGF receptor may be selected from FGF receptor I, FGF receptor II, FGF receptor III, FGF receptor IV. In a more preferred embodiment the FGF receptor I signalling is stimulated.

10 In a preferred embodiment of the invention the interaction of the present compound with the FGF receptor is resulting in the stimulation of FGF receptor signalling. When the compound of the invention interacts with the FGF receptor a cascade of chemical events and physiological changes occurs. The interaction of the present compound with the FGF receptor causes presumably conformational changes or clustering of the receptor by which chemical  
15 signals are created and propagated from the site of interaction to the inside of the cell. The signals are said to be transduced from the outside to the inside of the cell, the latter resulting in a physiological response of the cell.

According to the invention the FGF receptor signalling is measured as phosphorylation of the FGF receptor when a predetermined concentration of the compound is applied to cells expressing the FGF receptor. The degree of phosphorylation is at least 20% above the control  
20 value, such as at least 20-200 %, for example at least 50-200%.

When testing the present compound with respect to for example measuring signalling the concentration of the said compound may be between 0.1-1000  $\mu$ M, 1-1000  $\mu$ M, for example  
25 1-200  $\mu$ M, for example 10-200  $\mu$ M, such as 20-180  $\mu$ M, for example 30-160  $\mu$ M, such as 40-140  $\mu$ M, for example 50-130  $\mu$ M, such as 60-120  $\mu$ M, for example 70-110  $\mu$ M, such as 80-100  $\mu$ M.

30 The amino acid sequence of the compound of the invention may be of any suitable length, in that the length of the amino acid sequence is dictated by the functionality of the peptide and the formulation of the compound into a pharmaceutical composition. Thus, the compound normally comprises amino acid residues in the range of from 3-100 amino acid residues, such as from 10-90 amino acid residues, for example from 15-85 amino acid residues, such as from 20-80 amino acid residues, for example from 25-75 amino acid residues, such as  
35 from 30-70 amino acid residues, for example from 35-65 amino acid residues, such as from 40-60 amino acid residues, for example from 45-55 amino acid residues.

In another aspect the compound comprises amino acid residues in the range of from 3 to 20 amino acid residues, such as from 3-19 amino acid residues, for example from 3-18 amino



acid residues, such as from 3-17 amino acid residues, for example from 3-16 amino acid residues, such as from 3-15 amino acid residues, for example from 3-14 amino acid residues, such as from 3-13 amino acid residues.

5 The peptides of the invention may serve as tools for identifying a motif in peptide ligands expected to bind to the FGF receptor and/or ATP. Such peptide ligands may be found through a peptide and/or a non-peptide library. Any peptide sequence comprising said peptides capable of binding the FGF receptor and/or ATP and/or L1 are part of the present invention.

10 These mentioned compounds and compositions can be used to treat conditions affecting the peripheral and/or the central nervous system and/or muscles and other tissues expressing FGF receptors or NCAM ligands as well as other conditions in which a stimulation of FGF receptor function or the function of other NCAM ligand is beneficial.

15 Putative artificial ligands may be selected and identified from peptide or non-peptide libraries. Any peptide or non-peptide library may be used. Synthetic peptide and non-peptide libraries as well as libraries containing fragmented natural occurring proteins, may be used in the search for useful peptides. Any kind of libraries comprising non-peptide compounds may  
20 similarly be used.

Peptides characterised by a certain sequence of amino acids may be a variant of a certain area of a protein. Naturally occurring proteins consist of L-amino acid residues. However, artificial peptides may also consist of or comprise D-amino acid residues. By combinatorial  
25 chemistry, mixtures of beads carrying peptides of equal length can be constructed, in which each bead carries peptides of a unique sequence (Lam et al., 1991). Such a mixture of peptides on beads is called a peptide library.

30 In the present invention, peptides, fragments or variants may be identified by screening synthetic random peptide libraries comprising resin-bound peptides with purified recombinant NCAM or recombinant FGF receptor or recombinant L1 or other NCAM ligands. The synthesis of the resin-bound one-bead one-peptide library may be performed using the portioning, mix procedure of Furka, A., Sebestyén, F., Asgedom, M. And Dibó, G. (1991) Int. J. Pep. Prot. Res. 37, 487-493) optionally modified as known to the person skilled in the art. It is to be understood that the method chosen for identification and selection of interesting peptides is not  
35 critical for the identification of a putative motif.

Libraries of small organic compounds may be screened to identify FGF receptor ligands or L1 ligands or other NCAM counter-receptor ligands capable of interacting with Fibroblast

Growth Factor (FGF) receptor and/or Adenosine-Tri-Phosphate (ATP) and/or L1. Such libraries or their construction are commonly known and the screening for useful ligands may follow the methods for screening disclosed in the present specification, or in ways obvious to the skilled person.

5

The compound of the present invention may preferably be in the form of an oligomer (multimer) of monomers, wherein each monomer is as defined for the compound above. Particularly, multimeric peptides such as dendrimers may form conformational determinants or clusters due to the presence of multiple flexible peptide monomers. In one embodiment the compound is a dimer. In a more preferred embodiment the compound is a dendrimer, such as four peptides linked to a lysine backbone, or coupled to a polymer carrier, for example a protein carrier, such as BSA. Polymerisation such as repetitive sequences or attachment to various carriers are well-known in the art, e.g. lysine backbones, such as lysine dendrimers carrying 4 peptides, 8 peptides, 16 peptides, or 32 peptides. Other carriers may be lipophilic dendrimers, or micelle-like carriers formed by lipophilic derivatives, or starburst (star-like) carbon chain polymer conjugates.

10

15

20

The compound preferably comprises monomers independently capable of stimulating FGF receptor signalling and/or modulating proliferation and/or differentiation, regeneration, survival and/or neuronal plasticity of cells presenting an FGF receptor and/or NCAM ligand/counterreceptor and/or L1.

25

The individual monomers may be homologous, i.e. identical to one another, or the individual monomers may be heterologous, i.e. different from one another. The latter type of monomers may comprise at least two different monomers. In general dimers and multimers may comprise two or more identical monomers, or two or more monomers different from one another.

### **Pharmaceutical composition**

30

35

The invention also relates to a pharmaceutical composition comprising one or more of the compounds defined above comprising the third Immunoglobulin (Ig3) module, and/or the fourth Immunoglobulin (Ig4) module, and/or the fifth Immunoglobulin (Ig5) module, and/or the first Fibronectin III (Fn3,1) module, and/or the second Fibronectin III (Fn3,2) module of neural cell adhesion molecule (NCAM), or a fragment, or a variant thereof, wherein the compound is capable of interacting with an Fibroblast Growth Factor (FGF) receptor and/or Adenosine-Tri-Phosphate (ATP) and/or L1.

In the present context the term "pharmaceutical composition" is used synonymously with the term "medicament".

In one embodiment the pharmaceutical composition comprises the NCAM F3,2 module, or a fragment thereof, or a variant thereof. In another embodiment the composition comprises the NCAM F3,1 module, or a fragment thereof, or a variant thereof.

5

The compositions are preferably formulated as multimers or dimers as discussed above.

10

The invention further concerns a pharmaceutical composition capable of stimulating FGF receptor signalling and/or modulating proliferation and/or inducing differentiation and/or stimulating regeneration, neuronal plasticity and/or survival of cells presenting an FGF receptor.

15

The pharmaceutical composition may in one aspect prevent death of cells *in vitro* or *in vivo*, wherein the composition is administered to a subject, *in vitro* or *in vivo* in an effective amount of one or more of the compounds described above or a composition as described below, so as to prevent cell death of FGF receptor presenting cells and/or L1 presenting cells in several tissues and organs as discussed herein.

20

The medicament of the invention comprises an effective amount of one or more of the compounds as defined above, or a composition as defined above in combination with pharmaceutically acceptable additives. Such medicament may suitably be formulated for oral, percutaneous, intramuscular, intravenous, intracranial, intrathecal, intracerebroventricular, intranasal or pulmonal administration.

25

Strategies in formulation development of medicaments and compositions based on the compounds of the present invention generally correspond to formulation strategies for any other protein-based drug product. Potential problems and the guidance required to overcome these problems are dealt with in several textbooks, e.g. "Therapeutic Peptides and Protein Formulation. Processing and Delivery Systems", Ed. A.K. Banga, Technomic Publishing AG, Basel, 1995.

30

35

Injectables are usually prepared either as liquid solutions or suspensions, solid forms suitable for solution in, or suspension in, liquid prior to injection. The preparation may also be emulsified. The active ingredient is often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like, and combinations thereof. In addition, if desired, the preparation may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, or which enhance the effectiveness or transportation of the preparation.

Formulations of the compounds of the invention can be prepared by techniques known to the person skilled in the art. The formulations may contain pharmaceutically acceptable carriers and excipients including microspheres, liposomes, microcapsules, nanoparticles or the like.

5

The preparation may suitably be administered by injection, optionally at the site, where the active ingredient is to exert its effect. Additional formulations which are suitable for other modes of administration include suppositories, nasal, pulmonal and, in some cases, oral formulations. For suppositories, traditional binders and carriers include polyalkylene glycols or triglycerides. Such suppositories may be formed from mixtures containing the active ingredient(s) in the range of from 0.5% to 10%, preferably 1-2%. Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and generally contain 10-95% of the active ingredient(s), preferably 25-70%.

10

15

Other formulations are such suitable for nasal and pulmonal administration, e.g. inhalators and aerosols.

20

25

The active compound may be formulated as neutral or salt forms. Pharmaceutically acceptable salts include acid addition salts (formed with the free amino groups of the peptide compound) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic acid, oxalic acid, tartaric acid, mandelic acid, and the like. Salts formed with the free carboxyl group may also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.

30

35

The preparations are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective. The quantity to be administered depends on the subject to be treated, including, e.g. the weight and age of the subject, the disease to be treated and the stage of disease. Suitable dosage ranges are per kilo body weight normally of the order of several hundred  $\mu\text{g}$  active ingredient per administration with a preferred range of from about 0.1  $\mu\text{g}$  to 5000  $\mu\text{g}$  per kilo body weight. Using monomeric forms of the compounds, the suitable dosages are often in the range of from 0.1  $\mu\text{g}$  to 5000  $\mu\text{g}$  per kilo body weight, such as in the range of from about 0.1  $\mu\text{g}$  to 3000  $\mu\text{g}$  per kilo body weight, and especially in the range of from about 0.1  $\mu\text{g}$  to 1000  $\mu\text{g}$  per kilo body weight. Using multimeric forms of the compounds, the suitable dosages are often in the range of from 0.1  $\mu\text{g}$  to

1000  $\mu$ g per kilo body weight, such as in the range of from about 0.1  $\mu$ g to 750  $\mu$ g per kilo body weight, and especially in the range of from about 0.1  $\mu$ g to 500  $\mu$ g per kilo body weight such as in the range of from about 0.1  $\mu$ g to 250  $\mu$ g per kilo body weight. In particular when administering nasally smaller dosages are used than when administering by other routes.

5 Administration may be performed once or may be followed by subsequent administrations. The dosage will also depend on the route of administration and will vary with the age and weight of the subject to be treated. A preferred dosage of multimeric forms would be in the interval 1 mg to 70 mg per 70 kg body weight.

10 For most indications a localised or substantially localised application is preferred.

Some of the compounds of the present invention are sufficiently active, but for some of the others, the effect will be enhanced if the preparation further comprises pharmaceutically acceptable additives and/or carriers. Such additives and carriers will be known in the art. In

15 some cases, it will be advantageous to include a compound, which promote delivery of the active substance to its target.

In many instances, it will be necessary to administrate the formulation multiple times. Administration may be a continuous infusion, such as intraventricular infusion or administration

20 in more doses such as more times a day, daily, more times a week, weekly, etc. It is preferred that administration of the medicament is initiated before or shortly after the individual has been subjected to the factor(s) that may lead to cell death. Preferably the medicament is administered within 8 hours from the factor onset, such as within 5 hours from the factor onset. Many of the compounds exhibit a long term effect whereby administration of the com-

25 pounds may be conducted with long intervals, such as 1 week or 2 weeks.

In connection with the use in nerve guides, the administration may be continuous or in small portions based upon controlled release of the active compound(s). Furthermore, precursors may be used to control the rate of release and/or site of release. Other kinds of implants and

30 well as oral administration may similarly be based upon controlled release and/or the use of precursors.

As discussed above, the present invention relates to treatment of individuals for inducing differentiation, modulating proliferation, stimulate regeneration, neuronal plasticity and survival of FGF receptor presenting cells or L1 presenting cells or other NCAM ligand presenting cells *in vitro* or *in vivo*, the treatment involving administering an effective amount of one

35 or more compounds as defined above.

Another strategy for administration is to implant or inject cells capable of expressing and

secreting the compound in question. Thereby the compound may be produced at the location where it is going to act.

### Treatment

5

In a further aspect, the present invention relates to said peptides, fragments, or variants thereof for use in the modulation of proliferation and/or induction of differentiation and/or stimulation of regeneration, neuronal plasticity and/or survival of cells presenting an FGF receptor. The use is for the treatment for preventing diseases and conditions of the central and peripheral nervous system, and of the muscles or of various organs.

10

Treatment by the use of the compounds/compositions according to the invention is in one embodiment useful for inducing differentiation, modulating proliferation, stimulate regeneration, neuronal plasticity and survival of cells being implanted or transplanted. This is particularly useful when using compounds having a long term effect.

15

In further embodiment the treatment may be for stimulation of survival of cells which are at risk of dying due to a variety of factors, such as traumas and injuries, acute diseases, chronic diseases and/or disorders, in particular degenerative diseases normally leading to cell death, other external factors, such as medical and/or surgical treatments and/or diagnostic methods that may cause formation of free radicals or otherwise have cytotoxic effects, such as X-rays and chemotherapy. In relation to chemotherapy the NCAM binding compounds according to the invention are useful in cancer treatment of all cancer cells presenting NCAM ligands.

20

Thus, the treatment comprises treatment and/or prophylaxis of cell death in relation to diseases or conditions of the central and peripheral nervous system, such as postoperative nerve damage, traumatic nerve damage, e.g. resulting from spinal cord injury, impaired myelination of nerve fibers, postischaemic damage, e.g. resulting from a stroke, multiinfarct dementia, multiple sclerosis, nerve degeneration associated with diabetes mellitus, neuro-muscular degeneration, schizophrenia, Alzheimer's disease, Parkinson's disease, or Huntington's disease.

25

30

Also, in relation to diseases or conditions of the muscles including conditions with impaired function of neuro-muscular connections, such as genetic or traumatic atrophic muscle disorders; or for the treatment of diseases or conditions of various organs, such as degenerative conditions of the gonads, of the pancreas, such as diabetes mellitus type I and II, of the kidney, such as nephrosis the compounds according to the invention may be used for inducing differentiation, modulating proliferation, stimulate regeneration, neuronal plasticity and sur-

35

vival , i.e. stimulating survival.

Furthermore, the compound and/or pharmaceutical composition may be for preventing cell death of heart muscle cells, such as after acute myocardial infarction, in order to induce angiogenesis. Furthermore, in one embodiment the compound and/or pharmaceutical composition is for the stimulation of the survival of heart muscle cells, such as survival after acute myocardial infarction. In another aspect the compound and/or pharmaceutical composition is for revascularisation, such as after injuries.

It is also within the scope of the invention to use the compound and/or pharmaceutical composition for the promotion of wound-healing. The present compounds are capable of stimulating angiogenesis and thereby promote the wound healing process.

The invention further discloses the use of the compound and/or pharmaceutical composition in the treatment of cancer. NCAM regulates motility and inhibits cancer cells from spreading.

In yet a further embodiment the use of the compound and/or pharmaceutical composition is for the stimulation of the ability to learn and/or of the short and/or long term memory.

In particular the compound and/or pharmaceutical composition of the invention may be used in the treatment of clinical conditions, such as Neoplasms such as malignant neoplasms, benign neoplasms, carcinoma in situ and neoplasms of uncertain behavior, diseases of endocrine glands, such as diabetes mellitus, psychoses, such as senile and presenile organic psychotic conditions, alcoholic psychoses, drug psychoses, transient organic psychotic conditions, Alzheimer's disease, cerebral lipidoses, epilepsy, general paresis [syphilis], hepatolenticular degeneration, Huntington's chorea, Jakob-Creutzfeldt disease, multiple sclerosis, Pick's disease of the brain, syphilis, Schizophrenic disorders, affective psychoses, neurotic disorders, personality disorders, including character neurosis, nonpsychotic personality disorder associated with organic brain syndromes, paranoid personality disorder, fanatic personality, paranoid personality (disorder), paranoid traits, sexual deviations and disorders, mental retardation, disease in the nervous system and sense organs, cognitive anomalies, inflammatory disease of the central nervous system, such as meningitis, encephalitis, Cerebral degenerations such as Alzheimer's disease, Pick's disease, senile degeneration of brain, communicating hydrocephalus, obstructive hydrocephalus, Parkinson's disease including other extra pyramidal disease and abnormal movement disorders, spinocerebellar disease, cerebellar ataxia, Marie's, Sanger-Brown, Dyssynergia cerebellaris myoclonica, primary cerebellar degeneration, such as spinal muscular atrophy, familial, juvenile, adult spinal muscular atrophy, motor neuron disease, amyotrophic lateral sclerosis, motor neuron disease, progressive bulbar palsy, pseudobulbar palsy, primary lateral sclerosis, other anterior

5 horn cell diseases, anterior horn cell disease, unspecified, other diseases of spinal cord, syringomyelia and syringobulbia, vascular myelopathies, acute infarction of spinal cord (embolic) (nonembolic), arterial thrombosis of spinal cord, edema of spinal cord, subacute necrotic myelopathy, subacute combined degeneration of spinal cord in diseases classified  
10 elsewhere, myelopathy, drug-induced, radiation-induced myelitis, disorders of the autonomic nervous system, disorders of peripheral autonomic, sympathetic, parasympathetic, or vegetative system, familial dysautonomia [Riley-Day syndrome], idiopathic peripheral autonomic neuropathy, carotid sinus syncope or syndrome, cervical sympathetic dystrophy or paralysis. peripheral autonomic neuropathy in disorders classified elsewhere, amyloidosis, diseases of  
15 the peripheral nerve system, brachial plexus lesions, cervical rib syndrome, costoclavicular syndrome, scalenus anterior syndrome, thoracic outlet syndrome, brachial neuritis or radiculitis, including in newborn. Inflammatory and toxic neuropathy, including acute infective polyneuritis, Guillain-Barre syndrome, Postinfectious polyneuritis, polyneuropathy in collagen vascular disease, disorders affecting multiple structures of eye, purulent endophthalmitis, diseases of the ear and mastoid process, chronic rheumatic heart disease, ischaemic heart  
20 disease, arrhythmia, diseases in the pulmonary system, abnormality of organs and soft tissues in newborn, including in the nerve system, complications of the administration of anesthetic or other sedation in labor and delivery, diseases in the skin including infection, insufficient circulation problem, injuries, including after surgery, crushing injury, burns. Injuries to nerves and spinal cord, including division of nerve, lesion in continuity (with or without open wound), traumatic neuroma (with or without open wound), traumatic transient paralysis (with or without open wound), accidental puncture or laceration during medical procedure, injury to optic nerve and pathways, optic nerve injury, second cranial nerve, injury to optic chiasm, injury to optic pathways, injury to visual cortex, unspecified blindness, injury to other cranial  
25 nerve(s), injury to other and unspecified nerves. Poisoning by drugs, medicinal and biological substances, genetic or traumatic atrophic muscle disorders; or for the treatment of diseases or conditions of various organs, such as degenerative conditions of the gonads, of the pancreas, such as diabetes mellitus type I and II, of the kidney, such as nephrosis.

30 A further aspect of the invention is a process of producing a pharmaceutical composition, comprising mixing an effective amount of one or more of the compounds of the invention, or a pharmaceutical composition according to the invention with one or more pharmaceutically acceptable additives or carriers, and administer an effective amount of at least one of said compound, or said pharmaceutical composition to a subject.

35

In one embodiment of the process as mentioned above, the compounds are used in combination with a prosthetic device, wherein the device is a prosthetic nerve guide. Thus, in a further aspect, the present invention relates to a prosthetic nerve guide, characterised in that it comprises one or more of the compounds or the pharmaceutical composition as defined



above. Nerve guides are known in the art.

Another aspect of the invention relates to the use of a compound as defined above. In particular the use of a compound according to the invention is for the production of a pharmaceutical composition. The pharmaceutical composition is preferably for the treatment or prophylaxis of any of the diseases and conditions mentioned above.

In yet a further aspect the invention relates to a method of treating a disease or condition as discussed above by administering a compound as defined herein.

## Experimental

The following are non-limiting examples illustrating the present invention.

## Materials and methods

### Methods

The  $^{15}\text{N}$ -labelled and unlabelled protein corresponding to aminoacids 612-705 of rat NCAM (swissprot p13596) was produced in yeast *P. pastoris*. The expression product contains two N-terminal residues, A and G, from the vector and is sequentially numbered from 1 to 96. 2 mM unlabelled and 1 mM  $^{15}\text{N}$ -labelled protein (in 30 mM NaCl, 10 mM sodium phosphate buffer, pH 7.27) were used. The  $^1\text{H}$  and  $^{15}\text{N}$  resonances were assigned from spectra of DQF-COSY, TOCSY,  $^{15}\text{N}$  TOCSY-HSQC NMR experiments. All data were acquired at 298 K. The NOE constraints were derived from 80/200 ms NOESY and 125ms  $^{15}\text{N}$ -NOESY-HSQC spectra with upper bounds of 2.7, 3.3 and 6.0 Å increased by 0.5 Å if the constraint included a methyl group. 40  $\phi$  angles restraints with bounds of  $-120\pm 40^\circ$  and  $-57\pm 40^\circ$  (derived from the  $^3J_{\text{HNH}\alpha}$  coupling constants) and 4  $\chi^1$  angles (for valines) were applied. 96 structures were generated with a distance geometry/simulated annealing protocol using the X-PLOR program. After inspection of hydrogen bond energies, 80 hydrogen bond restraints were applied with upper bounds of 2 Å and 3 Å for the NH-O and N-O distances, respectively. All the structures had NOE violations of less than 0.3 Å, and rms deviations from idealized geometry for bond lengths and angles of less than 0.01 Å and  $2^\circ$ , respectively.

### HEK293 cell culture and transfection

Cells were grown in DMEM 1965 with 10% FCS, 100 U/ml penicillin, 100  $\mu\text{g}/\text{ml}$  streptomycin and 58.4 g/l Glutamax.  $\sim 0.8 \times 10^6$  cells were plated in 60 mm plates and cultured for 24 hrs before being transfected using LipofectAMIN PLUS<sup>tm</sup> reagent kit according to manufacturers instructions (Gibco BRL) with 0.2  $\mu\text{g}$  PcDNA3.1(+) plasmid encoding a his-tagged (C-

terminal hexa-histidine) version of FGFR-1. Cells were grown another 24 hrs in full medium, and then shifted to starving media (DMEM 1965 with 0.5% FCS) overnight.

#### Stimulation, Purification and Western Blot Analysis

5

FGFR-1 transfected cells, incubated with 50  $\mu$ g/ml NCAM derived recombinant FIII.2 or FG-loop for 20 minutes or non-stimulated, were lysed in 8M urea in PBS with 1 mM orthovanadate. The FGFR-1 was purified from total lysate via the His-tag moiety on an IMAC column. Equal amounts of lysate were loaded on  $\text{Ni}^{2+}$ /NTA-sepharose (Qiagen), washed in lysis buffer with 10 mM imidazole, and his-tagged FGFR-1 was eluted in lysis buffer with 250 mM imidazole. Samples were added SDS-PAGE sample buffer and analysed by western blotting using anti-pentahis ab (#34660 Qiagen) or anti-phosphotyrosine ab (PY20) (#11120 Transduction Laboratories). Bands were visualised by chemiluminescence and density was measured using a GeneGnome from SynGene with a 16 bit camera.

15

Neurons were grown on Permanox plastic (Nunc, Denmark) for 24 h at a density 6250 cells/cm<sup>2</sup>, at 37°C, 5% CO<sub>2</sub> in Neurobasal medium containing 20 mM Hepes, 100 U/ml penicillin, 100  $\mu$ g/ml streptomycin, 0.4% BSA supplemented with B27 (Gibco BRL, USA). After 24 h, cells were fixed with paraformaldehyde, stained with Coomassie Brilliant Blue R250 and analyzed.

20

To study the structural and functional properties of the second F3 module of NCAM as well as a possible interaction with the FGF-receptor, the recombinant proteins of the second F3 module of NCAM and the second and third Ig modules of the FGF-receptor were produced in the yeast expression system of *P. pastoris*. This expression system was selected because *P. pastoris* is capable of protein folding and processing similar to higher eukaryotes, and the protein secreted into the medium can be purified easily.

25

#### **Example 1**

30

##### Structure of the second F3 module of NCAM

The three-dimensional structure of the module was derived from 1434 experimentally determined restraints (15 restraints per residue): 1322 structurally significant nuclear Overhauser enhancement (NOE) distance restraints (as determined by means of the program DIANA), 44 dihedral angle restraints (40  $\phi$  and 4  $\chi_1$ ), and 68 hydrogen bond restraints. An overlay of 30 superimposed structures for the backbone atoms is shown in Fig. 1a. The global root mean square (rms) deviation (rmsd) from the average of the 30 superimposed structures is 0.25 Å for the backbone atoms and 0.68 Å for the heavy atoms. A ribbon representation of

35

the structure labeling the seven  $\beta$ -strands is shown in Fig. 1b. The summary of the NOE statistics, energy terms and deviations from the idealized geometry is shown in Table 1.

Table 1

5 a) Structural statistics

<sup>1</sup> Number of restraints	1434:	<sup>3</sup> <u>Structural precision:</u>	
Long range NOE restraints	717	Rms deviation for backbone atoms	0.25 Å
Medium range NOE restraints	122	Rms deviation for heavy atoms	0.68 Å
Sequential NOE restraints	364	<u>Rms deviations from idealized geometry:</u>	
Intra NOE restraints	119	bonds	0.0027±0.0000 Å
Dihedral angle restraints	44	bond angles	1.4558±0.0075 °
Hydrogen bond restraints	80	improper bond angles	0.8674±0.0198 °

<sup>2</sup>Energies (kcal/mol):

Bonds	2.23 ± 0.05	no restraints	5.02 ± 0.36
Bond angles	191.2 ± 0.8	dihedral angle restraints	0.004±0.005
hydrogen bonds	-157.5 ± 7.1	van der Waals	-395.9 ± 7.2
Dihedral bond angles	494.2 ± 11.4	improper bond angles	24.9 ± 2.2
Overall	164 ± 11.4		

10 <sup>1</sup>Number of non-redundant restraints. <sup>2</sup>The energies were calculated using CHARMM force field with force constants for NOE's of 10 kcal mol<sup>-1</sup> Å<sup>-2</sup> and for dihedral constraints of 200 kcal mol<sup>-1</sup> rad<sup>-2</sup>. <sup>3</sup>Rms deviations from the average for residues 3-96 in 30 structures. Residues 1-2 are extra residues from the vector DNA.

15 The structure consists of seven antiparallel  $\beta$ -strands arranged in a sandwich of two  $\beta$  sheets, one containing three strands (ABE) and the other four strands (GFCD). Both of the  $\beta$  sheets have a right-handed twist. The triple-stranded  $\beta$  sheet consists of residues Lys 7 – Gly 13 (A), Ser 18 – Ile 24 (B), His 59 – Lys 63 (E), and the four-stranded  $\beta$  sheet consists of residues Ile 33 – Ala 42 (C), Ile 51, Arg 52 (D), Glu 70 – Asn 79 (F) and Gly 82 – Arg 92 (G). Identification of the elements of the secondary structure was performed using the programs

20 PROCHECK and MOLMOL. There are two wide type  $\beta$ -bulges (Chan *et al.*, 1993) involving residues Lys 85, Ala 86 and Val 76 (G and F  $\beta$ -stands), and residues Ala 77 and His 35, Tyr 36 (F and C  $\beta$ -strands). The two  $\beta$ -bulges contribute to the right-handed twist conformation of the four-stranded  $\beta$ -sheet. The  $\beta$ -hairpins formed by the A and B  $\beta$ -strands, and the G and F  $\beta$ -strands are well defined. The  $\beta$ -hairpin between the A and B strands corresponds to a

25 4:6 type I turn with the average  $\phi$ ,  $\psi$  values for Glu 14 (i+1 residue) being -64±1°, 12±2°, and

for Asp 15 (i+2 residue)  $-80 \pm 1^\circ$ ,  $24 \pm 2^\circ$ ; whereas the  $\beta$ -hairpin between the G and F strands corresponds to a tight 2:2 type I turn with the average  $\phi$ ,  $\psi$  values for Gln 80 (i+1 residue)  $-38 \pm 3^\circ$ ,  $-42 \pm 4^\circ$ , and for Gln 81 (i+2 residue)  $-107 \pm 13^\circ$ ,  $28 \pm 30^\circ$  (Sibanda et al., 1989; Wilmot and Thornton, 1990). The loops between the D-E and E-F strands appear to be distorted type II turns with the average  $\phi$ ,  $\psi$  values for i+1 residues being  $-70 \pm 8^\circ$ ,  $93 \pm 17^\circ$  (Ser 55, D-E loop),  $-73 \pm 20^\circ$ ,  $154 \pm 3^\circ$  (Trp 67, E-F loop), and the average  $\phi$ ,  $\psi$  values for i+2 residues being  $109 \pm 9^\circ$ ,  $57 \pm 8^\circ$  (Gly 56, D-E loop),  $46 \pm 3^\circ$ ,  $48 \pm 2^\circ$  (Asn 68, E-F loop). The hydrophobic core, which is enclosed by the two  $\beta$ -sheets, consists of residues Leu 8, Met 12, Ile 19, Val 21, Leu 23, Ile 33, Tyr 36, Val 38, Tyr 40, Ala 42, Ile 51, Leu 53, Val 60, Leu 62, Leu 65, Tyr 71, Val 73, Val 75, Ala 77, Ala 87, Phe 89, Phe 91, and Thr 93. Interestingly, the two tryptophans Trp 47 and Trp 67, located in the C-D and E-F loops, respectively, and Tyr 74 (F strand) are exposed on the surface of the module, and they are not part of the hydrophobic core.

All of the 30 structures conform to the commonly applied acceptance criteria: no violations larger than 0.5 Å for NOE restraints and larger than 5° for dihedral angle restraints, root mean square deviations from idealized geometry for bond lengths and bond angles less than 0.01 Å and 2°, respectively. The quality of each structure was assessed using the program WHAT IF. The average Z-scores for the set of 30 structures are:  $-1.42 \pm 0.17$  for the 2<sup>nd</sup> generation packing quality,  $-1.94 \pm 0.27$  for the Ramachandran plot,  $-1.53 \pm 0.34$  for the  $\chi_1/\chi_2$  plot, and  $-2.10 \pm 0.20$  for the backbone conformation. The quality of the 30 structures was further analyzed using the program PROCHECK. All of the analyzed main-chain and side-chain parameters were found to be within the normal ranges when compared to the X-ray structures of 2.0 Å resolution. The number of residues in the most favored region of the Ramachandran plot is 75.3 %. NOE violations were analyzed using the program AQUA. The maximum NOE violation is 0.25 Å, and the rms NOE violation is  $0.0189 \pm 0.00067$  Å.

## Example 2

### 30 The second F3 module of NCAM binds to the FGF-receptor and ATP

Given the assignment of the NMR spectra of the module and its known three-dimensional structure, it is possible to locate the residues that form the binding site on the surface of the module. In the  $^{15}\text{N}$ -HSQC spectrum of the  $^{15}\text{N}$ -labeled protein, a signal for each amino acid with both a peptide nitrogen and proton can be observed. The changes in the chemical shifts of the signals provide a method for the identification of residues in a protein that are perturbed by the binding of another molecule. To the 0.05 mM  $^{15}\text{N}$ -labeled sample of the second F3 module of NCAM, 1 mM unlabeled the second or third Ig modules of the FGF-receptor, or 5 mM AMP-PCP (an non-hydrolysable analogue of ATP) were added. No significant

changes of the chemical shifts were found in the presence of the second Ig module of the FGF-receptor (data not shown). The recorded changes of the chemical shifts in the presence of the third Ig module of the FGF-receptor or ATP are shown in Fig. 2a-d. The changes in  $^1\text{H}$  and  $^{15}\text{N}$  chemical shifts in the presence of the third Ig module of the FGF-receptor were mapped onto the structure of the module (Fig. 2e), using a cutoff of 0.006 p.p.m. and 0.03 p.p.m. for the perturbed  $^1\text{H}$  and  $^{15}\text{N}$  chemical shifts, respectively.

The residues of the F3 module that experienced significant perturbation by the third Ig module of the FGF-receptor were Tyr 36, Leu 37, Val 38, Tyr 40, Leu 53, Tyr 71, Tyr 74, Val 75, Val 76, Ala 77, Asn 79, Gln 81, Gly 82, Lys 83, Ser 84, Lys 85, Ala 87, His 88, Phe 89, Val 90 (Fig. 2a,b). The changes of the chemical shifts of these residues demonstrate that the presence of the third Ig module of the FGF-receptor close to the second F3 module of NCAM alters the chemical environment at the perturbed residues of the F3 module. The perturbed residues are located in one well defined and coherent patch on the surface of the module, indicating that the perturbed residues are either a part or in the vicinity of the binding site for the interaction between the second F3 module of NCAM and the third Ig module of the FGF-receptor (Fig. 2E). The surface area of the perturbed residues is approximately  $2600 \text{ \AA}^2$ , which is significantly larger than the  $1000 \text{ \AA}^2$  minimal area generally considered to be required for a biologically specific interaction. However, the surface area of the binding site is likely to be smaller, since some of the perturbed residues probably are just located close to the site.

The residues of the F3 module perturbed by AMP-PCP were Tyr 74 and Val 75 (Fig. 2c-d). The side chain of Tyr 74 is exposed on the surface of the module and is located in the close vicinity of the ATP-binding consensus sequence of the module: Ala 77-Glu-Asn-Gln-Gln-Gly-Lys-Ser 84 and Lys 85 (Fig. 2f). Both Lys 83 and Lys 85 are exposed on the surface of the module and it is possible that the positively charged side chains of Lys 83 and Lys 85 interact with the negatively charged triphosphate moiety of ATP, whereas the side chain of Tyr 74 is involved in hydrophobic interaction with the adenosine moiety of ATP. A possible arrangement of the complex of ATP and the second F3 module is depicted in Fig. 2g. The residues perturbed by ATP (Tyr 74 and Val 75) were also perturbed by the third Ig module of the FGF-receptor, indicating that the ATP binding site and the FGF-receptor binding site are overlapping.

### Example 3

The FGF-receptor is activated by the second F3 module of NCAM and by the FGL peptide

Since the above NMR experiments demonstrate binding of the second F3 module of NCAM to the FGF-receptor, it was of interest to test if this binding can induce FGF-receptor activation in living cells. Therefore, HEK293 cells were grown for 24 h on plastic plates, and subsequently transfected with a His-tagged version of the FGF-receptor 1 and cultured for another 24 h. After incubation of the cells for 20 min with the below described compounds, cells were lysed in 8M urea and the FGF-receptor was purified from the total lysate via the His-tag moiety. The purified FGF-receptor 1 was then analyzed by immunoblotting using antibodies either to the His-tag or phosphotyrosine. FGF-receptor activation was estimated by the level of the FGF-receptor phosphorylation.

From Fig. 3, it appears that addition of 5  $\mu$ M second F3 module of NCAM increased FGF-receptor phosphorylation by approx. 150% compared to control cells. Most of the residues of the second F3 module of NCAM perturbed by the third Ig module of the FGF-receptor are located in the F, G  $\beta$ -strands and the FG turn region of the NCAM module. We therefore tested whether a synthetic peptide spanning these residues could variant the second F3 module in its ability to activate the FGF-receptor. Indeed, addition of a peptide corresponding to residues Glu 72 – Ala 86 (termed the FG loop peptide) at a concentration of 25  $\mu$ M also activated the FGF-receptor, increasing phosphorylation by approx. 100%, thus supporting the notion that these residues of the second F3 module are involved in the binding to the FGF-receptor (Fig. 3).

Thus, the present data demonstrate that binding of the second F3 module of NCAM to the FGF-receptor results in the activation of the latter.

#### Example 4

##### Activation of the FGF-receptor by the second F3 module of NCAM stimulates neurite growth

Because the second F3 module of NCAM and its FGF-receptor binding part (the FG loop peptide) activate the FGF-receptor, it may be expected that the F3 module and the FG loop peptide are capable of mimicking a characteristic function of NCAM stimulation: neuronal differentiation as reflected by neuritogenesis. To test this assumption, dissociated neurons from embryonic rat hippocampus were seeded on plastic and allowed to grow for 24 h in the presence of the below described compounds. Thereafter, cells were fixed with paraformaldehyde, stained with Coomassie Brilliant Blue R250 and the length of neurites was measured using a stereological approach (Rønn et al., 2000).

As can be seen from the phase-contrast pictures (Fig. 4a,b), addition of the second F3 module of NCAM at a 5  $\mu$ M concentration substantially increased the length of neurites per cell as compared to the control, non-stimulated neurons. The effect was quantified in a dose-response study (Fig. 4c) demonstrating that the F3 module, the FG loop peptide and a trun-

cated version of the peptide (Ala 77 – Lys 83) all induced neurite outgrowth, with a bell-shaped dose-response curve typical of growth factor induced neuritogenesis (Hatten et al., 1988). The potency of the peptides was lower than that of the module, as reflected by the fact that a 10 times higher concentration was required for maximum effect, and the truncated form was less efficient than the extended form. The stimulatory effect of the second F3 module and the FG loop peptide could be abrogated by an inhibitor of NCAM-stimulated neurite outgrowth, an antibody against the FGF-receptor. The effect of the antibody under control conditions and on neurite outgrowth induced by the second F3 module or the FG loop, is shown in Fig. 4d. In the latter case, a complete inhibition was achieved, further supporting the notion that the module and the FG loop peptide interact with the FGF-receptor.

To determine the functionally important amino acids of the FG loop peptide, the peptide was analyzed by truncations and alanine substitutions of various amino acids. Two truncated versions (from the N- and C-terminal) of the FG loop peptide were produced: the nonamer Val 76 – Ser 84 and the heptamer Ala 77 – Lys 83. Even though the truncated peptides were substantially shorter than the FG loop peptide, they both retained approximately 50% of the stimulatory effect as compared to the entire FG loop peptide (Fig. 5a), indicating that the turn region between the F and G  $\beta$ -strands (Gln 80, Gln 81) and a few adjacent amino acids from both sides of the turn are important for the interaction between the FGF-receptor and the second F3 module of NCAM. The heptameric peptide was subsequently analyzed by a so-called Ala-scan in which a series of peptides, in which each amino acid sequentially was substituted with an alanine, were tested. As can be seen from Fig. 5a, substitution of any amino acid in the peptide resulted in a decrease of the neuritogenic potency and a complete loss of function was achieved if Glu 78, Asn 79, Gln 80, Gly 82, Lys 83 were substituted with Ala, indicating that these residues are important for interaction with the FGF-receptor. Double substitution of the two amino acids from the turn region of the FG loop (Gln 80, Gln 81) for alanines in the entire FG loop peptide also resulted in a complete inactivation of the peptide (Fig.5a). These findings are corroborated by the fact that Asn 79, Gln 81, Gly 82 and Lys 83 were perturbed in the second F3 module by binding to the third module of the FGF-receptor. However, when the residues which seem to be important for interaction with ATP (Tyr 74, Lys 83 and Lys 85) were substituted for alanines in the FG loop peptide, the peptide retained about 60% of the stimulatory effect as compared to the non-mutated peptide (Fig.5a). The structure of the heptameric peptide in the F3 module was compared to the known three-dimensional structure of a natural ligand of the FGF-receptor, basic FGF (PDB code: 4FGF, Eriksson *et al.*, 1993), and it was found that the peptide had a structure and sequence similarity to a loop region in basic FGF, Ala 42 – Arg 48. The sequence and structure alignment of both of the peptides is shown in Fig. 6a, b. The heptameric peptide derived from basic FGF and a series of peptides with Ala substitutions were tested for their capability to induce neuritogenesis, and as can be seen from Fig. 5b, the peptide derived from

basic FGF induced neurite outgrowth to the same extent as the similar seven amino acids from the second F3 module of NCAM. Substitution of any amino acid for alanine resulted in a complete loss of function.

5 Since ATP inhibited activation of the FGF-receptor by the second F3 module of NCAM (Fig. 3), it was presumed that ATP also could inhibit the neuritogenic activity of the module. To test this assumption, neurons were stimulated with the below described compounds in the presence of ATP or a non-hydrolysable analogue of ATP, AMP-PCP (added at concentrations of 0, 0.4 or 1 mM). As can be seen from Fig. 7, both ATP and AMP-PCP substantially  
10 reduced the neuritogenic effect induced by the second F3 module and the FG loop peptide, whereas when these compounds were added alone, they did not have any effect. In case of AMP-PCP, a complete inhibition was achieved of the effect of both the F3 module and the FG loop peptide, and in case of ATP, a complete inhibition was achieved only of the effect of the FG loop, indicating that ATP is a less potent inhibitor than its non-hydrolysable analogue  
15 AMP-PCP. Most significantly, when the amino acid residues of the FG loop presumed to be of importance for ATP binding (Tyr 74, Lys 83 and Lys 85) were substituted with alanines, the peptide retained its neuritogenic potency. However, the stimulatory effect of the peptide could no longer be inhibited by ATP (Fig. 7), supporting the notion that ATP binding regulates interaction between the F3 module and the FGF-receptor.

20

These results indicate that activation of the FGF-receptor in neurons by the second F3 module of NCAM induces neuritogenesis and this effect can be inhibited by ATP.

### Example 5

25

#### Survival assay for testing compounds of the invention:

Cerebellar granule neurons (CGN) from 7-days old rats are grown for 7-8 days in the presence of high potassium (40 mM). Cells are washed twice with serum-free  
30 culture medium (basal Eagle's medium BME) containing low potassium (5 mM) and grown in serum-free medium supplemented with FGL peptide for two days. Cultures are assayed for cell survival (D'Mello et al., 1997; Villalba et al., 1997; Skaper et al., 1998), by measuring reduction of MTS. MTS is a novel tetrazolium compound (Promega, USA), which is bioreduced by cells into a formazan that is soluble in tissue culture medium.  
35 The absorbance of the formazan at 490nm is measured directly from 96 well assay plates without additional processing. The conversion of MTS into the aqueous soluble formazan is accomplished by dehydrogenase enzymes found in metabolically active cells. The quantity of formazan product as measured by the amount of 490nm absorbance is directly proportional to the number of living cells in culture (Yao and Cooper, 1995);



The number of cells were determined and the amount of cells surviving in the presence of high-concentration of potassium was set at 100 %. As can be seen approx. On Fig. 8 only 60 % survived in the presence of brains-derived neurotrophic factor or basic fibroblast growth factor. When FGL was added in a dose-range of 2-250 microgram per ml statistically significant survival was observed up to 90 % of the positive control at a dose of 250 microgram per ml of the monomeric form of the FGL peptide

### Example 6

#### FG loop fragments and variants

Peptides derived from the FG-loops of the neural cell adhesion molecules L1 and NCAM (third F3-module of L1 and first F3 module of NCAM) were prepared in different lengths, see Fig. 9a, and their effect on neurite outgrowth from primary hippocampal neurons were tested adding the various peptides in a concentration of 25 microM. Figure 9b. The NCAM peptides are referred to as FN3,1 and the L1 peptides are referred to as L1. The variants indicated in Fig. 9a are indicated by the number of amino acids in each peptide. As can be seen from the figure, the peptides had a stimulatory effect on neurite outgrowth reaching statistically significance for the nine amino acid variant of the Fgloop of first fibronectin type III module of NCAM and the nine amino acid variant of the FG-loop of the third fibronectin type III-module of L1.

#### References

Banga, A.K. (Editor). Therapeutic peptides and protein formulation. Processing and delivery systems. Technomic Publishing AG, Basel, 1995.

Berezin, V., Bock, E. and Poulsen, F.M.:The neural cell adhesion molecule. Curr Opin Drug Disc Dev, 2000, 3:605-609.

Chan AW, Hutchinson EG, Harris D, Thornton JM. Identification, classification, and analysis of beta-bulges in proteins. Protein Sci 1993 Oct;2(10):1574-90

DeMello S.R., Borodezt K. and Soltoff S.P. (1997) Insulin-like growth factor and potassium depolarization maintain neuronal survival by distinct pathways: possible involvement of PI 3-kinase in IGF-1 signaling. J. Neurosci. 17:1548-1560.

Doherty P, Walsh FS. CAM-FGF Receptor Interactions: A Model for Axonal Growth

Mol Cell Neurosci. 1996 2/3:99-111.

Dzhandzhugazyan K, Bock E. Demonstration of (Ca<sup>2+</sup>)-Mg<sup>2+</sup>)-ATPase activity of the neural cell adhesion molecule. FEBS Lett 1993 Dec 27;336(2):279-83

5

Dzhandzhugazyan K, Bock E. Demonstration of an extracellular ATP-binding site in NCAM: functional implications of nucleotide binding. Biochemistry 1997 Dec 9;36(49):15381-95

10

Eilers A, Whitfield J, Babij C, Rubin LL, Ham J. Role of the Jun kinase pathway in the regulation of c-Jun expression and apoptosis in sympathetic neurons. J Neurosci. 1998 Mar 1;18(5):1713-24.

Eriksson AE, Cousens LS, Matthews BW. Refinement of the structure of human basic fibroblast growth factor at 1.6 Å resolution and analysis of presumed heparin binding sites by selenate substitution. Protein Sci 1993 Aug;2(8):1274-84

15

Furka A, Sebestyen F, Asgedom M, Dibo G. General method for rapid synthesis of multi-component peptide mixtures. Int J Pept Protein Res. 1991 Jun;37(6):487-93.

20

Hatten ME, Lynch M, Rydel RE, Sanchez J, Joseph-Silverstein J, Moscatelli D, Rifkin DB. In vitro neurite extension by granule neurons is dependent upon astroglial-derived fibroblast growth factor. Dev Biol 1988 Feb;125(2):280-9

25

Horstkorte R, Schachner M, Magyar JP, Vorherr T, Schmitz B. The fourth immunoglobulin-like domain of NCAM contains a carbohydrate recognition domain for oligomannosidic glycans implicated in association with L1 and neurite outgrowth. J Cell Biol. 1993 Jun;121(6):1409-21.

30

Hulley P, Schachner M, Lubbert H. L1 neural cell adhesion molecule is a survival factor for fetal dopaminergic neurons. J Neurosci Res. 1998 Jul 15;53(2):129-34.

35

Jensen PH, Soroka V, Thomsen NK, Raets I, Berezin V, Bock E, Poulsen FM. Structure and interactions of NCAM modules 1 and 2, basic elements in neural cell adhesion. Nat Struct Biol 1999 6:486-93

Kasper C, Rasmussen H, Kastrup JS, Ikemizu S, Jones EY, Berezin V, Bock E, Larsen IK. Structural basis of cell-cell adhesion by NCAM. Nat Struct Biol 2000 May;7(5):389-93

- Kiselyov VV, Berezin V, Maar TE, Soroka V, Edvardsen K, Schousboe A, Bock E. The first immunoglobulin-like neural cell adhesion molecule (NCAM) domain is involved in double-reciprocal interaction with the second immunoglobulin-like NCAM domain and in heparin binding. *J Biol Chem* 1997 Apr 11;272(15):10125-34
- 5 Lam KS, Salmon SE, Hersch EM, Hruby VJ, Kazmierski WM, Knapp RJ. A new type of synthetic peptide library for identifying ligand-binding activity. *Nature*. 1991 354:82-84.
- 10 Ranheim TS, Edelman GM, Cunningham BA. Homophilic adhesion mediated by the neural cell adhesion molecule involves multiple immunoglobulin domains. *Proc Natl Acad Sci U S A* 1996 Apr 30;93(9):4071-5
- 15 Rao Y, Wu XF, Garipey J, Rutishauser U, Siu CH. Identification of a peptide sequence involved in homophilic binding in the neural cell adhesion molecule NCAM. *J Cell Biol* 1992 Aug;118(4):937-49
- 20 Rao Y, Zhao X, Siu CH. Mechanism of homophilic binding mediated by the neural cell adhesion molecule NCAM. Evidence for isologous interaction. *J Biol Chem*. 1994 Nov 4;269(44):27540-8.
- Retzler C, Gohring W, Rauch U. Analysis of neurocan structures interacting with the neural cell adhesion molecule N-CAM. *J Biol Chem*. 1996 Nov 1;271(44):27304-10.
- 25 Ronn LC, Bock E, Linnemann D, Jahnsen H. NCAM-antibodies modulate induction of long-term potentiation in rat hippocampal CA1. *Brain Res*. 1995 Apr 17;677(1):145-51.
- 30 Ronn LC, Olsen M, Ostergaard S, Kiselyov V, Berezin V, Mortensen MT, Lerche MH, Jensen PH, Soroka V, Saffell JL, Doherty P, Poulsen FM, Bock E, Holm A, Saffells JL. Identification of a neuritogenic ligand of the neural cell adhesion molecule using a combinatorial library of synthetic peptides. *Nat Biotechnol*. 1999 Oct;17(10):1000-5.
- 35 Ronn LC, Raets I, Hartz BP, Bech M, Berezin A, Berezin V, Moller A, Bock E. A simple procedure for quantification of neurite outgrowth based on stereological principles. *J Neurosci Methods*. 2000 Jul 31;100(1-2):25-32.
- Sibanda BL, Blundell TL, Thornton JM. Conformation of beta-hairpins in protein structures. A systematic classification with applications to modelling by homology, electron density fitting and protein engineering. *J Mol Biol* 1989 Apr 20;206(4):759-77

Skaper SD, Floreani M, Negro A, Facci L, Giusti P. Neurotrophins rescue cerebellar granule neurons from oxidative stress-mediated apoptotic death: selective involvement of phosphatidylinositol 3-kinase and the mitogen-activated protein kinase pathway. J Neurochem. 1998 May;70(5):1859-68.

5

Skladchikova G, Ronn LC, Berezin V, Bock E. Extracellular adenosine triphosphate affects neural cell adhesion molecule (NCAM)-mediated cell adhesion and neurite outgrowth. J Neurosci Res 1999 Jul 15;57(2):207-18

10 Villalba M, Bockaert J, Journot L. Pituitary adenylate cyclase-activating polypeptide (PACAP-38) protects cerebellar granule neurons from apoptosis by activating the mitogen-activated protein kinase (MAP kinase) pathway. J Neurosci. 1997 Jan 1;17(1):83-90.

15 Wilmot CM, Thornton JM. Beta-turns and their distortions: a proposed new nomenclature. Protein Eng. 1990 May;3(6):479-93.

Yao R, Cooper GM. Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science. 1995 Mar 31;267(5206):2003-6.

20

25

30

35

**Claims**

1. A compound comprising the third Immunoglobulin (Ig3) module, and/or the fourth Immunoglobulin (Ig4) module, and/or the fifth Immunoglobulin (Ig5) module, and/or the first Fibronectin III (Fn3,1) module, and/or the second Fibronectin III (Fn3,2) module of neural cell adhesion molecule (NCAM), or a fragment, or a variant thereof, capable of interacting with a Fibroblast Growth Factor (FGF) receptor and/or Adenosine-Tri-Phosphate (ATP) and/or L1.
2. A compound comprising the fourth Immunoglobulin (Ig4) module, and/or the fifth Immunoglobulin (Ig5) module, and/or the first Fibronectin III (Fn3,1) module, and/or the second Fibronectin III (Fn3,2) module of neural cell adhesion molecule (NCAM), or a fragment, or a variant, or a mimic thereof, capable of interacting with an FGF receptor and/or Adenosine-Tri-Phosphate (ATP) and/or L1.
3. The compound according to claims 1 or 2, capable of interacting with the FGF receptor.
4. The compound according to claims 1, 2 or 3, wherein the FGF receptor is selected from FGF receptor I, FGF receptor II, FGF receptor III, FGF receptor IV.
5. The compound according to any of the preceding claims, capable of stimulating FGF receptor signalling.
6. The compound according to claim 4, wherein the FGF receptor I signalling is stimulated.
7. The compound according to claim 1, wherein the compound comprises the second Fibronectin 3 (Fn3,2) module of NCAM, or a fragment, or a variant thereof.
8. The compound according to claim 1, wherein the compound comprises the first Fibronectin 3 (Fn3,1) module of NCAM, or a fragment, or a variant thereof.
9. The compound according to claim 8, comprising an amino acid sequence of the formula L1-A-L2-B-L3-C-L4
- wherein

one of A, B, C is selected from a basic amino acid,  
one of A, B, C is selected from a hydrophobic amino acid,  
one of A, B, C is glycine, and  
L1, L2, L3, L4 may be selected from a chemical bond or an amino acid sequence having  
5 n amino acid residues, wherein n is an integer of from 0 to 5.

10. The compound according to claim 9, wherein B is glycine, A is a basic amino acid residue, and C is a hydrophobic amino acid residue.

10 11. The compound according to claim 9, wherein A is lysine (K), and C is leucine (L) or alanine (A).

12. The compound according to claim 9-11 comprising the sequence NGKGL and/or NGRGL.

15 13. The compound according to claim 7, comprising an amino acid sequence of the formula

L1-A-L2-B-L3-C-L4-D-L5, wherein

20 one of A, B, C, D is selected from a basic amino acid residue,  
one of A, B, C, D is selected from a hydrophobic amino acid residue,  
one of A, B, C, D is selected from an acidic amino acid residue,  
one of A, B, C, D is glycine, and  
L1, L2, L3, L4 and L5 may be selected from a chemical bond or an amino acid sequence  
25 having n amino acid residues, wherein n is an integer of from 0 to 5.

14. The compound according to any of the preceding claims, wherein said compound comprises a peptide homologous to the FG loop of the Fn3,2 module of the NCAM molecule, or a fragment, or a variant thereof.

30 15. The compound according to claim 14, wherein said compound comprises a peptide sequence having the motif A-E-N-Q-X-X-K, wherein X may be any amino acid residue.

35 16. The compound according to claim 15, wherein X is selected from Glutamine (Q), Alanine (A) and/or Asparagine (N) and/or Glycine (G).

17. The compound according to any of the preceding claims, wherein said compound comprises at least one peptide comprising the sequence

5 EVYVVAENQQGKSKA (SEQ ID NO 1),  
EVAVVAENQQGASAA (SEQ ID NO 2),  
VAENQQGKS (SEQ ID NO 3),  
AENQQGKS (SEQ ID NO 4),  
AENQQGK (SEQ ID NO 5),  
AENQAGK (SEQ ID NO 6),  
10 AMKEDGR (SEQ ID NO 7),  
ALNGKGLG (SEQ ID NO 8),  
AFNGRGLG (SEQ ID NO 9),  
LNGKGLG (SEQ ID NO 10),  
LNGKGL (SEQ ID NO 11),  
15 ALNGKG (SEQ ID NO 12),  
LNGNALGE (SEQ ID NO 13),  
LNGKALG (SEQ ID NO 14),  
ALNGKAL (SEQ ID NO 15),  
ALNLKGLGD (SEQ ID NO 16),  
20 LNGKELG (SEQ ID NO 17),  
LTGKGLAE (SEQ ID NO 18),  
LKGKGLLEE (SEQ ID NO 19),  
LNSKGLVE (SEQ ID NO 20),  
LNGKALVE (SEQ ID NO 21),  
25 LAAKGLGE (SEQ ID NO 22),  
LDGKGL (SEQ ID NO 23),  
KGLGE (SEQ ID NO 24),  
DGKSLGE (SEQ ID NO 25),  
NGKGL (SEQ ID NO 26),  
30 NGRGL (SEQ ID NO 27),  
QAFNGRGLGP (SEQ ID NO 28),  
EVQAFNGRGLGPPAS (SEQ ID NO 29),  
AALNGKGLGE (SEQ ID NO 30),  
RLAALNGKGLGEIS (SEQ ID NO 31),  
35 ALNGKGAP (SEQ ID NO 32),  
VALNGKGAPR (SEQ ID NO 33),  
MYVALNGKGAPRRQ (SEQ ID NO 34),  
LNGRG (SEQ ID NO 35),  
LNGKG (SEQ ID NO 36),

MYVALNGKGAPRRGQ (SEQ ID NO 37),  
MFLALDRRGGPRPGG (SEQ ID NO 38),  
MFLALDSQGIPRQGQ (SEQ ID NO 39),  
MFVALNQKGIPVRG (SEQ ID NO 40),  
5 MFVALNQKGIPVKG (SEQ ID NO 41),  
MFVALNQKGLPVKG (SEQ ID NO 42),  
WYVSVNGKGRPRRG (SEQ ID NO 43),  
YYVALNKDGTPREG (SEQ ID NO 44),  
YYVALNKDGSPREG (SEQ ID NO 45),  
10 YFVALNKDGTPRDG (SEQ ID NO 46),  
WYVALNKRKGAKRG (SEQ ID NO 47),  
WYLGLNKEGEIMKG (SEQ ID NO 48),  
WFLGLNKEGQIMKG (SEQ ID NO 49),  
TYIALSKYGRVKRG (SEQ ID NO 50),  
15 WFLGLNKEGQAMKG (SEQ ID NO 51),  
WFLGLNKEGQVMKG (SEQ ID NO 52),  
WYLGLDKEGQVMKG (SEQ ID NO 53),  
WYLGLDKEGRVMKG (SEQ ID NO 54),  
WYVALKRTGQYKLG (SEQ ID NO 55),  
20 WFLVGLKKNKGCKRG (SEQ ID NO 56),  
ANRYLAMKEDGRLLAS (SEQ ID NO 57),  
TGQYLAMDTEGLLYGS (SEQ ID NO 58),  
TGQYLAMDTDGLLYGS (SEQ ID NO 59),  
TGQYLAMDTSGLLYGS (SEQ ID NO 60),  
25 TGQFLAMDTDGLLYGS (SEQ ID NO 61),  
SRFFVAMSSKGKLYGS (SEQ ID NO 62),  
SRFFVAMSSRGKLFV (SEQ ID NO 63),  
SRFFVAMSSRGRLYGS (SEQ ID NO 64),  
SGLFVAMNSKGKLYGS (SEQ ID NO 65),  
30 SNKFLAMSKKGKLHAS (SEQ ID NO 66),  
SALFVAMNSKGRLYAT (SEQ ID NO 67),  
SALFIAMNSKGRLYTT (SEQ ID NO 68),  
SGRYLAMNKRGRLYAS (SEQ ID NO 69),  
SEYYLAMNKEGKLYAK (SEQ ID NO 70),  
35 SEYYLAMNKQGLYAK (SEQ ID NO 71),  
SEFYLAMNKEGKLYAK (SEQ ID NO 72),  
SGLYLGMNEKGELYGS (SEQ ID NO 73),  
SGLYLGMNDKGELYGS (SEQ ID NO 74),  
SGLYLGMNERGELYGS (SEQ ID NO 75),



5 SGLYLGMNERGELFGS (SEQ ID NO 76),  
SNYYLAMNKKGKLYGS (SEQ ID NO 77),  
SGFYVAMNRRGRLYGS (SEQ ID NO 78),  
TGLYIAMNGEGYLYPS (SEQ ID NO 79),  
ASLYVAMNGEGYLYSS (SEQ ID NO 80),  
TKLYLAMNSEGYLYTS (SEQ ID NO 81),  
TGLYICMNKKGKLIKS (SEQ ID NO 82),  
LGHYAMNAEGLLYSS (SEQ ID NO 83),  
TEFYLCMNRKGKLVGK (SEQ ID NO 84),  
10 SVRYLCMGADGKMQL (SEQ ID NO 85),  
WVGLKKNGS CKRG (SEQ ID NO 86),  
WYVALKRTGQ YKLG (SEQ ID NO 87),  
WYVSVNGKGR PRRG (SEQ ID NO 88),  
GMFIALSKNG KTKKG (SEQ ID NO 89),  
15 GMFMALSKNG RTKKG (SEQ ID NO 91),  
GMFIALSKNG KAKKG (SEQ ID NO 92),  
WYVALNKRKG AKRG (SEQ ID NO 93),  
TYIALSKYGR VKRG (SEQ ID NO 94),  
MFVALNQKGI PVRG (SEQ ID NO 95),  
20 MFVALNQKGI PVKG (SEQ ID NO 96),  
MFVALNQKGL PVKG (SEQ ID NO 97),  
WYMAFTRKGR PRKG (SEQ ID NO 98),  
YYVALNKDGT PREG (SEQ ID NO 99),  
MYVALNGKGA PRRGQ (SEQ ID NO 100),  
25 WYLGLDKEGQ VMKG (SEQ ID NO 101),  
WYLGLDKEGR VMKG (SEQ ID NO 102),  
WFLGLNKEGQ IMKG (SEQ ID NO 103),  
WYLGLNKEGE IMKG (SEQ ID NO 104),  
WFLGLNKEGQ AMKG (SEQ ID NO 105),  
30 WFLGLNKEGQ VMKG (SEQ ID NO 106),  
YYVALNKDGS PREG (SEQ ID NO 107),  
WFMAFTRQGR PRQ (SEQ ID NO 108),  
WVGLKKNGS CKRG (SEQ ID NO 109),  
WYVGFTKKGR PRKG (SEQ ID NO 110),  
35 YFVALNKDGT PRDG (SEQ ID NO 111),  
MFLALDRRG PRPGG (SEQ ID NO 112),  
MFLALDSQGI PRQGQ (SEQ ID NO 113),  
TGQYLAMDTE GLLYGS (SEQ ID NO 114),  
TGQYLAMDTD GLLYGS (SEQ ID NO 115),

5 TGQYLAMDTs GLLYGS (SEQ ID NO 116),  
TGQFLAMDTD GLLYGS (SEQ ID NO 118),  
ANRYLAMKED GRLLAS (SEQ ID NO 119),  
SGRYLAMNKR GRLYAS (SEQ ID NO 120),  
SRFFVAMSSK GKLYGS (SEQ ID NO 121),  
SRFFVAMSSR GKLFGV (SEQ ID NO 122),  
SRFFVAMSSR GRLYGS (SEQ ID NO 123),  
SGLFVAMNSK GKLYGS (SEQ ID NO 124),  
10 SNKFLAMSKK GKLHAS (SEQ ID NO 125),  
SALFVAMNSK GRLYAT (SEQ ID NO 126),  
SALFIAMNSK GRLYTT (SEQ ID NO 127),  
SEYYLAMNKE GKLYAK (SEQ ID NO 128),  
SEYYLAMNKQ GLYAK (SEQ ID NO 129),  
SEFYLAMNKE GKLYAK (SEQ ID NO 130),  
15 TGLYICMNKK GKLIAS (SEQ ID NO 131),  
SGLYLGMNEK GELYGS (SEQ ID NO 132),  
SNYYLAMNKK GKLYGS (SEQ ID NO 133),  
LGHYMAMNAE GLLYSS (SEQ ID NO 134),  
ASLYVAMNGE GYLYSS (SEQ ID NO 135),  
20 TKLYLAMNSE GYLYTS (SEQ ID NO 136),  
TGLYIAMNGE GYLYPS (SEQ ID NO 137),  
SVRYLCMSAD GKIYG (SEQ ID NO 138),  
SGLYLGMNER GELYGS (SEQ ID NO 139),  
SGLYLGMNER GELFGS (SEQ ID NO 140),  
25 SEKYICMNKR GKLIQ (SEQ ID NO 141),  
TEFYLCMNRK GKLVGK (SEQ ID NO 142),  
SVRYLCMGAD GKMQGL (SEQ ID NO 143),  
SGLYLGMNDK GELYGS (SEQ ID NO 144),  
TSRFLCQRPD GALYG (SEQ ID NO 145),  
30 ASRFLCQQPD GALYG (SEQ ID NO 146),  
SGFYVAMNRR GRLYGS (SEQ ID NO 147),  
SRRYLCMDFR GNIFGS (SEQ ID NO 148),  
TRRFLCMDLH GNIFGS (SEQ ID NO 149),  
GLKKNQSC (SEQ ID NO 150),  
35 ALKRTGQY (SEQ ID NO 151),  
SVNGKGRP (SEQ ID NO 152),  
IALSKNGKT (SEQ ID NO 153),  
MALSKNGRT (SEQ ID NO 154),  
IALSKNGKA (SEQ ID NO 155),

5 ALNKRGA (SEQ ID NO 156),  
ALSKYGRV (SEQ ID NO 157),  
ALNQKGIP (SEQ ID NO 158),  
ALNQKGLP (SEQ ID NO 159),  
AFTRKGRP (SEQ ID NO 160),  
ALNKDGTP (SEQ ID NO 161),  
ALNGKGAPR (SEQ ID NO 162),  
GLDKEGQV (SEQ ID NO 163),  
GLDKEGRV (SEQ ID NO 164),  
10 GLNKEGQI (SEQ ID NO 165),  
GLNKEGEI (SEQ ID NO 166),  
GLNKEGQA (SEQ ID NO 167),  
GLNKEGQV (SEQ ID NO 168),  
ALNKDGSP (SEQ ID NO 169),  
15 AFTRQGR (SEQ ID NO 170),  
GLKKNKSC (SEQ ID NO 171),  
GFTKKGRP (SEQ ID NO 172),  
ALNKDGTP (SEQ ID NO 173),  
ALDRRGPR (SEQ ID NO 174),  
20 ALDSQGIPR (SEQ ID NO 175),  
AMDTDGL (SEQ ID NO 176),  
AMDTEGL (SEQ ID NO 177),  
AMDTSGL (SEQ ID NO 178),  
AMKEDGR (SEQ ID NO 179),  
25 AMNKRGR (SEQ ID NO 180),  
AMSSKGK (SEQ ID NO 181),  
AMSSRGK (SEQ ID NO 182),  
AMNSKGK (SEQ ID NO 183),  
AMSKKGK (SEQ ID NO 184),  
30 AMNSKGR (SEQ ID NO 185),  
AMNKEGK (SEQ ID NO 186),  
AMNKEGK (SEQ ID NO 187),  
AMNKQGL (SEQ ID NO 188),  
CMNKKKGK (SEQ ID NO 189),  
35 GMNEKGE (SEQ ID NO 190),  
AMNKKKGK (SEQ ID NO 191),  
AMNAEGL (SEQ ID NO 192),  
AMNGEGY (SEQ ID NO 193),  
AMNSEGY (SEQ ID NO 194),

5 AMNGEGY (SEQ ID NO 195),  
CMSADGK (SEQ ID NO 196),  
GMNERGE (SEQ ID NO 197),  
CMNKRKGK (SEQ ID NO 198),  
CMNRKGGK (SEQ ID NO 199),  
CMGADGK (SEQ ID NO 200),  
GMNDKGE (SEQ ID NO 201),  
LCQRPDG (SEQ ID NO 202),  
LCQQPDG (SEQ ID NO 203),  
10 AMNRRGR (SEQ ID NO 204),  
CMDFRGN (SEQ ID NO 205), and/or  
CMDLHGN (SEQ ID NO 206)

15 18. The compound according to claim 13, wherein the amino acid sequence has the formula  
AENQ-L4-G, wherein L4 is as defined in claim 13.

19. The compound according to claim 7, comprising an amino acid sequence of the formula  
20 A-B-L3-L4-C-L4, wherein  
A is a hydrophobic amino acid residue,  
B is an acidic amino acid residue,  
L3 is one or more hydrophilic amino acid residue(s),  
25 L4 is an amino acid sequence as defined in claim 13 for L4, and  
C is glycine.

20. The compound according to any of the preceding claims comprising a sequence of the  
formula  
30 L1-A-L2-B-L3-C-L4-D-L5-E-L6, wherein

at least one of L1, L2, L3, or L4 comprises the amino acid residue Y and one of the other  
comprises the amino acid residue K, and L5 and/or L6 individually is K, and A, B, C, D, E  
35 is any amino acid, with the proviso, that the distance between Y and K is at least 5  
amino acids, such as at least 7 amino acid residues, such as at least 9 amino acid resi-

dues, such as at least 11 amino acid residue

21. The compound according to claim 20, capable of binding adenosine-tri-phosphate (ATP).
- 5 22. The compound according to any of the preceding claims, wherein the compound is a dimer.
23. The compound according to the claims any of the claims 1-21, wherein the compound is a multimer, such as a dendrimer.
- 10 24. The compound according to any of the preceding claims, wherein the compound comprises monomers independently capable of stimulating FGF receptor signalling and/or modulating proliferation and/or inducing differentiation and/or stimulating regeneration, neuronal plasticity and/or survival of cells presenting an FGF receptor.
- 15 25. The compound according claim 22 or 23, wherein the monomers are homologous.
26. The compound according claim 22 or 23, wherein the monomers are heterologous.
- 20 27. The compound according to any of the preceding claims, wherein the FGF receptor signalling is measured as phosphorylation of the FGF receptor when a predetermined concentration of the compound is applied to cells expressing the FGF receptor.
- 25 28. The compound according to claim 27, wherein the degree of phoshorylation is at least 20% above the control value.
29. The compound according to claim 27 or 28, wherein the predetermined concentration of said compound is between 0.1-200  $\mu\text{M}$ , such as 1-200  $\mu\text{M}$ , such as 10-200  $\mu\text{M}$ , such as 20-180  $\mu\text{M}$ , for example 30-160  $\mu\text{M}$ , such as 40-140  $\mu\text{M}$ , for example 50-130  $\mu\text{M}$ , such as 60-120  $\mu\text{M}$ , for example 70-110  $\mu\text{M}$ , such as 80-100  $\mu\text{M}$ .
- 30 30. The compound according to claim 1 or 2, comprising amino acid residues in the range of from 3 to 100 amino acid residues, such as from 10-90 amino acid residues, for example from 15-85 amino acid residues, such as from 20-80 amino acid residues, for example from 25-75 amino acid residues, such as from 30-70 amino acid residues, for example
- 35

from 35-65 amino acid residues, such as from 40-60 amino acid residues, for example from 45-55 amino acid residues.

- 5 31. The compound according to claim 1 or 2, comprising amino acid residues in the range of from 3 to 20 amino acid residues, such as from 3-19 amino acid residues, for example from 3-18 amino acid residues, such as from 3-17 amino acid residues, for example from 3-16 amino acid residues, such as from 3-15 amino acid residues, for example from 3-14 amino acid residues, such as from 3-13 amino acid residues.
- 10 32. The compound according to claim 1 or 2, capable of modulating proliferation and/or differentiation and/or regeneration and/or neuronal plasticity and/or survival of cells.
- 15 33. A pharmaceutical composition comprising at least one compound as defined in any of the claims 1-32.
34. The pharmaceutical composition according to claim 33, wherein the compound is the NCAM Fn3,2 module, or a fragment thereof, or a variant thereof.
- 20 35. The pharmaceutical composition according to any of the claims 33-34, wherein the compounds are formulated as dimers.
36. The pharmaceutical composition according to any of the claims 33-34, wherein the compounds are formulated as multimers.
- 25 37. The pharmaceutical composition according to any of the claims 33-36 formulated for oral, percutaneous, intramuscular, intravenous, intracranial, intrathecal, intracerebroventricular, intranasal or pulmonal administration.
- 30 38. The pharmaceutical composition according to claim 37, wherein the administration is continuous.
- 35 39. A process of producing a pharmaceutical composition, comprising mixing an effective amount of one or more of the compounds according to the claims 1-32, or a pharmaceutical composition according to any of the claims 33-38 with one or more pharmaceutically acceptable additives or carriers.

40. The process according to claim 39, wherein the compound as defined in the claims 1-32 are used in combination with a prosthetic device.

41. The process according to claim 40, wherein the device is a prosthetic nerve guide.

42. The process according to claim 41, wherein the prosthetic nerve guide is characterised in that it comprises at least one compound as defined in any of the claims 1-32, or a pharmaceutical composition as defined in any of the claims 33-38.

43. The process according to the claims 39-42, wherein an effective amount of at least one compound as defined in any of the claims 1-32, or a pharmaceutical composition according to any of the claims 33-38 is administered to a subject.

44. Use of a compound as defined in any of the claims 1 to 36.

45. The use according to claim 44 of a compound 1-32 in the manufacture of a medicament.

46. The use according to any of the claims 45, wherein the compound and/or pharmaceutical composition is for the treatment of diseases or conditions of the central and peripheral nervous system, such as postoperative nerve damage, traumatic nerve damage, e.g. resulting from spinal cord injury, impaired myelination of nerve fibers, postischaemic damage, e.g. resulting from a stroke, multiinfarct dementia, multiple sclerosis, nerve degeneration associated with diabetes mellitus, neuro-muscular degeneration, schizophrenia, mood disorders, such as manic depressive disorders, Alzheimer's disease, Parkinson's disease, or Huntington's disease.

47. The use according to any of the preceding claims 45, wherein the compound and/or pharmaceutical composition is for the treatment of diseases or conditions of the muscles including conditions with impaired function of neuro-muscular connections, such as genetic or traumatic atrophic muscle disorders; or for the treatment of diseases or conditions of various organs, such as degenerative conditions of the gonads, of the pancreas, such as diabetes mellitus type I and II, of the kidney, such as nephrosis.


48. The use according to claim 45, wherein the compound and/or pharmaceutical composition is for preventing cell death of heart muscle cells, such as after acute myocardial in-

farction.


- 5
49. The use according to claim 45, wherein the compound and/or pharmaceutical composition is for revascularisation.
50. The use according to claim 45, wherein the compound and/or pharmaceutical composition is for the promotion of wound-healing.
- 10
51. The use according to claim 45, wherein the compound and/or pharmaceutical composition is capable of inhibiting angiogenesis.
52. The use according to any of the claims 45 or 51, wherein the compound and/or pharmaceutical composition is for the treatment of cancer.
- 15
53. The use according to any of the claims 45, wherein the compound is for the stimulation of the ability to learn and/or of the short and/or long term memory.
- 20
54. The use according to the claims 45, capable of modulating proliferation and/or differentiation and/or regeneration and/or neuronal plasticity and/or survival of cells.



Fig. 1



b



a





Fig. 2



3/13

Fig. 2 E




Fig. 2 F






Fig. 2 G



6/13


Fig. 3




7/13

Fig. 4


a




b



c




d



8/13

Fig. 5

a



b






Fig. 6A







Fig. 6B

10/13


Fig. 7



11/13

Fig. 8

Effect of the FGL peptide on survival of cerebellar granule cells (CGC)



**Fig. 9A**


Peptides derived from the FG-loop of the third fibronectin type III-module of the neural cell adhesion molecule L1:

- AFNGRGLG
- QAFNGRGLGP
- EVQAFNGRGLGPPAS

Peptides derived from the FG-loop of the first fibronectin type III-module of NCAM:

- ALNGKGLG
- AALNGKGLGE
- RLAALNGKGLGEIS

Fig. 9B



## SEQUENCE LISTING

<110> ENKAM

<120> NCAM/FG-Loop

<130> P 513 PC00

<160> 204

<170> PatentIn version 3.1

<210> 1

<211> 15

<212> PRT

<213> Human, mouse, rat

<400> 1

Glu Val Tyr Val Val Ala Glu Asn Gln Gln Gly Lys Ser Lys Ala  
1 5 10 15

<210> 2

<211> 15

<212> PRT

<213> Human, mouse, rat

<400> 2

Glu Val Ala Val Val Ala Glu Asn Gln Gln Gly Ala Ser Ala Ala  
1 5 10 15

<210> 3

<211> 9

<212> PRT

<213> Human, mouse, rat

<400> 3

Val Ala Glu Asn Gln Gln Gly Lys Ser  
1 5

<210> 4

<211> 7

<212> PRT

<213> Human, mouse, rat

<400> 4

Ala Glu Asn Gln Gln Gly Lys  
1 5

<210> 5

<211> 7

<212> PRT

<213> Human, mouse, rat

<400> 5

Ala Glu Asn Gln Ala Gly Lys  
1 5

<210> 6

<211> 7

<212> PRT

<213> Human, mouse, rat

<400> 6

Ala Glu Asn Gln Ala Gly Lys  
1 5

<210> 7

<211> 7

<212> PRT

<213> Human, mouse, rat

<400> 7

Ala Met Lys Glu Asp Gly Arg  
1 5

<210> 8

<211> 8

<212> PRT

<213> Human, mouse, rat

<400> 8

Ala Leu Asn Gly Lys Gly Leu Gly  
1 5

<210> 9

<211> 8

<212> PRT

<213> Human, mouse, rat

<400> 9

Ala Phe Asn Gly Arg Gly Leu Gly  
1 5

<210> 10

<211> 7

<212> PRT

<213> Human, mouse, rat

<400> 10

Leu Asn Gly Lys Gly Leu Gly  
1 5

<210> 11  
<211> 6  
<212> PRT  
<213> Human, mouse, rat

<400> 11

Leu Asn Gly Lys Gly Leu  
1 5

<210> 12  
<211> 6  
<212> PRT  
<213> Human, mouse, rat

<400> 12

Ala Leu Asn Gly Lys Gly  
1 5

<210> 13  
<211> 8  
<212> PRT  
<213> Human, mouse, rat

<400> 13

Leu Asn Gly Asn Ala Leu Gly Glu  
1 5

<210> 14  
<211> 7  
<212> PRT  
<213> Human, mouse, rat

<400> 14

Leu Asn Gly Lys Ala Leu Gly  
1 5

<210> 15  
<211> 7  
<212> PRT  
<213> Human, mouse, rat

<400> 15

Ala Leu Asn Gly Lys Ala Leu  
1 5



<210> 16  
<211> 9  
<212> PRT  
<213> Human, mouse, rat

<400> 16

Ala Leu Asn Leu Lys Gly Leu Gly Asp  
1 5

<210> 17  
<211> 7  
<212> PRT  
<213> Human, mouse, rat

<400> 17

Leu Asn Gly Lys Glu Leu Gly  
1 5

<210> 18  
<211> 8  
<212> PRT  
<213> Human, mouse, rat

<400> 18

Leu Thr Gly Lys Gly Leu Ala Glu  
1 5

<210> 19  
<211> 8  
<212> PRT  
<213> Human, mouse, rat

<400> 19

Leu Lys Gly Lys Gly Leu Glu Glu  
1 5

<210> 20  
<211> 8  
<212> PRT  
<213> Human, mouse, rat

<400> 20

Leu Asn Ser Lys Gly Leu Val Glu  
1 5

<210> 21  
<211> 8  
<212> PRT  
<213> Human, mouse, rat

<400> 21

Leu Asn Gly Lys Ala Leu Val Glu  
1 5

<210> 22

<211> 8

<212> PRT

<213> Human, mouse, rat

<400> 22

Leu Ala Ala Lys Gly Leu Gly Glu  
1 5

<210> 23

<211> 6

<212> PRT

<213> Human, mouse, rat

<400> 23

Leu Asp Gly Lys Gly Leu  
1 5

<210> 24

<211> 5

<212> PRT

<213> Human, mouse, rat

<400> 24

Lys Gly Leu Gly Glu  
1 5

<210> 25

<211> 7

<212> PRT

<213> Human, mouse, rat

<400> 25

Asp Gly Lys Ser Leu Gly Glu  
1 5

<210> 26

<211> 5

<212> PRT

<213> Human, mouse, rat

<400> 26

Asn Gly Lys Gly Leu

1

5

<210> 27  
<211> 5  
<212> PRT  
<213> Human, mouse, rat

<400> 27

Asn Gly Arg Gly Leu  
1 5

<210> 28  
<211> 10  
<212> PRT  
<213> Human, mouse, rat

<400> 28

Gln Ala Phe Asn Gly Arg Gly Leu Gly Pro  
1 5 10

<210> 29  
<211> 15  
<212> PRT  
<213> Human, mouse, rat

<400> 29

Glu Val Gln Ala Phe Asn Gly Arg Gly Leu Gly Pro Pro Ala Ser  
1 5 10 15

<210> 30  
<211> 10  
<212> PRT  
<213> Human, mouse, rat

<400> 30

Ala Ala Leu Asn Gly Lys Gly Leu Gly Glu  
1 5 10

<210> 31  
<211> 14  
<212> PRT  
<213> Human, mouse, rat

<400> 31

Arg Leu Ala Ala Leu Asn Gly Lys Gly Leu Gly Glu Ile Ser  
1 5 10

<210> 32

SUBSTITUTE SHEET (RULE 26)

<211> 8  
<212> PRT  
<213> Human, mouse, rat

<400> 32

Ala Leu Asn Gly Lys Gly Ala Pro  
1 5

<210> 33  
<211> 10  
<212> PRT  
<213> Human, mouse, rat

<400> 33

Val Ala Leu Asn Gly Lys Gly Ala Pro Arg  
1 5 10

<210> 34  
<211> 14  
<212> PRT  
<213> Human, mouse, rat

<400> 34

Met Tyr Val Ala Leu Asn Gly Lys Gly Ala Pro Arg Arg Gln  
1 5 10

<210> 35  
<211> 5  
<212> PRT  
<213> Human, mouse, rat

<400> 35

Leu Asn Gly Arg Gly  
1 5

<210> 36  
<211> 5  
<212> PRT  
<213> Human, mouse, rat

<400> 36

Leu Asn Gly Lys Gly  
1 5

<210> 37  
<211> 15  
<212> PRT  
<213> Human, mouse, rat

&lt;400&gt; 37

Met Tyr Val Ala Leu Asn Gly Lys Gly Ala Pro Arg Arg Gly Gln  
1 5 10 15

&lt;210&gt; 38

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Human, mouse, rat

&lt;400&gt; 38

Met Phe Leu Ala Leu Asp Arg Arg Gly Gly Pro Arg Pro Gly Gly  
1 5 10 15

&lt;210&gt; 39

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Human, mouse, rat

&lt;400&gt; 39

Met Phe Leu Ala Leu Asp Ser Gln Gly Ile Pro Arg Gln Gly Gln  
1 5 10 15

&lt;210&gt; 40

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Human, mouse, rat

&lt;400&gt; 40

Met Phe Val Ala Leu Asn Gln Lys Gly Ile Pro Val Arg Gly  
1 5 10

&lt;210&gt; 41

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Human, mouse, rat

&lt;400&gt; 41

Met Phe Val Ala Leu Asn Gln Lys Gly Ile Pro Val Lys Gly  
1 5 10

&lt;210&gt; 42

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Human, mouse, rat

&lt;400&gt; 42

Met Phe Val Ala Leu Asn Gln Lys Gly Leu Pro Val Lys Gly  
1 5 10

SUBSTITUTE SHEET (RULE 26)

<210> 43  
<211> 14  
<212> PRT  
<213> Human, mouse, rat

<400> 43

Trp Tyr Val Ser Val Asn Gly Lys Gly Arg Pro Arg Arg Gly  
1 5 10

<210> 44  
<211> 14  
<212> PRT  
<213> Human, mouse, rat

<400> 44

Tyr Tyr Val Ala Leu Asn Lys Asp Gly Thr Pro Arg Glu Gly  
1 5 10

<210> 45  
<211> 14  
<212> PRT  
<213> Human, mouse, rat

<400> 45

Tyr Tyr Val Ala Leu Asn Lys Asp Gly Ser Pro Arg Glu Gly  
1 5 10

<210> 46  
<211> 14  
<212> PRT  
<213> Human, mouse, rat

<400> 46

Tyr Phe Val Ala Leu Asn Lys Asp Gly Thr Pro Arg Asp Gly  
1 5 10

<210> 47  
<211> 14  
<212> PRT  
<213> Human, mouse, rat

<400> 47

Trp Tyr Val Ala Leu Asn Lys Arg Gly Lys Ala Lys Arg Gly  
1 5 10

<210> 48  
<211> 14

<212> PRT  
<213> Human, mouse, rat

<400> 48

Trp Tyr Leu Gly Leu Asn Lys Glu Gly Glu Ile Met Lys Gly  
1 5 10

<210> 49  
<211> 14  
<212> PRT  
<213> Human, mouse, rat

<400> 49

Trp Phe Leu Gly Leu Asn Lys Glu Gly Gln Ile Met Lys Gly  
1 5 10

<210> 50  
<211> 14  
<212> PRT  
<213> Human, mouse, rat

<400> 50

Thr Tyr Ile Ala Leu Ser Lys Tyr Gly Arg Val Lys Arg Gly  
1 5 10

<210> 51  
<211> 14  
<212> PRT  
<213> Human, mouse, rat

<400> 51

Trp Phe Leu Gly Leu Asn Lys Glu Gly Gln Ala Met Lys Gly  
1 5 10

<210> 52  
<211> 14  
<212> PRT  
<213> Human, mouse, rat

<400> 52

Trp Phe Leu Gly Leu Asn Lys Glu Gly Gln Val Met Lys Gly  
1 5 10

<210> 53  
<211> 14  
<212> PRT  
<213> Human, mouse, rat

<400> 53

Trp Tyr Leu Gly Leu Asp Lys Glu Gly Gln Val Met Lys Gly  
1 5 10

<210> 54  
<211> 14  
<212> PRT  
<213> Human, mouse, rat

<400> 54

Trp Tyr Leu Gly Leu Asp Lys Glu Gly Arg Val Met Lys Gly  
1 5 10

<210> 55  
<211> 14  
<212> PRT  
<213> Human, mouse, rat

<400> 55

Trp Tyr Val Ala Leu Lys Arg Thr Gly Gln Tyr Lys Leu Gly  
1 5 10

<210> 56  
<211> 14  
<212> PRT  
<213> Human, mouse, rat

<400> 56

Trp Phe Val Gly Leu Lys Lys Asn Gly Ser Cys Lys Arg Gly  
1 5 10

<210> 57  
<211> 16  
<212> PRT  
<213> Human, mouse, rat

<400> 57

Ala Asn Arg Tyr Leu Ala Met Lys Glu Asp Gly Arg Leu Leu Ala Ser  
1 5 10 15

<210> 58  
<211> 16  
<212> PRT  
<213> Human, mouse, rat

<400> 58

Thr Gly Gln Tyr Leu Ala Met Asp Thr Glu Gly Leu Leu Tyr Gly Ser  
1 5 10 15



<210> 59  
<211> 16  
<212> PRT  
<213> Human, mouse, rat

<400> 59

Thr Gly Gln Tyr Leu Ala Met Asp Thr Asp Gly Leu Leu Tyr Gly Ser  
1 5 10 15

<210> 60  
<211> 16  
<212> PRT  
<213> Human, mouse, rat

<400> 60

Thr Gly Gln Tyr Leu Ala Met Asp Thr Ser Gly Leu Leu Tyr Gly Ser  
1 5 10 15

<210> 61  
<211> 16  
<212> PRT  
<213> Human, mouse, rat

<400> 61

Thr Gly Gln Phe Leu Ala Met Asp Thr Asp Gly Leu Leu Tyr Gly Ser  
1 5 10 15

<210> 62  
<211> 16  
<212> PRT  
<213> Human, mouse, rat

<400> 62

Ser Arg Phe Phe Val Ala Met Ser Ser Lys Gly Lys Leu Tyr Gly Ser  
1 5 10 15

<210> 63  
<211> 16  
<212> PRT  
<213> Human, mouse, rat

<400> 63

Ser Arg Phe Phe Val Ala Met Ser Ser Arg Gly Lys Leu Phe Gly Val  
1 5 10 15

<210> 64  
<211> 16  
<212> PRT

<213> Human, mouse, rat

<400> 64

Ser	Arg	Phe	Phe	Val	Ala	Met	Ser	Ser	Arg	Gly	Arg	Leu	Tyr	Gly	Ser
1				5					10					15	

<210> 65

<211> 16

<212> PRT

<213> Human, mouse, rat

<400> 65

Ser	Gly	Leu	Phe	Val	Ala	Met	Asn	Ser	Lys	Gly	Lys	Leu	Tyr	Gly	Ser
1				5					10					15	

<210> 66

<211> 16

<212> PRT

<213> Human, mouse, rat

<400> 66

Ser	Asn	Lys	Phe	Leu	Ala	Met	Ser	Lys	Lys	Gly	Lys	Leu	His	Ala	Ser
1				5					10					15	

<210> 67

<211> 16

<212> PRT

<213> Human, mouse, rat

<400> 67

Ser	Ala	Leu	Phe	Val	Ala	Met	Asn	Ser	Lys	Gly	Arg	Leu	Tyr	Ala	Thr
1				5					10					15	

<210> 68

<211> 16

<212> PRT

<213> Human, mouse, rat

<400> 68

Ser	Ala	Leu	Phe	Ile	Ala	Met	Asn	Ser	Lys	Gly	Arg	Leu	Tyr	Thr	Thr
1				5					10					15	

<210> 69

<211> 16

<212> PRT

<213> Human, mouse, rat

<400> 69

Ser Gly Arg Tyr Leu Ala Met Asn Lys Arg Gly Arg Leu Tyr Ala Ser  
1 5 10 15

<210> 70  
<211> 16  
<212> PRT  
<213> Human, mouse, rat  
  
<400> 70

Ser Glu Tyr Tyr Leu Ala Met Asn Lys Glu Gly Lys Leu Tyr Ala Lys  
1 5 10 15

<210> 71  
<211> 15  
<212> PRT  
<213> Human, mouse, rat  
  
<400> 71

Ser Glu Tyr Tyr Leu Ala Met Asn Lys Gln Gly Leu Tyr Ala Lys  
1 5 10 15

<210> 72  
<211> 16  
<212> PRT  
<213> Human, mouse, rat  
  
<400> 72

Ser Glu Phe Tyr Leu Ala Met Asn Lys Glu Gly Lys Leu Tyr Ala Lys  
1 5 10 15

<210> 73  
<211> 16  
<212> PRT  
<213> Human, mouse, rat  
  
<400> 73

Ser Gly Leu Tyr Leu Gly Met Asn Glu Lys Gly Glu Leu Tyr Gly Ser  
1 5 10 15

<210> 74  
<211> 16  
<212> PRT  
<213> Human, mouse, rat  
  
<400> 74

Ser Gly Leu Tyr Leu Gly Met Asn Asp Lys Gly Glu Leu Tyr Gly Ser  
1 5 10 15

<210> 75  
<211> 16  
<212> PRT  
<213> Human, mouse, rat

<400> 75

Ser Gly Leu Tyr Leu Gly Met Asn Glu Arg Gly Glu Leu Tyr Gly Ser  
1 5 10 15

<210> 76  
<211> 16  
<212> PRT  
<213> Human, mouse, rat

<400> 76

Ser Gly Leu Tyr Leu Gly Met Asn Glu Arg Gly Glu Leu Phe Gly Ser  
1 5 10 15

<210> 77  
<211> 16  
<212> PRT  
<213> Human, mouse, rat

<400> 77

Ser Asn Tyr Tyr Leu Ala Met Asn Lys Lys Gly Lys Leu Tyr Gly Ser  
1 5 10 15

<210> 78  
<211> 16  
<212> PRT  
<213> Human, mouse, rat

<400> 78

Ser Gly Phe Tyr Val Ala Met Asn Arg Arg Gly Arg Leu Tyr Gly Ser  
1 5 10 15

<210> 79  
<211> 16  
<212> PRT  
<213> Human, mouse, rat

<400> 79

Thr Gly Leu Tyr Ile Ala Met Asn Gly Glu Gly Tyr Leu Tyr Pro Ser  
1 5 10 15

<210> 80  
<211> 16  
<212> PRT  
<213> Human, mouse, rat

&lt;400&gt; 80

Ala Ser Leu Tyr Val Ala Met Asn Gly Glu Gly Tyr Leu Tyr Ser Ser  
1 5 10 15

&lt;210&gt; 81

&lt;211&gt; 16

&lt;212&gt; PRT

&lt;213&gt; Human, mouse, rat

&lt;400&gt; 81

Thr Lys Leu Tyr Leu Ala Met Asn Ser Glu Gly Tyr Leu Tyr Thr Ser  
1 5 10 15

&lt;210&gt; 82

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Human, mouse, rat

&lt;400&gt; 82

Thr Gly Leu Tyr Ile Cys Met Asn Lys Lys Gly Lys Leu Ile Ala Lys  
1 5 10 15

Ser

&lt;210&gt; 83

&lt;211&gt; 16

&lt;212&gt; PRT

&lt;213&gt; Human, mouse, rat

&lt;400&gt; 83

Leu Gly His Tyr Met Ala Met Asn Ala Glu Gly Leu Leu Tyr Ser Ser  
1 5 10 15

&lt;210&gt; 84

&lt;211&gt; 16

&lt;212&gt; PRT

&lt;213&gt; Human, mouse, rat

&lt;400&gt; 84

Thr Glu Phe Tyr Leu Cys Met Asn Arg Lys Gly Lys Leu Val Gly Lys  
1 5 10 15

&lt;210&gt; 85

&lt;211&gt; 16

&lt;212&gt; PRT

&lt;213&gt; Human, mouse, rat

SUBSTITUTE SHEET (RULE 26)

&lt;400&gt; 85

Ser Val Arg Tyr Leu Cys Met Gly Ala Asp Gly Lys Met Gln Gly Leu  
1 5 10 15

&lt;210&gt; 86

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Human, mouse

&lt;400&gt; 86

Trp Phe Val Gly Leu Lys Lys Asn Gly Ser Cys Lys Arg Gly  
1 5 10

&lt;210&gt; 87

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Human, mouse, rat

&lt;400&gt; 87

Trp Tyr Val Ala Leu Lys Arg Thr Gly Gln Tyr Lys Leu Gly  
1 5 10

&lt;210&gt; 88

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Human, mouse

&lt;400&gt; 88

Trp Tyr Val Ser Val Asn Gly Lys Gly Arg Pro Arg Arg Gly  
1 5 10

&lt;210&gt; 89

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Human

&lt;400&gt; 89

Gly Met Phe Ile Ala Leu Ser Lys Asn Gly Lys Thr Lys Lys Gly  
1 5 10 15

&lt;210&gt; 90

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Mouse

&lt;400&gt; 90

Gly Met Phe Met Ala Leu Ser Lys Asn Gly Arg Thr Lys Lys Gly

SUBSTITUTE SHEET (RULE 26)

1 5 10 15

<210> 91  
<211> 15  
<212> PRT  
<213> Bovine

<400> 91

Gly Met Phe Ile Ala Leu Ser Lys Asn Gly Lys Ala Lys Lys Gly  
1 5 10 15

<210> 92  
<211> 14  
<212> PRT  
<213> Human, mouse, rat

<400> 92

Trp Tyr Val Ala Leu Asn Lys Arg Gly Lys Ala Lys Arg Gly  
1 5 10

<210> 93  
<211> 14  
<212> PRT  
<213> Human, mouse

<400> 93

Thr Tyr Ile Ala Leu Ser Lys Tyr Gly Arg Val Lys Arg Gly  
1 5 10

<210> 94  
<211> 14  
<212> PRT  
<213> Human

<400> 94

Met Phe Val Ala Leu Asn Gln Lys Gly Ile Pro Val Arg Gly  
1 5 10

<210> 95  
<211> 14  
<212> PRT  
<213> Mouse

<400> 95

Met Phe Val Ala Leu Asn Gln Lys Gly Ile Pro Val Lys Gly  
1 5 10

<210> 96

<211> 14  
<212> PRT  
<213> Rat

<400> 96

Met Phe Val Ala Leu Asn Gln Lys Gly Leu Pro Val Lys Gly  
1 5 10

<210> 97  
<211> 14  
<212> PRT  
<213> Human, mouse

<400> 97

Trp Tyr Met Ala Phe Thr Arg Lys Gly Arg Pro Arg Lys Gly  
1 5 10

<210> 98  
<211> 14  
<212> PRT  
<213> Human, mouse, rat

<400> 98

Tyr Tyr Val Ala Leu Asn Lys Asp Gly Thr Pro Arg Glu Gly  
1 5 10

<210> 99  
<211> 15  
<212> PRT  
<213> Human, mouse

<400> 99

Met Tyr Val Ala Leu Asn Gly Lys Gly Ala Pro Arg Arg Gly Gln  
1 5 10 15

<210> 100  
<211> 14  
<212> PRT  
<213> Human

<400> 100

Trp Tyr Leu Gly Leu Asp Lys Glu Gly Gln Val Met Lys Gly  
1 5 10

<210> 101  
<211> 14  
<212> PRT  
<213> Mouse



&lt;400&gt; 101

Trp Tyr Leu Gly Leu Asp Lys Glu Gly Arg Val Met Lys Gly  
1 5 10

&lt;210&gt; 102

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Human

&lt;400&gt; 102

Trp Phe Leu Gly Leu Asn Lys Glu Gly Gln Ile Met Lys Gly  
1 5 10

&lt;210&gt; 103

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Human, mouse

&lt;400&gt; 103

Trp Tyr Leu Gly Leu Asn Lys Glu Gly Glu Ile Met Lys Gly  
1 5 10

&lt;210&gt; 104

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Human

&lt;400&gt; 104

Trp Phe Leu Gly Leu Asn Lys Glu Gly Gln Ala Met Lys Gly  
1 5 10

&lt;210&gt; 105

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Mouse

&lt;400&gt; 105

Trp Phe Leu Gly Leu Asn Lys Glu Gly Gln Val Met Lys Gly  
1 5 10

&lt;210&gt; 106

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Human, mouse, rat

&lt;400&gt; 106

Tyr Tyr Val Ala Leu Asn Lys Asp Gly Ser Pro Arg Glu Gly  
1 5 10

SUBSTITUTE SHEET (RULE 26)

<210> 107  
<211> 13  
<212> PRT  
<213> Human, mouse

<400> 107

Trp Phe Met Ala Phe Thr Arg Gln Gly Arg Pro Arg Gln  
1 5 10

<210> 108  
<211> 14  
<212> PRT  
<213> Human

<400> 108

Trp Phe Val Gly Leu Lys Lys Asn Gly Ser Cys Lys Arg Gly  
1 5 10

<210> 109  
<211> 14  
<212> PRT  
<213> mouse, rat

<400> 109

Trp Tyr Val Gly Phe Thr Lys Lys Gly Arg Pro Arg Lys Gly  
1 5 10

<210> 110  
<211> 14  
<212> PRT  
<213> Human

<400> 110

Tyr Phe Val Ala Leu Asn Lys Asp Gly Thr Pro Arg Asp Gly  
1 5 10

<210> 111  
<211> 15  
<212> PRT  
<213> Human

<400> 111

Met Phe Leu Ala Leu Asp Arg Arg Gly Gly Pro Arg Pro Gly Gly  
1 5 10 15

<210> 112  
<211> 15

<212> PRT  
<213> Mouse

<400> 112

Met Phe Leu Ala Leu Asp Ser Gln Gly Ile Pro Arg Gln Gly Gln  
1 5 10 15

<210> 113  
<211> 16  
<212> PRT  
<213> Mouse

<400> 113

Thr Gly Gln Tyr Leu Ala Met Asp Thr Glu Gly Leu Leu Tyr Gly Ser  
1 5 10 15

<210> 114  
<211> 16  
<212> PRT  
<213> Human

<400> 114

Thr Gly Gln Tyr Leu Ala Met Asp Thr Asp Gly Leu Leu Tyr Gly Ser  
1 5 10 15

<210> 115  
<211> 16  
<212> PRT  
<213> Pig

<400> 115

Thr Gly Gln Tyr Leu Ala Met Asp Thr Ser Gly Leu Leu Tyr Gly Ser  
1 5 10 15

<210> 116  
<211> 16  
<212> PRT  
<213> Bovine

<400> 116

Thr Gly Gln Phe Leu Ala Met Asp Thr Asp Gly Leu Leu Tyr Gly Ser  
1 5 10 15

<210> 117  
<211> 16  
<212> PRT  
<213> Human, mouse, rat, sheep, bovine, rabbit, chick

<400> 117

SUBSTITUTE SHEET (RULE 26)

Ala Asn Arg Tyr Leu Ala Met Lys Glu Asp Gly Arg Leu Leu Ala Ser  
1 5 10 15

<210> 118  
<211> 16  
<212> PRT  
<213> Human, mouse, chick

<400> 118

Ser Gly Arg Tyr Leu Ala Met Asn Lys Arg Gly Arg Leu Tyr Ala Ser  
1 5 10 15

<210> 119  
<211> 16  
<212> PRT  
<213> Human

<400> 119

Ser Arg Phe Phe Val Ala Met Ser Ser Lys Gly Lys Leu Tyr Gly Ser  
1 5 10 15

<210> 120  
<211> 16  
<212> PRT  
<213> Mouse

<400> 120

Ser Arg Phe Phe Val Ala Met Ser Ser Arg Gly Lys Leu Phe Gly Val  
1 5 10 15

<210> 121  
<211> 16  
<212> PRT  
<213> Bovine

<400> 121

Ser Arg Phe Phe Val Ala Met Ser Ser Arg Gly Arg Leu Tyr Gly Ser  
1 5 10 15

<210> 122  
<211> 16  
<212> PRT  
<213> Chick

<400> 122

Ser Gly Leu Phe Val Ala Met Asn Ser Lys Gly Lys Leu Tyr Gly Ser  
1 5 10 15

SUBSTITUTE SHEET (RULE 26)

<210> 123  
<211> 16  
<212> PRT  
<213> Human, mouse, rat

<400> 123

Ser Asn Lys Phe Leu Ala Met Ser Lys Lys Gly Lys Leu His Ala Ser  
1 5 10 15

<210> 124  
<211> 16  
<212> PRT  
<213> Human

<400> 124

Ser Ala Leu Phe Val Ala Met Asn Ser Lys Gly Arg Leu Tyr Ala Thr  
1 5 10 15

<210> 125  
<211> 16  
<212> PRT  
<213> Mouse

<400> 125

Ser Ala Leu Phe Ile Ala Met Asn Ser Lys Gly Arg Leu Tyr Thr Thr  
1 5 10 15

<210> 126  
<211> 16  
<212> PRT  
<213> Human, pi, sheep

<400> 126

Ser Glu Tyr Tyr Leu Ala Met Asn Lys Glu Gly Lys Leu Tyr Ala Lys  
1 5 10 15

<210> 127  
<211> 15  
<212> PRT  
<213> Human

<400> 127

Ser Glu Tyr Tyr Leu Ala Met Asn Lys Gln Gly Leu Tyr Ala Lys  
1 5 10 15

<210> 128  
<211> 16  
<212> PRT

&lt;213&gt; Rat

&lt;400&gt; 128

Ser Glu Phe Tyr Leu Ala Met Asn Lys Glu Gly Lys Leu Tyr Ala Lys  
1 5 10 15

&lt;210&gt; 129

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Human, mouse

&lt;400&gt; 129

Thr Gly Leu Tyr Ile Cys Met Asn Lys Lys Gly Lys Leu Ile Ala Lys  
1 5 10 15

Ser

&lt;210&gt; 130

&lt;211&gt; 16

&lt;212&gt; PRT

&lt;213&gt; Human, mouse, rat

&lt;400&gt; 130

Ser Gly Leu Tyr Leu Gly Met Asn Glu Lys Gly Glu Leu Tyr Gly Ser  
1 5 10 15

&lt;210&gt; 131

&lt;211&gt; 16

&lt;212&gt; PRT

&lt;213&gt; Human, mouse, rat

&lt;400&gt; 131

Ser Asn Tyr Tyr Leu Ala Met Asn Lys Lys Gly Lys Leu Tyr Gly Ser  
1 5 10 15

&lt;210&gt; 132

&lt;211&gt; 16

&lt;212&gt; PRT

&lt;213&gt; Human, mouse

&lt;400&gt; 132

Leu Gly His Tyr Met Ala Met Asn Ala Glu Gly Leu Leu Tyr Ser Ser  
1 5 10 15

&lt;210&gt; 133

&lt;211&gt; 16

&lt;212&gt; PRT

<213> Human

<400> 133

Ala Ser Leu Tyr Val Ala Met Asn Gly Glu Gly Tyr Leu Tyr Ser Ser  
1 5 10 15

<210> 134

<211> 16

<212> PRT

<213> Human, mouse

<400> 134

Thr Lys Leu Tyr Leu Ala Met Asn Ser Glu Gly Tyr Leu Tyr Thr Ser  
1 5 10 15

<210> 135

<211> 16

<212> PRT

<213> Human, mouse

<400> 135

Thr Gly Leu Tyr Ile Ala Met Asn Gly Glu Gly Tyr Leu Tyr Pro Ser  
1 5 10 15

<210> 136

<211> 15

<212> PRT

<213> Mouse

<400> 136

Ser Val Arg Tyr Leu Cys Met Ser Ala Asp Gly Lys Ile Tyr Gly  
1 5 10 15

<210> 137

<211> 16

<212> PRT

<213> Human

<400> 137

Ser Gly Leu Tyr Leu Gly Met Asn Glu Arg Gly Glu Leu Tyr Gly Ser  
1 5 10 15

<210> 138

<211> 16

<212> PRT

<213> Rat

<400> 138

Ser Gly Leu Tyr Leu Gly Met Asn Glu Arg Gly Glu Leu Phe Gly Ser  
1 5 10 15

<210> 139  
<211> 15  
<212> PRT  
<213> Human, mouse

<400> 139

Ser Glu Lys Tyr Ile Cys Met Asn Lys Arg Gly Lys Leu Ile Gly  
1 5 10 15

<210> 140  
<211> 16  
<212> PRT  
<213> Human, mouse, rat

<400> 140

Thr Glu Phe Tyr Leu Cys Met Asn Arg Lys Gly Lys Leu Val Gly Lys  
1 5 10 15

<210> 141  
<211> 16  
<212> PRT  
<213> Human

<400> 141

Ser Val Arg Tyr Leu Cys Met Gly Ala Asp Gly Lys Met Gln Gly Leu  
1 5 10 15

<210> 142  
<211> 16  
<212> PRT  
<213> Human

<400> 142

Ser Gly Leu Tyr Leu Gly Met Asn Asp Lys Gly Glu Leu Tyr Gly Ser  
1 5 10 15

<210> 143  
<211> 15  
<212> PRT  
<213> Human

<400> 143

Thr Ser Arg Phe Leu Cys Gln Arg Pro Asp Gly Ala Leu Tyr Gly  
1 5 10 15



<210> 144  
<211> 15  
<212> PRT  
<213> Mouse

<400> 144

Ala Ser Arg Phe Leu Cys Gln Gln Pro Asp Gly Ala Leu Tyr Gly  
1 5 10 15

<210> 145  
<211> 16  
<212> PRT  
<213> Human, mouse

<400> 145

Ser Gly Phe Tyr Val Ala Met Asn Arg Arg Gly Arg Leu Tyr Gly Ser  
1 5 10 15

<210> 146  
<211> 16  
<212> PRT  
<213> Human

<400> 146

Ser Arg Arg Tyr Leu Cys Met Asp Phe Arg Gly Asn Ile Phe Gly Ser  
1 5 10 15

<210> 147  
<211> 16  
<212> PRT  
<213> Mouse

<400> 147

Thr Arg Arg Phe Leu Cys Met Asp Leu His Gly Asn Ile Phe Gly Ser  
1 5 10 15

<210> 148  
<211> 8  
<212> PRT  
<213> Human, mouse

<400> 148

Gly Leu Lys Lys Asn Gly Ser Cys  
1 5

<210> 149  
<211> 8  
<212> PRT  
<213> Human, mouse, rat

&lt;400&gt; 149

Ala Leu Lys Arg Thr Gly Gln Tyr  
1 5

&lt;210&gt; 150

&lt;211&gt; 8

&lt;212&gt; PRT

&lt;213&gt; Human, mouse

&lt;400&gt; 150

Ser Val Asn Gly Lys Gly Arg Pro  
1 5

&lt;210&gt; 151

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Human

&lt;400&gt; 151

Ile Ala Leu Ser Lys Asn Gly Lys Thr  
1 5

&lt;210&gt; 152

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Mouse

&lt;400&gt; 152

Met Ala Leu Ser Lys Asn Gly Arg Thr  
1 5

&lt;210&gt; 153

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Bovine

&lt;400&gt; 153

Ile Ala Leu Ser Lys Asn Gly Lys Ala  
1 5

&lt;210&gt; 154

&lt;211&gt; 8

&lt;212&gt; PRT

&lt;213&gt; Human, mouse, rat

&lt;400&gt; 154

Ala Leu Asn Lys Arg Gly Lys Ala

1 5

<210> 155  
<211> 8  
<212> PRT  
<213> Human, mouse

<400> 155

Ala Leu Ser Lys Tyr Gly Arg Val  
1 5

<210> 156  
<211> 8  
<212> PRT  
<213> Human, mouse

<400> 156

Ala Leu Asn Gln Lys Gly Ile Pro  
1 5

<210> 157  
<211> 8  
<212> PRT  
<213> Rat

<400> 157

Ala Leu Asn Gln Lys Gly Leu Pro  
1 5

<210> 158  
<211> 8  
<212> PRT  
<213> Human, mouse

<400> 158

Ala Phe Thr Arg Lys Gly Arg Pro  
1 5

<210> 159  
<211> 8  
<212> PRT  
<213> Human, mouse, rat

<400> 159

Ala Leu Asn Lys Asp Gly Thr Pro  
1 5

<210> 160

<211> 9  
<212> PRT  
<213> Human, mouse

<400> 160

Ala Leu Asn Gly Lys Gly Ala Pro Arg  
1 5

<210> 161  
<211> 8  
<212> PRT  
<213> Human

<400> 161

Gly Leu Asp Lys Glu Gly Gln Val  
1 5

<210> 162  
<211> 8  
<212> PRT  
<213> Mouse

<400> 162

Gly Leu Asp Lys Glu Gly Arg Val  
1 5

<210> 163  
<211> 8  
<212> PRT  
<213> Human

<400> 163

Gly Leu Asn Lys Glu Gly Gln Ile  
1 5

<210> 164  
<211> 8  
<212> PRT  
<213> Human, mouse

<400> 164

Gly Leu Asn Lys Glu Gly Glu Ile  
1 5

<210> 165  
<211> 8  
<212> PRT  
<213> Human

&lt;400&gt; 165

Gly Leu Asn Lys Glu Gly Gln Ala  
1 5

&lt;210&gt; 166

&lt;211&gt; 8

&lt;212&gt; PRT

&lt;213&gt; Mouse

&lt;400&gt; 166

Gly Leu Asn Lys Glu Gly Gln Val  
1 5

&lt;210&gt; 167

&lt;211&gt; 8

&lt;212&gt; PRT

&lt;213&gt; Human, mouse, rat

&lt;400&gt; 167

Ala Leu Asn Lys Asp Gly Ser Pro  
1 5

&lt;210&gt; 168

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Human, mouse

&lt;400&gt; 168

Ala Phe Thr Arg Gln Gly Arg  
1 5

&lt;210&gt; 169

&lt;211&gt; 8

&lt;212&gt; PRT

&lt;213&gt; Human

&lt;400&gt; 169

Gly Leu Lys Lys Asn Gly Ser Cys  
1 5

&lt;210&gt; 170

&lt;211&gt; 8

&lt;212&gt; PRT

&lt;213&gt; mouse, rat

&lt;400&gt; 170

Gly Phe Thr Lys Lys Gly Arg Pro  
1 5

<210> 171  
<211> 8  
<212> PRT  
<213> Human

<400> 171

Ala Leu Asn Lys Asp Gly Thr Pro  
1 5

<210> 172  
<211> 9  
<212> PRT  
<213> Human

<400> 172

Ala Leu Asp Arg Arg Gly Gly Pro Arg  
1 5

<210> 173  
<211> 9  
<212> PRT  
<213> mouse

<400> 173

Ala Leu Asp Ser Gln Gly Ile Pro Arg  
1 5

<210> 174  
<211> 7  
<212> PRT  
<213> Human, bovine

<400> 174

Ala Met Asp Thr Asp Gly Leu  
1 5

<210> 175  
<211> 7  
<212> PRT  
<213> mouse

<400> 175

Ala Met Asp Thr Glu Gly Leu  
1 5

<210> 176  
<211> 7

<212> PRT  
<213> Pig

<400> 176

Ala Met Asp Thr Ser Gly Leu  
1 5

<210> 177  
<211> 7  
<212> PRT  
<213> Human, mouse, rat, sheep, bovine, rabbit, chick

<400> 177

Ala Met Lys Glu Asp Gly Arg  
1 5

<210> 178  
<211> 7  
<212> PRT  
<213> Human, mouse, chick

<400> 178

Ala Met Asn Lys Arg Gly Arg  
1 5

<210> 179  
<211> 7  
<212> PRT  
<213> Human

<400> 179

Ala Met Ser Ser Lys Gly Lys  
1 5

<210> 180  
<211> 7  
<212> PRT  
<213> mouse, bovine

<400> 180

Ala Met Ser Ser Arg Gly Lys  
1 5

<210> 181  
<211> 7  
<212> PRT  
<213> Chick

<400> 181

Ala Met Asn Ser Lys Gly Lys  
1 5

<210> 182  
<211> 7  
<212> PRT  
<213> Human, mouse, rat

<400> 182

Ala Met Ser Lys Lys Gly Lys  
1 5

<210> 183  
<211> 7  
<212> PRT  
<213> Human, mouse

<400> 183

Ala Met Asn Ser Lys Gly Arg  
1 5

<210> 184  
<211> 7  
<212> PRT  
<213> mouse, pig, sheep

<400> 184

Ala Met Asn Lys Glu Gly Lys  
1 5

<210> 185  
<211> 7  
<212> PRT  
<213> Human

<400> 185

Ala Met Asn Lys Glu Gly Lys  
1 5

<210> 186  
<211> 7  
<212> PRT  
<213> rat

<400> 186

Ala Met Asn Lys Gln Gly Leu  
1 5



<210> 187  
<211> 7  
<212> PRT  
<213> Human, mouse

<400> 187

Cys Met Asn Lys Lys Gly Lys  
1 5

<210> 188  
<211> 7  
<212> PRT  
<213> Human, mouse, rat

<400> 188

Gly Met Asn Glu Lys Gly Glu  
1 5

<210> 189  
<211> 7  
<212> PRT  
<213> Human, mouse, rat

<400> 189

Ala Met Asn Lys Lys Gly Lys  
1 5

<210> 190  
<211> 7  
<212> PRT  
<213> Human, mouse

<400> 190

Ala Met Asn Ala Glu Gly Leu  
1 5

<210> 191  
<211> 7  
<212> PRT  
<213> Human

<400> 191

Ala Met Asn Gly Glu Gly Tyr  
1 5

<210> 192  
<211> 7  
<212> PRT

<213> Human, mouse

<400> 192

Ala Met Asn Ser Glu Gly Tyr  
1 5

<210> 193

<211> 7

<212> PRT

<213> Human, mouse

<400> 193

Ala Met Asn Gly Glu Gly Tyr  
1 5

<210> 194

<211> 7

<212> PRT

<213> mouse

<400> 194

Cys Met Ser Ala Asp Gly Lys  
1 5

<210> 195

<211> 7

<212> PRT

<213> Human, rat

<400> 195

Gly Met Asn Glu Arg Gly Glu  
1 5

<210> 196

<211> 7

<212> PRT

<213> Human, mouse

<400> 196

Cys Met Asn Lys Arg Gly Lys  
1 5

<210> 197

<211> 7

<212> PRT

<213> Human, mouse, rat

<400> 197

Cys Met Asn Arg Lys Gly Lys  
1 5

<210> 198  
<211> 7  
<212> PRT  
<213> Human

<400> 198

Cys Met Gly Ala Asp Gly Lys  
1 5

<210> 199  
<211> 7  
<212> PRT  
<213> Human

<400> 199

Gly Met Asn Asp Lys Gly Glu  
1 5

<210> 200  
<211> 7  
<212> PRT  
<213> Human

<400> 200

Leu Cys Gln Arg Pro Asp Gly  
1 5

<210> 201  
<211> 7  
<212> PRT  
<213> mouse

<400> 201

Leu Cys Gln Gln Pro Asp Gly  
1 5

<210> 202  
<211> 7  
<212> PRT  
<213> Human

<400> 202

Cys Met Asp Phe Arg Gly Asn  
1 5

<210> 203  
<211> 7  
<212> PRT  
<213> mouse

<400> 203

Cys Met Asp Leu His Gly Asn  
1 5

<210> 204  
<211> 7  
<212> PRT  
<213> Human, mouse

<400> 204

Ala Met Asn Arg Arg Gly Arg  
1 5

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
27 February 2003 (27.02.2003)

PCT

(10) International Publication Number  
**WO 2003/016351 A3**

(51) International Patent Classification<sup>7</sup>: **C07K 14/705**,  
A61K 38/17, A61P 21/00, 25/00, 17/02, 35/00, C07K  
7/00, A61K 38/04

LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,  
MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD,  
SE, SG, SI, SK (utility model), SK, SL, TJ, TM, TN, TR,  
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:  
PCT/DK2002/000541

(22) International Filing Date: 19 August 2002 (19.08.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
PA 2001 01228 17 August 2001 (17.08.2001) DK  
PA 2002 00667 2 May 2002 (02.05.2002) DK

(71) Applicant (for all designated States except US): **ENKAM  
PHARMACEUTICALS A/S** [DK/DK]; Fruebjergvej 3,  
DK-2100 Copenhagen Ø (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KISELYOV**,  
Vladislav, V. [UA/DK]; Visbygade 6, st.th., DK-2100  
Copenhagen Ø (DK). **SKLADCHIKOVA**, Galina  
[RU/DK]; Callisensvej 20, 4.th., DK-2900 Hellerup (DK).  
**BEREZIN**, Vladimir [UA/DK]; Nørrebrogade 223,  
1.th., DK-2200 Copenhagen N (DK). **BOCK**, Elisabeth  
[DK/DK]; Tonysvej 20, DK-2920 Charlottenlund (DK).

(74) Agent: **HØIBERG A/S**; Store Kongensgade 59 A,  
DK-1264 Copenhagen K (DK).

(81) Designated States (national): AE, AG, AL, AM, AT (util-  
ity model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,  
CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (util-  
ity model), DE, DK (utility model), DK, DM, DZ, EC, EE  
(utility model), EE, ES, FI (utility model), FI, GB, GD, GE,  
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,  
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted  
a patent (Rule 4.17(ii)) for the following designations AE,  
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,  
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,  
MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD,  
SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ,  
VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS,  
MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent  
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent  
(AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB,  
GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF,  
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,  
TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

**Published:**

- with international search report

(88) Date of publication of the international search report:  
25 March 2004

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: N - CAM RELATED COMPOUNDS MODULATING CELL GROTH

(57) Abstract: The present invention relates to a compound comprising the third Immunoglobulin (Ig3) module, and/or the fourth Immunoglobulin (Ig4) module, and/or the fifth Immunoglobulin (Ig5) module, and/or the first Fibronectin III (Fn3, 1) module, and/or the second Fibronectin III (Fn3, 2) module of neural cell adhesion molecule (NCAM), or a fragment, or a variant thereof, capable of interacting with a Fibroblast Growth Factor (FGF) receptor and/or Adenosine-Tri-Phosphate (ATP) and/or L1, and thereby the compounds are capable of inducing differentiation, modulating proliferation, stimulate regeneration, neuronal plasticity and/or survival of cells. Further, the present invention relates to a pharmaceutical composition comprising said compound, a process of producing a pharmaceutical composition and the use of said compound.



WO 2003/016351 A3

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/DK 02/00541

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/705 A61K38/17 A61P21/00 A61P25/00 A61P17/02  
A61P35/00 C07K7/00 A61K38/04

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K A61K A61P

Documentation searched other than minimum: documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	V.V. KISELYOV ET AL: "Structure of the second fibronectin type III module of NCAM. identification of a neuritogenic site" EUROPEAN JOURNAL OF NEUROSCIENCE, vol. 12, no. 11, 2000, page 274 XP002253822 the whole document	7,8,12, 15-18, 22-54
X	--- GALINA SKLADCHIKOVA ET AL: "Extracellular adenosine triphosphate affects neural cell adhesion molecule (NCAM)-Mediated cell adhesion and neurite outgrowth." JOURNAL OF NEUROSCIENCE RESEARCH, vol. 57, 1999, pages 207-218, XP002902868 Wiley-liss inc. see specially page 215, column 2, line 17. (AENQQGKS) --- -/-	7,15-18

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

10 September 2003

Date of mailing of the international search report

30. 09. 2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

MICAEL OWALD /EÖ

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/DK 02/00541

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHRISTINA KASPER ET AL: "Functional Characterization of NCAM Fibronectin Type III Domains: Demonstration of Modulatory Effects of the Proline-Rich Sequence Encoded by Alternatively Spliced Exons a and AAG " JOURNAL OF NEUROSCIENCE RESEARCH, vol. 46, 1996, pages 173-186, XP002253823 the whole document and see specially page 183, column 2, line 28 - page 184, column 1, line 4 ---	7,8,12, 15-18, 22-54
X	US 6 576 607 B1 (SCHACHNER MELITTA) 10 June 2003 (2003-06-10)  see specially claims ---	7,8,12, 15-18, 22-47, 53,54
X	MING YI ET AL: "A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis." PNAS, vol. 98, no. 2, 16 January 2001 (2001-01-16), pages 620-624, XP002902853 the whole document ---	7,8,12, 15-18, 22-45, 49,51, 52,54
X	US 5 837 813 A (RUOSLAHTI ERKKI I ET AL) 17 November 1998 (1998-11-17)  the whole document ---	7,8,12, 15-18, 22-47, 50,53,54
A	FREI T ET AL: "Different extracellular domains of the neural cell adhesion molecule (N-CAM) are involved in different functions" JOURNAL OF CELL BIOLOGY, ROCKEFELLER UNIVERSITY PRESS, NEW YORK, US, US, vol. 118, no. 1, July 1992 (1992-07), pages 177-194, XP002104607 ISSN: 0021-9525 the whole document ---	7,8,12, 15-18, 22-54
P,X	WO 01 96364 A (IMP COLLEGE INNOVATIONS ;KING S COLLEGE LONDON (GB); SAFFELL JANE) 20 December 2001 (2001-12-20) the whole document ---	7,8,12, 15-18, 22-54
P,X	US 6 313 265 B1 (PHILLIPS G ET AL) 6 November 2001 (2001-11-06)  see figure 3, Seq ID No 72, claim 3 -----	8,12,17, 22-33, 35-47, 53,54

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/DK 02/00541

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1-6,9-11,13-14,19-21 completely and 22-33, 35-54 partially  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

As a result of the prior review under R. 40.2(e) PCT,  
all additional fees are to be refunded.

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:  
  
The search has been directed to subject 1-3 which covers claims 7-8, 12, 15-16, 17 (parts related to SEQ ID No 1-6, 8-11 and 26-31), 18, 22-33 (partially), 34 and 35-54 (partially).
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☒ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-6,9-11,13-14,19-21 completely and 22-33, 35-54 partially

Claims 1-6, 9-11, 13-14, 19-21 completely and 22-33, 35-54 parts that are not subordinated to claim 7, 8 or 34.

Present claims 1-6, 9-11, 13-14, 19-33, and 35-54 relate to an extremely large number of possible compounds and related processes and uses. Support within the meaning of Article 6 PCT and or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts related to the compounds comprising the first or second Fibronectin 3 (Fn 3,2 or Fn 3,1) module of NCAM or fragments thereof in general.

The wording "a variant thereof", in e.g. claims 7 and 34, is defined as any peptide or non-peptide substance having similar properties as a the related NCAM amino acid sequence, the application provides no support within the meaning of Article 6 PCT and / or disclosure within the meaning of Article 5 PCT for such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compounds by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search impossible. No variants have been searched.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 8, 12, 17

Compounds comprising the sequence NGKGL or NGRGL e.g. SEQ ID NO 8-11,26-31 In particular claims 8, 12, 17.

2. Claims: 7,15-18, 34

AENQXXK as defined in claim 15 e.g. SEQ ID NO 3-6, in particular claims 7, 15-18, 34.

3. Claims: 7, 17-18, 34

Compounds comprising the sequence AENQ-L4-K as defined in claim 18 e.g. SEQ ID NO 1-2, in particular claims 7, 17-18, 34.

4. Claims: -

Compounds comprising SEQ ID NO 7,176-188, 191-195 and 204.

5. Claims: -

Compounds comprising SEQ ID NO 12.

6. Claims: -

Compounds comprising SEQ ID NO 13 and 14.

7. Claims: -

Compounds comprising SEQ ID NO 15-17.

8. Claims: -

Compounds comprising SEQ ID NO 18-22.

9. Claims: -

Compounds comprising SEQ ID NO 23 and 25.

10. Claims: -

Compounds comprising SEQ ID NO 24.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

11. Claims: -

Compounds comprising SEQ ID NO 32-34 and 37-42.

12. Claims: -

Compounds comprising SEQ ID NO 35-36.

13. Claims: -

Compounds comprising SEQ ID NO 43-48, 93, 99, 107 and 110-111.

14. Claims: -

Compounds comprising SEQ ID NO 49 and 101-106.

15. Claims: -

Compounds comprising SEQ ID NO 50 and 94

16. Claims: -

Compounds comprising SEQ ID NO 51-54.

17. Claims: -

Compounds comprising SEQ ID NO 55-56, 86 and 109.

18. Claims: -

Compounds comprising SEQ ID NO 57 and 119-120.

19. Claims: -

Compounds comprising SEQ ID NO 58-61.

20. Claims: -

Compounds comprising SEQ ID NO 62-68 and 121-127.

21. Claims: -

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Compounds comprising SEQ ID NO 69-78, 128-130 and 132-133, 144-147.

22. Claims: -

Compounds comprising SEQ ID NO 79-81, 83, 134-137 and 139-140.

23. Claims: -

Compounds comprising SEQ ID NO 82 and 131.

24. Claims: -

Compounds comprising SEQ ID NO 84 and 142.

25. Claims: -

Compounds comprising SEQ ID NO 85, 138 and 143.

26. Claims: -

Compounds comprising SEQ ID NO 87.

27. Claims: -

Compounds comprising SEQ ID NO 88.

28. Claims: -

Compounds comprising SEQ ID NO 89-92.

29. Claims: -

Compounds comprising SEQ ID NO 95-97.

30. Claims: -

Compounds comprising SEQ ID NO 98 and 108.

31. Claims: -

Compounds comprising SEQ ID NO 100.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

32. Claims: -

Compounds comprising SEQ ID NO 112-113.

33. Claims: -

Compounds comprising SEQ ID NO 114-116 and 118.

34. Claims: -

Compounds comprising SEQ ID NO 141.

35. Claims: -

Compounds comprising SEQ ID NO 145-146.

36. Claims: -

Compounds comprising SEQ ID NO 148-149.

37. Claims: -

Compounds comprising SEQ ID NO 150 and 171.

38. Claims: -

Compounds comprising SEQ ID NO 151 and 170.

39. Claims: -

Compounds comprising SEQ ID NO 152.

40. Claims: -

Compounds comprising SEQ ID NO 153-155.

41. Claims: -

Compounds comprising SEQ ID NO 156-159, 161-162, 169 and 173.

42. Claims: -

Compounds comprising SEQ ID NO 160.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

43. Claims: -

Compounds comprising SEQ ID NO 163-168.

44. Claims: -

Compounds comprising SEQ ID NO 174-175.

45. Claims: -

Compounds comprising SEQ ID NO 189-190, 197-199 and 201.

46. Claims: -

Compounds comprising SEQ ID NO 196 and 200.

47. Claims: -

Compounds comprising SEQ ID NO 202-203.

48. Claims: -

Compounds comprising SEQ ID NO 205-206.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/DK 02/00541

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 6576607	B1	10-06-2003	AU 718508 B2 13-04-2000
			AU 5557296 A 07-11-1996
			CA 2218599 A1 24-10-1996
			CZ 9703301 A3 15-04-1998
			EA 970323 A1 30-04-1998
			EP 0821591 A1 04-02-1998
			HU 9900060 A2 28-04-1999
			JP 11504211 T 20-04-1999
			NO 974811 A 19-12-1997
			PL 322947 A1 02-03-1998
			SK 142497 A3 06-08-1999
			TR 9701203 T1 21-03-1998
			TR 9801650 T2 22-03-1999
			WO 9632959 A1 24-10-1996
			US 5792743 A 11-08-1998
US 5837813	A	17-11-1998	US 5629291 A 13-05-1997
			US 5453489 A 26-09-1995
			US 5747452 A 05-05-1998
			AT 152173 T 15-05-1997
			AU 3656893 A 01-09-1993
			CA 2129115 A1 05-08-1993
			DE 69310145 D1 28-05-1997
			DK 624196 T3 03-11-1997
			EP 0624196 A1 17-11-1994
			FI 943568 A 29-07-1994
			JP 7506342 T 13-07-1995
			NO 942825 A 29-09-1994
			WO 9315203 A2 05-08-1993
WO 0196364	A	20-12-2001	EP 1294744 A2 26-03-2003
			WO 0196364 A2 20-12-2001
US 6313265	B1	06-11-2001	NONE

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
27 February 2003 (27.02.2003)

PCT

(10) International Publication Number  
**WO 2003/016351 A3**

(51) International Patent Classification<sup>7</sup>: **C07K 14/705**,  
A61K 38/17, A61P 21/00, 25/00, 17/02, 35/00, C07K  
7/00, A61K 38/04

SE, SG, SI, SK (utility model), SK, SL, TJ, TM, TN, TR,  
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:  
PCT/DK2002/000541

(22) International Filing Date: 19 August 2002 (19.08.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
PA 2001 01228 17 August 2001 (17.08.2001) DK  
PA 2002 00667 2 May 2002 (02.05.2002) DK

(71) Applicant (for all designated States except US): **ENKAM  
PHARMACEUTICALS A/S** [DK/DK]; Fruebjergvej 3,  
DK-2100 Copenhagen Ø (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KISELYOV**,  
Vladislav, V. [UA/DK]; Visbygade 6, st.th., DK-2100  
Copenhagen Ø (DK). **SKLADCHIKOVA**, Galina  
[RU/DK]; Callisensvej 20, 4.th., DK-2900 Hellerup (DK).  
**BEREZIN**, Vladimir [UA/DK]; Nørrebrogade 223,  
1.th., DK-2200 Copenhagen N (DK). **BOCK**, Elisabeth  
[DK/DK]; Tonysvej 20, DK-2920 Charlottenlund (DK).

(74) Agent: **HØIBERG A/S**; Store Kongensgade 59 A,  
DK-1264 Copenhagen K (DK).

(81) Designated States (national): AE, AG, AL, AM, AT (util-  
ity model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,  
CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (util-  
ity model), DE, DK (utility model), DK, DM, DZ, EC, EE  
(utility model), EE, ES, FI (utility model), FI, GB, GD, GE,  
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,  
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,  
MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD,

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,  
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted  
a patent (Rule 4.17(ii)) for the following designations AE,  
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,  
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,  
MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD,  
SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ,  
VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS,  
MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent  
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent  
(AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB,  
GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF,  
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,  
TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

**Published:**

- with international search report  
— with amended claims

(88) Date of publication of the international search report:  
25 March 2004

Date of publication of the amended claims: 6 May 2004

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: N - CAM RELATED COMPOUNDS MODULATING CELL GROTH

(57) Abstract: The present invention relates to a compound comprising the third Immunoglobulin (Ig3) module, and/or the fourth Immunoglobulin (Ig4) module, and/or the fifth Immunoglobulin (Ig5) module, and/or the first Fibronectin III (Fn3, 1) module, and/or the second Fibronectin III (Fn3, 2) module of neural cell adhesion molecule (NCAM), or a fragment, or a variant thereof, capable of interacting with a Fibroblast Growth Factor (FGF) receptor and/or Adenosine-Tri-Phosphate (ATP) and/or L1, and thereby the compounds are capable of inducing differentiation, modulating proliferation, stimulate regeneration, neuronal plasticity and/or survival of cells. Further, the present invention relates to a pharmaceutical composition comprising said compound, a process of producing a pharmaceutical composition and the use of said compound.



56

PCT/DK02/00541

**AMENDED CLAIMS**

**[Received by the International Bureau on 27 November 2003 (27.11.03)  
original claim 1 amended ; original claims 2,3 and 8 cancelled ; remaining claims  
renumbered]**

## AMENDED CLAIMS

[Received by the International Bureau on 27 November 2003 (27.11.03)  
original claim 1 amended ; original claims 2,3 and 8 cancelled ; remaining claims  
renumbered]

1. A compound capable of interacting with Fibroblast Growth Factor (FGF) receptor comprising
  - (i) the second Fibronectin III (Fn3,2) module of the neural cell adhesion molecule (NCAM), or a fragment, or a variant thereof, and/or
  - (ii) a fragment, or a variant of the first Fibronectin III (Fn3,1) module of NCAM, said fragment, or said variant being homologues to the FG-loop of the Fn3,2 module of NCAM.
2. The compound according to claim 1, wherein the FGF receptor is selected from FGF receptor I, FGF receptor II, FGF receptor III, or FGF receptor IV.
3. The compound according to claim 1 or 2, capable of stimulating FGF receptor signalling.
4. The compound according to claim 3, wherein FGF receptor I signalling is stimulated.
5. The compound according to claim 1, comprising the second Fn 3,2 module of NCAM, or a fragment, or a variant thereof.
6. The compound according to claim 1, wherein (ii) comprising an amino acid sequence of the formula  
L1-A-L2-B-L3-C-L4, wherein  
one of A, B, C is selected from a basic amino acid,  
one of A, B, C is selected from a hydrophobic amino acid,  
one of A, B, C is glycine, and  
L1, L2, L3, L4 may be selected from a chemical bond or an amino acid sequence having n amino acid residues, wherein n is an integer of from 0 to 5.
7. The compound according to claim 6, wherein B is glycine, A is a basic amino acid residue, and C is a hydrophobic amino acid residue.
8. The compound according to claim 7, wherein A is lysine (K), and C is leucine (L) or alanine (A).
9. The compound according to claims 6-8, comprising the sequence NGKGL or NGRGL.

10. The compound according to claim 1, wherein (i) comprising an amino acid sequence of the formula  
L1-A-L2-B-L3-C-L4-D-L5, wherein  
5 one of A, B, C, D is selected from a basic amino acid residue,  
one of A, B, C, D is selected from a hydrophobic amino acid residue,  
one of A, B, C, D is selected from an acidic amino acid residue,  
one of A, B, C, D is glycine, and  
L1, L2, L3, L4 and L5 may be selected from a chemical bond or an amino acid sequence  
10 having n amino acid residues, wherein n is an integer of from 0 to 5.
11. The compound according to any of the preceding claims, wherein said compound comprises a peptide homologous to the FG loop of the Fn3,2 module of the NCAM molecule, or a fragment, or a variant thereof.  
15
12. The compound according to claim 11, wherein said compound comprises a peptide sequence having the motif A-E-N-Q-X-X-K, wherein X may be any amino acid residue.
13. The compound according to claim 12, wherein X is selected from Glutamine (Q),  
20 Alanine (A) and/or Asparagine (N) and/or Glycine (G).
14. The compound according to any of the preceding claims, wherein said compound comprises at least one peptide comprising the sequence  
25 EVYVVAENQQGKSKA (SEQ ID NO 1),  
EVAVVAENQQGASAA (SEQ ID NO 2),  
VAENQQGKS (SEQ ID NO 3),  
AENQQGKS (SEQ ID NO 4),  
AENQQGK (SEQ ID NO 5),  
30 AENQAGK (SEQ ID NO 6),  
AMKEDGR (SEQ ID NO 7),  
ALNGKGLG (SEQ ID NO 8),  
AFNGRGLG (SEQ ID NO 9),  
LNGKGLG (SEQ ID NO 10),  
35 LNGKGL (SEQ ID NO 11),  
ALNGKG (SEQ ID NO 12),  
LNGNALGE (SEQ ID NO 13),  
LNGKALG (SEQ ID NO 14),

ALNGKAL (SEQ ID NO 15),  
ALNLKGLGD (SEQ ID NO 16),  
LNGKELG (SEQ ID NO 17),  
LTGKGLAE (SEQ ID NO 18),  
5 LKGKGLEE (SEQ ID NO 19),  
LNSKGLVE (SEQ ID NO 20),  
LNGKALVE (SEQ ID NO 21),  
LAAKGLGE (SEQ ID NO 22),  
LDGKGL (SEQ ID NO 23),  
10 KGLGE (SEQ ID NO 24),  
DGKSLGE (SEQ ID NO 25),  
NGKGL (SEQ ID NO 26),  
NGRGL (SEQ ID NO 27),  
QAFNGRGLGP (SEQ ID NO 28),  
15 EVQAFNGRGLGPPAS (SEQ ID NO 29),  
AALNGKGLGE (SEQ ID NO 30),  
RLAALNGKGLGEIS (SEQ ID NO 31),  
ALNGKGAP (SEQ ID NO 32),  
VALNGKGAPR (SEQ ID NO 33),  
20 MYVALNGKGAPRRQ (SEQ ID NO 34),  
LNGRG (SEQ ID NO 35),  
LNGKG (SEQ ID NO 36),  
MYVALNGKGAPRRGQ (SEQ ID NO 37),  
MFLALDRRGPRPGG (SEQ ID NO 38),  
25 MFLALDSQGIPRQGQ (SEQ ID NO 39),  
MFVALNQKGIPVRG (SEQ ID NO 40),  
MFVALNQKGIPVKG (SEQ ID NO 41),  
MFVALNQKGLPVKG (SEQ ID NO 42),  
WYVSVNGKGRPRRG (SEQ ID NO 43),  
30 YYVALNKDGTPREG (SEQ ID NO 44),  
YYVALNKDGSPREG (SEQ ID NO 45),  
YFVALNKDGTPRDG (SEQ ID NO 46),  
WYVALNKRKAKRG (SEQ ID NO 47),  
WYLGLNKEGEIMKG (SEQ ID NO 48),  
35 WFLGLNKEGQIMKG (SEQ ID NO 49),  
TYIALSKYGRVKRG (SEQ ID NO 50),  
WFLGLNKEGQAMKG (SEQ ID NO 51),  
WFLGLNKEGQVMKG (SEQ ID NO 52),  
WYGLDKEGQVMKG (SEQ ID NO 53),

WYLGLDKEGRVMKG (SEQ ID NO 54),  
WYVALKRTGQYKLG (SEQ ID NO 55),  
WVGLKKNKNGSCKRG (SEQ ID NO 56),  
ANRYLAMKEDGRLLAS (SEQ ID NO 57),  
5 TGQYLAMDTGGLLYGS (SEQ ID NO 58),  
TGQYLAMDTDGGLLYGS (SEQ ID NO 59),  
TGQYLAMDTSGLLYGS (SEQ ID NO 60),  
TGQFLAMDTDGGLLYGS (SEQ ID NO 61),  
SRFFVAMSSKGKLYGS (SEQ ID NO 62),  
10 SRFFVAMSSRGKLFV (SEQ ID NO 63),  
SRFFVAMSSRGRLYGS (SEQ ID NO 64),  
SGLFVAMNSKGKLYGS (SEQ ID NO 65),  
SNKFLAMSKKGKLHAS (SEQ ID NO 66),  
SALFVAMNSKGRLYAT (SEQ ID NO 67),  
15 SALFIAMNSKGRLYTT (SEQ ID NO 68),  
SGRYLAMNKRGRLYAS (SEQ ID NO 69),  
SEYYLAMNKEGKLYAK (SEQ ID NO 70),  
SEYYLAMNKQGLYAK (SEQ ID NO 71),  
SEFYLAMNKEGKLYAK (SEQ ID NO 72),  
20 SGLYLGMNEKGELYGS (SEQ ID NO 73),  
SGLYLGMNDKGELYGS (SEQ ID NO 74),  
SGLYLGMNERGELYGS (SEQ ID NO 75),  
SGLYLGMNERGELFGS (SEQ ID NO 76),  
SNYYLAMNKKGKLYGS (SEQ ID NO 77),  
25 SGFYVAMNRRGRLYGS (SEQ ID NO 78),  
TGLYIAMNGEGYLYPS (SEQ ID NO 79),  
ASLYVAMNGEGYLYSS (SEQ ID NO 80),  
TKLYLAMNSEGELYTS (SEQ ID NO 81),  
TGLYICMNKKGKLIAS (SEQ ID NO 82),  
30 LGHYMAMNAEGLLYSS (SEQ ID NO 83),  
TEFYLCMNRKGKLVGK (SEQ ID NO 84),  
SVRYLCMGADGKMQGL (SEQ ID NO 85),  
WVGLKKNKNGS CKRG (SEQ ID NO 86),  
WYVALKRTGQ YKLG (SEQ ID NO 87),  
35 WYVSVNGKGR PRRG (SEQ ID NO 88),  
GMFIALSKNG KTKKG (SEQ ID NO 89),  
GMFMALSKNG RTKKG (SEQ ID NO 91),  
GMFIALSKNG KAKKG (SEQ ID NO 92),  
WYVALNKRKGK AKRG (SEQ ID NO 93),

TYIALSKYGR VKRG (SEQ ID NO 94),  
MFVALNQKGI PVRG (SEQ ID NO 95),  
MFVALNQKGI PVKG (SEQ ID NO 96),  
MFVALNQKGL PVKG (SEQ ID NO 97),  
5 WYMAFTRKGR PRKG (SEQ ID NO 98),  
YYVALNKDGT PREG (SEQ ID NO 99),  
MYVALNGKGA PRRGQ (SEQ ID NO 100),  
WYLGLDKEGQ VMKG (SEQ ID NO 101),  
WYLGLDKEGR VMKG (SEQ ID NO 102),  
10 WFLGLNKEGQ IMKG (SEQ ID NO 103),  
WYLGLNKEGE IMKG (SEQ ID NO 104),  
WFLGLNKEGQ AMKG (SEQ ID NO 105),  
WFLGLNKEGQ VMKG (SEQ ID NO 106),  
YYVALNKDGS PREG (SEQ ID NO 107),  
15 WFMAFTRQGR PRQ (SEQ ID NO 108),  
WFGVGLKKNKS CKRG (SEQ ID NO 109),  
WYVGFTKKGR PRKG (SEQ ID NO 110),  
YFVALNKDGT PRDG (SEQ ID NO 111),  
MFLALDRRGG PRPGG (SEQ ID NO 112),  
20 MFLALDSQGI PRQGQ (SEQ ID NO 113),  
TGQYLAMDTE GLLYGS (SEQ ID NO 114),  
TGQYLAMDTD GLLYGS (SEQ ID NO 115),  
TGQYLAMDTS GLLYGS (SEQ ID NO 116),  
TGQFLAMDTD GLLYGS (SEQ ID NO 118),  
25 ANRYLAMKED GRLLAS (SEQ ID NO 119),  
SGRYLAMNKR GRLYAS (SEQ ID NO 120),  
SRFFVAMSSK GKLYGS (SEQ ID NO 121),  
SRFFVAMSSR GKLFGV (SEQ ID NO 122),  
SRFFVAMSSR GRLYGS (SEQ ID NO 123),  
30 SGLFVAMNSK GKLYGS (SEQ ID NO 124),  
SNKFLAMSKK GKLHAS (SEQ ID NO 125),  
SALFVAMNSK GRLYAT (SEQ ID NO 126),  
SALFIAMNSK GRLYTT (SEQ ID NO 127),  
SEYYLAMNKE GKLYAK (SEQ ID NO 128),  
35 SEYYLAMNKQ GLYAK (SEQ ID NO 129),  
SEFYLAMNKE GKLYAK (SEQ ID NO 130),  
TGLYICMNKK GKLIAS (SEQ ID NO 131),  
SGLYLGMNEK GELYGS (SEQ ID NO 132),  
SNYYLAMNKK GKLYGS (SEQ ID NO 133),

LGHYMAMNAE GLLYSS (SEQ ID NO 134),  
ASLYVAMNGE GYLYSS (SEQ ID NO 135),  
TKLYLAMNSE GYLYTS (SEQ ID NO 136),  
TGLYIAMNGE GYLYPS (SEQ ID NO 137),  
5 SVRYLCMSAD GKIYG (SEQ ID NO 138),  
SGLYLGMNER GELYGS (SEQ ID NO 139),  
SGLYLGMNER GELFGS (SEQ ID NO 140),  
SEKYICMNKR GKLIG (SEQ ID NO 141),  
TEFYLCMNRK GKLVGK (SEQ ID NO 142),  
10 SVRYLCMGAD GKMQL (SEQ ID NO 143),  
SGLYLGMNDK GELYGS (SEQ ID NO 144),  
TSRFLCQRPD GALYG (SEQ ID NO 145),  
ASRFLCQQPD GALYG (SEQ ID NO 146),  
SGFYVAMNRR GRLYGS (SEQ ID NO 147),  
15 SRRYLCMDFR GNIFGS (SEQ ID NO 148),  
TRRFLCMDLH GNIFGS (SEQ ID NO 149),  
GLKKNQSC (SEQ ID NO 150),  
ALKRTGQY (SEQ ID NO 151),  
SVNGKGRP (SEQ ID NO 152),  
20 IALSKNGKT (SEQ ID NO 153),  
MALSKNGRT (SEQ ID NO 154),  
IALSKNGKA (SEQ ID NO 155),  
ALNKRGA (SEQ ID NO 156),  
ALSKYGRV (SEQ ID NO 157),  
25 ALNQKGIP (SEQ ID NO 158),  
ALNQKGLP (SEQ ID NO 159),  
AFTRKGRP (SEQ ID NO 160),  
ALNKDGTP (SEQ ID NO 161),  
ALNGKGAPR (SEQ ID NO 162),  
30 GLDKEGQV (SEQ ID NO 163),  
GLDKEGRV (SEQ ID NO 164),  
GLNKEGQI (SEQ ID NO 165),  
GLNKEGEI (SEQ ID NO 166),  
GLNKEGQA (SEQ ID NO 167),  
35 GLNKEGQV (SEQ ID NO 168),  
ALNKDGSP (SEQ ID NO 169),  
AFTRQGR (SEQ ID NO 170),  
GLKKNQSC (SEQ ID NO 171),  
GFTKKGRP (SEQ ID NO 172),

ALNKDGTP (SEQ ID NO 173),  
ALDRRGGPR (SEQ ID NO 174),  
ALDSQGIPR (SEQ ID NO 175),  
AMDTDGL (SEQ ID NO 176),  
5 AMDTEGL (SEQ ID NO 177),  
AMDTSGL (SEQ ID NO 178),  
AMKEDGR (SEQ ID NO 179),  
AMNKRGR (SEQ ID NO 180),  
AMSSKGK (SEQ ID NO 181),  
10 AMSSRGK (SEQ ID NO 182),  
AMNSKGK (SEQ ID NO 183),  
AMSKKGK (SEQ ID NO 184),  
AMNSKGR (SEQ ID NO 185),  
AMNKEGK (SEQ ID NO 186),  
15 AMNKEGK (SEQ ID NO 187),  
AMNKQGL (SEQ ID NO 188),  
CMNKKGK (SEQ ID NO 189),  
GMNEKGE (SEQ ID NO 190),  
AMNKKGK (SEQ ID NO 191),  
20 AMNAEGL (SEQ ID NO 192),  
AMNGEGY (SEQ ID NO 193),  
AMNSEGY (SEQ ID NO 194),  
AMNGEGY (SEQ ID NO 195),  
CMSADGK (SEQ ID NO 196),  
25 GMNERGE (SEQ ID NO 197),  
CMNKR GK (SEQ ID NO 198),  
CMNRKGK (SEQ ID NO 199),  
CMGADGK (SEQ ID NO 200),  
GMNDKGE (SEQ ID NO 201),  
30 LCQRPDG (SEQ ID NO 202),  
LCQQPDG (SEQ ID NO 203),  
AMNRRGR (SEQ ID NO 204),  
CMDFRGN (SEQ ID NO 205), and/or  
CMDLHGN (SEQ ID NO 206).  
35

15. The compound according to claim 10, wherein the amino acid sequence has the formula

AENQ-L4-G, wherein L4 is as defined in claim 10.



16. The compound according to claim 1, wherein (i) comprising an amino acid sequence of the formula  
A-B-L3-L4-C-L4, wherein  
5 A is a hydrophobic amino acid residue,  
B is an acidic amino acid residue,  
L3 is one or more hydrophilic amino acid residue(s),  
L4 is an amino acid sequence as defined in claim 10 for L4, and  
C is glycine.
- 10 17. The compound according to any of the preceding claims comprising a sequence of the formula L1-A-L2-B-L3-C-L4-D-L5-E-L6, wherein  
at least one of L1, L2, L3, or L4 comprises the amino acid residue Y and one of the other  
comprises the amino acid residue K,  
15 L5 and/or L6 individually is K, and A, B, C, D, E is any amino acid, with the proviso, that  
the distance between Y and K is at least 5 amino acids, such as at least 7 amino acid  
residues, such as at least 9 amino acid residues, such as at least 11 amino acid residue.
18. The compound according to claim 17, capable of binding adenosine-tri-phosphate (ATP).
- 20 19. The compound according to any of the preceding claims, wherein the compound is a  
dimer.
20. The compound according to the claims any of the claims 1-18, wherein the compound is  
25 a multimer, such as a dendrimer.
21. The compound according to any of the preceding claims, wherein the compound comprises monomers independently capable of stimulating FGF receptor signalling and/or  
modulating proliferation and/or inducing differentiation and/or stimulating regeneration,  
30 neuronal plasticity and/or survival of cells presenting an FGF receptor.
22. The compound according claim 19 or 20, wherein the monomers are homologous.
23. The compound according claim 19 or 20, wherein the monomers are heterologous.

35

24. The compound according to any of the preceding claims, wherein the FGF receptor signalling is measured as phosphorylation of the FGF receptor when a predetermined concentration of the compound is applied to cells expressing the FGF receptor.
- 5 25. The compound according to claim 24, wherein the degree of phosphorylation is at least 20% above the control value.
- 10 26. The compound according to claim 24 or 25, wherein the predetermined concentration of said compound is between 0.1-200  $\mu\text{M}$ , such as 1-200  $\mu\text{M}$ , such as 10-200  $\mu\text{M}$ , such as 20-180  $\mu\text{M}$ , for example 30-160  $\mu\text{M}$ , such as 40-140  $\mu\text{M}$ , for example 50-130  $\mu\text{M}$ , such as 60-120  $\mu\text{M}$ , for example 70-110  $\mu\text{M}$ , such as 80-100  $\mu\text{M}$ .
- 15 27. The compound according to claim 1, comprising amino acid residues in the range of from 3 to 100 amino acid residues, such as from 10-90 amino acid residues, for example from 15-85 amino acid residues, such as from 20-80 amino acid residues, for example from 25-75 amino acid residues, such as from 30-70 amino acid residues, for example from 35-65 amino acid residues, such as from 40-60 amino acid residues, for example from 45-55 amino acid residues.
- 20 28. The compound according to claim 1, comprising amino acid residues in the range of from 3 to 20 amino acid residues, such as from 3-19 amino acid residues, for example from 3-18 amino acid residues, such as from 3-17 amino acid residues, for example from 3-16 amino acid residues, such as from 3-15 amino acid residues, for example from 3-14 amino acid residues, such as from 3-13 amino acid residues.
- 25 29. The compound according to claim 1, capable of modulating proliferation and/or differentiation and/or regeneration and/or neuronal plasticity and/or survival of cells.
- 30 30. A pharmaceutical composition comprising at least one compound as defined in any of the claims 1-29.
- 35 31. The pharmaceutical composition according to claim 30, wherein the compound is the NCAM Fn3,2 module, or a fragment thereof, or a variant thereof.
32. The pharmaceutical composition according to any of the claims 30-31, wherein the compounds are formulated as dimers.

33. The pharmaceutical composition according to any of the claims 30-31, wherein the compounds are formulated as multimers.
- 5 34. The pharmaceutical composition according to any of the claims 30-33 formulated for oral, percutaneous, intramuscular, intravenous, intracranial, intrathecal, intracerebroventricular, intranasal or pulmonal administration.
- 10 35. The pharmaceutical composition according to claim 34, wherein the administration is continuous.
- 15 36. A process of producing a pharmaceutical composition, comprising mixing an effective amount of one or more of the compounds according to the claims 1-29, or a pharmaceutical composition according to any of the claims 30-35 with one or more pharmaceutically acceptable additives or carriers.
- 20 37. The process according to claim 36, wherein the compound as defined in the claims 1-29 are used in combination with a prosthetic device.
- 25 38. The process according to claim 37, wherein the device is a prosthetic nerve guide.
- 30 39. The process according to claim 38, wherein the prosthetic nerve guide is characterised in that it comprises at least one compound as defined in any of the claims 1-29, or a pharmaceutical composition as defined in any of the claims 30-35.
- 35 40. The process according to the claims 36-39, wherein an effective amount of at least one compound as defined in any of the claims 1-30, or a pharmaceutical composition according to any of the claims 31-36 is administered to a subject.
41. Use of a compound as defined in any of the claims 1 to 29.
42. The use according to claim 41, wherein the compound is for the manufacture of a medicament.
43. The use according to any of the claims 41-42, wherein the compound and/or pharma-

5 ceutical composition is for the treatment of diseases or conditions of the central and peripheral nervous system, such as postoperative nerve damage, traumatic nerve damage, e.g. resulting from spinal cord injury, impaired myelination of nerve fibers, postischaemic damage, e.g. resulting from a stroke, multiinfarct dementia, multiple sclerosis, nerve degeneration associated with diabetes mellitus, neuro-muscular degeneration, schizophrenia, mood disorders, such as manic depressive disorders, Alzheimer's disease, Parkinson's disease, or Huntington's disease.

10 44. The use according to any of the claims 41-42, wherein the compound and/or pharmaceutical composition is for the treatment of diseases or conditions of the muscles including conditions with impaired function of neuro-muscular connections, such as genetic or traumatic atrophic muscle disorders; or for the treatment of diseases or conditions of various organs, such as degenerative conditions of the gonads, of the pancreas, such as diabetes mellitus type I and II, of the kidney, such as nephrosis.

15

45. The use according to claim 44, wherein the compound and/or pharmaceutical composition is for preventing cell death of heart muscle cells, such as after acute myocardial infarction.

20

46. The use according to claim 45, wherein the compound and/or pharmaceutical composition is for revascularisation.

25

47. The use according to claim 42, wherein the compound and/or pharmaceutical composition is for the promotion of wound-healing.

48. The use according to claims 42, wherein the compound and/or pharmaceutical composition is capable of inhibiting angiogenesis.

30

49. The use according to any of the claims 42 or 48, wherein the compound and/or pharmaceutical composition is for the treatment of cancer.

50. The use according to any of the claims 42 or 43, wherein the compound is for the stimulation of the ability to learn and/or of the short and/or long term memory.

35

51. The use according to the claims 42, capable of modulating proliferation and/or differen-

tiation and/or regeneration and/or neuronal plasticity and/or survival of cells.